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Abstract 
The E2F1 transcription factor regulates the expression of key genes involved in cell 
proliferation and differentiation to maintain skin homeostasis. The expression of E2F1 is 
tightly regulated during cell cycle progression and when cells are committed to 
differentiate, as well as in response to DNA damage. In keratinocytes, E2F1 protein and 
transcript levels increase following UV-induced DNA damage, whereas, in response to 
Ca2+-induced differentiation, both E2F1 protein and transcript levels decrease. In this 
thesis, I examined in detail the mechanism that modulates E2F1 stability following DNA 
damage and during keratinocyte differentiation. I show that E2F1 associates with hHR23 
and together these proteins participate in the nucleotide excision repair (NER) pathway. 
hHR23A stabilizes E2F1 by inhibiting its proteasomal degradation. Moreover, E2F1 
regulates hHR23A subcellular localization and recruits hHR23A to sites of DNA 
photodamage to facilitate DNA repair. These results unveil a novel mechanism involving 
E2F1 and hHR23A to enhance the repair of damaged DNA, contributing to the 
maintenance of genomic stability following UV-induced DNA damage in epidermal 
cells. In contrast to DNA damage, proper keratinocyte differentiation occurs when E2F1 
is down regulated. Although the regulation of E2F1 that leads to its nuclear export and 
degradation has been reported, the exact mechanisms are poorly characterized. When 
E2F1 Ser403 and/or Thr433 are substituted to an alanine (E2F1 ST/A), a significant 
increase in the half-life of this mutant in differentiated keratinocytes is observed. 
Furthermore, the E2F1 ST/A mutant does not form appreciable levels of K11- or K48-
linked polyubiquitylation, which is associated with degradation. Moreover, I show that 
  
iii 
Cdh1, an activator protein of the anaphase-promoting complex/cyclosome (APC/C) 
complex, interacts with E2F1 in keratinocytes, and its inactivation prevents the turnover 
of E2F1 following Ca2+-induced differentiation. Collectively, these results reveal a new 
mechanism involving E2F1 and Cdh1 in coordinating its degradation through post-
translational modification and nuclear export in differentiated keratinocytes. By 
elucidating the appropriate events required for the turnover of E2F1, we can better 
understand and treat various epidermal diseases such as non-melanoma skin carcinoma. 
Keywords 
Keratinocytes, epidermis, E2F, phosphorylation, ubiquitylation, hHR23, DNA 
photodamage, ubiquitin ligase, Cdh1, UBC13. 
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Chapter 1  
1 Introduction 
1.1 The Skin 
The skin serves as the first line of defense against environmental and physical insults, and 
excessive loss of water and electrolytes. A major role of the skin is to provide a barrier 
protection between the organism and the external environment. Other functions of the 
skin include maintenance of body temperature, synthesis of vitamin D, and tactile 
sensation. Extensive damage to the skin can have substantial negative consequences, 
including increased risk of infection and water-electrolyte imbalance. Therefore, proper 
maintenance of skin structure and function is crucial for keeping our body healthy. 
The skin is composed of three main layers: the hypodermis, the dermis and the epidermis 
(Figure 1.1). The skin also contains epidermal appendages including sweat glands, 
sebaceous glands, apocrine glands, and hair follicles. Signaling events can lead to the 
activation of differentiation processes, giving rise to the stratified epidermis, hair follicles 
and sebaceous glands (Fuchs, 2007). The epidermis is derived from the embryonic 
ectoderm and the dermis and hypodermis are mesodermal in origin (Hardy, 1992). The 
epidermis and the dermis are attached to each other through a basement membrane.  
 Epidermal morphogenesis is regulated through many signaling pathways, including the 
canonical wingless-related (Wnt), bone morphogenetic proteins (BMP), and Notch 
signaling pathways (Fuchs, 2007). Wnt signaling events promote the activation of BMP 
signaling in early ectoderm progenitor cells to initiate the progression towards epidermal  
  
 
 
 
 
 
Figure 1.1: The skin structure.  
The three distinct layers of the skin are shown: epidermis (orange), dermis (pink) and 
hypodermis (yellow). At the dermal-epidermal junction, a basement membrane lies 
between the epidermis and dermis. Dermal papillae are finger-like projections of dermis 
that project up to the epidermis, increasing the surface area. Nerve endings and blood 
vessels present in the dermis are also shown. Below the dermis is the hypodermis, 
composed mainly of adipose tissue. The skin also contains epithelial appendages 
structures including hair follicles, sweat glands, and sebaceous glands. The hair follicle 
bulge where epithelial stem cells reside is also shown. 
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morphogenesis. In chick embryos, expression of Wnt signaling represses fibroblast 
growth factor (FGF) signals, allowing for the activation of BMP signaling, inducing 
neural cell fate to switch into epidermal cell fate (Wilson et al., 2001). The Wnt signaling 
pathway also plays an essential role in the initiation of epidermal appendages, such as 
hair follicles (Fuchs, 2007). Constitutive expression of the Wnt inhibitor, Dickkopf-
related protein 1 (Dkk1) prevents the formation of hair follicles in the epidermis (Andl et 
al., 2002). Finally, the activation of Notch signaling events promote stratification of the 
epidermis (Wilson and Radtke, 2006). 
1.1.1 The epidermis 
The epidermis is a keratinized stratified squamous epithelium and is the outermost 
protective layer of the skin. The epidermis consists of four cell types: keratinocytes, 
derived from surface ectoderm, Langerhans cells derived from the bone marrow, 
melanocytes and Merkel cells, both derived from the neural crest (Carlson, 1994). 
Keratinocytes constitute about 80% of all epidermal cells, whereas other cell types are 
scarcely found throughout the epidermis (Rook and Burns, 2004). 
In humans and other mammals, the epidermis is composed of several layers (Figure 1.2). 
The lowermost layer, or stratum basale, contains a heterogeneous population of 
proliferating and differentiating cells that are characterized into three categories: 
keratinocyte stem cells (KSC), transit amplifying cells (TAC), and postmitotic 
differentiating cells (Kaur and Li, 2000; Li et al., 1998). KSC divide symmetrically or 
asymmetrically (Clayton et al., 2007). During symmetric cell division (delamination), 
cells expressing low levels of integrins differentiate and move out to the basal epidermal  
  
 
 
 
Figure 1.2: The epidermal layers. 
There are several distinct layers of the epidermis and keratinocytes are the dominant cells 
aligned through the layers. Other cells found in the epidermis include melanocytes, 
Merkel cells, and Langerhans cells. The stratum basale is the bottom single layer of cells 
attached to the basement membrane. Epidermal stem cells are located in the basal layer 
and during mitosis, it gives rise to two daughter cells. One retains the properties of a 
keratinocyte stem cell (KSC), and the other differentiates into transient amplifying cells 
(TAC) that migrate to the epidermal surface forming the protective layer of the skin. The 
stratum spinosum begins to synthesize intermediate filaments called keratins. These 
intermediate filaments are anchored to the desmosomes joining adjacent cells. In the 
stratum granulosum, the cells begin to lose their nuclei and the cytoplasm looks granular. 
The cells in this layer exocytose lamellar granules to generate a waterproof barrier 
between the outer dead cells and the lower layer of active epidermal cells. The stratum 
lucidum is a thin transparent layer present in thick skins such as palms and soles. The 
outermost layer of the epidermis is called the stratum corneum. This layer is made up of 
hexagonal-shaped, non-nucleated cells known as corneocytes. The corneocytes are filled 
with keratin fibers and lipids. This structure provides the protective barrier function of the 
skin. 
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layer and high integrin expressing cells remain attached to the basement membrane (Frye 
et al., 2007). These cells also expresses Numb, an inhibitor of Notch signaling, which is 
required for stratification of the epidermis (Clayton et al., 2007). During asymmetric cell 
division, a stem cell divides into two daughter cells, giving rise to a new cell that retains 
the stem cell capability, and a TAC, which divides rapidly and initiates the process 
towards differentiation to give rise to suprabasal layers (Figure 1.2). Both modes of 
division contribute to the balance of epidermal self-renewal, differentiation, and 
regeneration after injury. However, the mechanisms involved in one versus the other are 
poorly understood (Fuchs and Chen, 2013). Over the basal layer, the stratum spinosum 
and stratum granulosum are found, in body areas with thicker skin, such as the foot sole, 
the stratum lucidum is found above the granular layer in human epidermis. The outermost 
layer of the epidermis is the stratum corneum, which protects the inner body from foreign 
invasion (Fuchs, 2009; Fuchs and Raghavan, 2002).  
The cells in the stratum spinosum are metabolically and transcriptionally active. This 
layer is characterized by the formation of desmosomes, which provide strong adhesion 
between adjacent cells by linking the outer aspect of two cells to each other, and their 
cytoplasmic domains are linked to keratin filaments providing mechanical strength. Early 
markers of keratinocyte differentiation, including involucrin, and keratin-1 and -10 (K1, 
K10) are expressed in this layer (Ekanayake-Mudiyanselage et al., 1998). The stratum 
granulosum contains keratinocytes that are enriched in lipid-lamellar granules that 
function as a water repellent, contributing to the barrier function of the skin. The 
activation of transglutaminase in this layer irreversibly cross-links lysine- and glutamine- 
rich proteins to give rise to the cornified envelope (Koster and Roop, 2007; Steinert and 
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Marekov, 1999). As granular cells progress to form the stratum corneum, metabolic 
activity is halted and cytoplasmic organelles are lost. The keratinocytes in this layer, also 
termed corneocytes, exhibit the terminal stage of differentiation of all epidermal cells, 
and are constantly shed and replaced by new differentiated cells moving outwards (Mack 
et al., 2005).   
Melanocytes are found in the basal layer of the interfollicular epidermis and in the hair 
follicle (Figure 2.2). Melanocytes primarily function to produce the pigment melanin and 
help in protecting against the harmful effects of ultraviolet (UV) radiation (Tsatmali et 
al., 2002). The Merkel cells are also found in the basal layer, and are specialized in the 
touch sensation (Moll et al., 2005). Langerhans cells are dendritic and are situated in the 
suprabasal layer. They are involved in immunity, and function in antigen presentation. 
These cells are central components of cutaneous allergic reactions (Merad et al., 2008). 
1.1.2 The dermis and hypodermis 
The dermis sustains and provides support to the epidermis. The dermis is composed of 
two layers, papillary dermis, and reticular dermis. The elasticity and strength of the 
dermis are achieved through elastin and collagen fibers, which are secreted by dermal 
fibroblasts. Fibroblasts, mast cells, macrophages, and adipocytes are present within the 
dermis and hypodermis. The hypodermis is beneath the dermis, and its main function is 
for fat storage. 
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1.2 Regulation of keratinocyte proliferation and 
differentiation 
A balance between epidermal proliferation and differentiation must be maintained to 
ensure proper epidermal homeostasis. Defects in epidermal proliferation can lead to thin 
and fragile skins (Raghavan et al., 2000). Abnormalities in epidermal differentiation and 
disruption of the epidermal barrier function can lead to chronic skin inflammatory 
disorders, such as atopic dermatitis, psoriasis, as well as to basal- or squamous-cell 
carcinoma. In the following section, I will describe some of the main transcription factors 
and mechanisms that regulate keratinocyte proliferation and differentiation. 
1.2.1 Keratinocyte stem cells 
The epidermis is constantly undergoing self-renewal to replace cells that have terminally 
differentiated and been shed. Self-renewal and regeneration after injury are possible 
through the presence of KSC. The stem cells present in the hair follicle bulge are 
multipotent, as they have the ability to give rise to keratinocytes in the epidermis, hair 
follicles, and sebaceous glands (Figure 1.1). 
KSC express high levels of integrins. Integrins are essential for keratinocyte viability and 
adhesion to the basement membrane, and non-pathologic loss of adhesion is associated 
with epidermal differentiation (Carter et al., 1990). The main integrins found in basal 
keratinocytes in intact epidermis are α2β1, α3β1 and α6β4 (Peltonen et al., 1989). KSC and 
TAC exp ress h igh  levels o f β1 and α6 integrins whereas suprabasal postmitotic 
differentiated cells do not show detectable integrins (Kaur and Li, 2000; Li et al., 1998). 
KSC population can be distinguished from TAC population through the expression of a 
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cell surface marker, the transferrin receptor (CD71), where the latter expresses high 
levels of CD71 (Kaur and Li, 2000; Tani et al., 2000). Therefore, KSC can be enriched in 
culture by selecting cells expressing high levels of α6 integrins and low levels of CD71. 
Other cell surface markers of the KSC located in the hair follicle bulge include K15 
(Morris et al., 2004), CD34 (Trempus et al., 2003), Lgr5 (Jaks et al., 2008) and Sox9 
(Vidal et al., 2005).  
The transcription factor p63 is preferentially expressed in the basal epidermis and is 
essential for normal epidermal morphogenesis (Mills et al., 1999). The p63 protein is 
necessary for maintaining the epidermal proliferative capacity, commitment to KSC, and 
keratinocyte differentiation (Koster et al., 2004; Senoo et al., 2007). There are two 
isoforms of the p63 gene, the transactivating TAp63, and the non-transactivating ΔNp63 
generated through the use of alternate promoters (Blanpain and Fuchs, 2007). Ectopic 
expression of TAp63 results in hyperplasia of keratinocytes, and inactivation of ΔNp63 
leads to formation of a single-layered epidermis, which indicate defects in keratinocyte 
differentiation (Koster et al., 2004; Romano et al., 2012). In the current proposed model, 
the function of TAp63 is to maintain high proliferative potential during embryogenesis 
while limiting the differentiation process, and ΔNp63 functions as a dominant-negative 
protein to inhibit TAp63 to promote differentiation (McKeon, 2004).  p63 also functions 
to prevent the activation of p16INK4A, an inhibitor of the G1-S phase transition of the cell 
cycle (Su et al., 2009). Inhibition of p16INK4A allows for CDK4/6-Cyclin D activation, 
consequently regulating the E2F/Rb pathway to promote cell proliferation. Thus, p63 is 
necessary for epidermal proliferation. In addition to p63 transcriptional repression on 
p16IK4A, p63 prevents the activation of Notch-targeted genes including p21Cip1/Waf1, 
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involucrin and Hes1. Reciprocally, Notch activation leads to suppression of p63 
expression in differentiated keratinocytes. Hence, the cross-talk between p63 and Notch 
signaling is one of the mechanisms that maintain the balance between epidermal cell 
proliferation and differentiation (Nguyen et al., 2006). 
1.2.2 Regulation of keratinocyte differentiation 
The Notch signaling pathway is a key regulator of keratinocyte differentiation and is 
activated in the suprabasal layer, where it induces p21Cip1/Waf1 expression in an RBP-Jκ-
dependent manner (Rangarajan et al., 2001; Watt et al., 2008). Activation of p21Cip1/Waf1 
expression leads to keratinocyte growth arrest and initiation of terminal differentiation. 
Moreover, Neurogenic locus notch homolog protein 1 (Notch1) and Notch2 induce the 
expression of the early differentiation markers involucrin and K1 through an RBP-Jκ-
independent pathway (Rangarajan et al., 2001). Notch activity is stimulated when 
cultured keratinocytes are induced to differentiate by increasing the extracellular calcium 
ion (Ca2+) concentration (Kolly et al., 2005).  
A Ca2+ gradient is observed throughout the epidermal layers, with lower Ca2+ levels in 
the basal layer and higher concentration in the granular compartment (Mascia et al., 
2012). This Ca2+ gradient plays a crucial role in epidermal homeostasis and 
differentiation. Any disruption to the gradient leads to abnormal keratinocyte 
differentiation and loss of epidermal barrier function (Elias et al., 2002). Cultured 
keratinocytes can be induced to differentiate by modulating the extracellular Ca2+ 
concentration (Hennings et al., 1980; Yuspa et al., 1989). When keratinocytes are 
cultured in low Ca2+ medium (0.02 to 0.09 mM), they are undifferentiated and maintain 
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their proliferative capacity. These cells model basal keratinocytes. An increase in the 
extracellular Ca2+ concentration to >0.1 mM leads to cell cycle arrest and up regulation of 
differentiation markers, such as involucrin (Xie et al., 2005). Ca2+ activates a variety of 
signaling pathways, including Notch, phospholipase C (PLC), protein kinase C (PKC) 
and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) (Denning et al., 1995; 
Rangarajan et al., 2001; Xie and Bikle, 1999; Xie et al., 2005).  
Ca2+-induced keratinocyte differentiation occurs through the PLC/PKC signaling 
pathway. PLCγ activation hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 binds its receptor and 
activates the release of intracellular Ca2+. Both Ca2+ and DAG subsequently activate PKC 
to initiate differentiation (Mascia et al., 2012). There are nine PKC family members, of 
those, the classical PKCα (activated by both Ca2+ and DAG), the novel PKCδ, PKCη, and 
PKCε (stimulated by DAG and not Ca2+)  and the atypical PKCζ (not activated by Ca2+ or 
DAG) are present in keratinocytes (Denning et al., 1995). 
PKCδ and PKCη are key for keratinocyte differentiation. The expression levels of PKCδ 
and PKCη increase following Ca2+-induced keratinocyte differentiation (Denning et al., 
1995; Deucher et al., 2002; Kashiwagi et al., 2002). The increase in PKCη leads to 
transcriptional activation of proteins involved in the formation of the cornified envelope 
at the suprabasal layer of the epidermis including transglutaminase I and involucrin 
(Efimova and Eckert, 2000; Ueda et al., 1996). The transcriptional activation of 
involucrin occurs through the nPKC/Ras/MEKK/MEK3/p38δ-ERK1-2 signaling 
pathway, resulting in an increase in transcription factor CCAAT/enhancer-binding 
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protein (C/EBP), activator protein 1 (AP1) and specificity protein 1 (Sp1) levels and 
binding to the involucrin promoter sequence, thereby increasing involucrin gene 
transcription (Agarwal et al., 1999; Crish et al., 2006; Efimova et al., 2002; Efimova et 
al., 1998). PKCη activates Fyn and p21Cip1/Waf1, which lead to cell cycle arrest followed 
by keratinocyte differentiation (Cabodi et al., 2000; Kashiwagi et al., 2000). PKCη 
phosphorylates p21Cip1/Waf1 at serine 146 and inhibits CDK2 kinase activity, which leads 
to G1 arrest through dephosphorylation of the retinoblastoma protein (pRb) (Kashiwagi 
et al., 2000). 
1.3 Keratinocyte responses to UV radiation 
The epidermis of the skin is constantly exposed to environmental insults and therefore 
has established endogenous processes to prevent, protect, and repair damage. There are a 
number of signals that sense the presence of damaged DNA, which lead to cell cycle 
arrest, allowing time for the repair to occur, or force cells to undergo apoptosis if the 
damage is beyond repair. If the damage is not repaired properly, it will result in loss of 
DNA integrity and accumulation of mutations that can lead to cancer. 
Solar UV radiation is a major environmental factor that influences and affects the 
survival of epidermal keratinocytes, which can lead to the development of premature skin 
aging and skin cancer (Diffey, 1991). Nonmelanoma skin carcinomas are the most 
frequent cancers in humans, accounting for about 40% of all diagnosed cancers in North 
America (Christenson et al., 2005). UV radiation is composed of UVA (320-420nm), 
UVB (280-320 nm), and UVC (200-280 nm). UVC radiation is highly bioactive, 
however, most of the rays are absorbed by the atmospheric ozone layer, and therefore, we 
14 
 
 
are not exposed to significant levels of UVC (unless you live in Antarctica). UVB 
radiation causes direct DNA damage and reaches the epidermis. UVA radiation 
penetrates the dermis and increases levels of reactive oxygen species (ROS) that can 
induce DNA mutations.  
1.3.1 Nucleotide excision repair 
UV radiation causes specific mutations in epidermal keratinocytes. This occurs through 
the reaction between UV photons and cellular DNA (Grossman and Leffell, 1997). In the 
presence of UV light, two pyrimidines on the same DNA strand can undergo dimerization 
and become covalently bound to each other, forming cyclobutane pyrimidine dimers 
(CPD) and (6-4) pyrimidine pyrimidone ((6-4)PP) photoproducts (Sancar et al., 2004). 
Approximately 85% of primary lesions caused by UV radiation give rise to CPD 
photoproducts and (6-4)PP accounts for 10 to 20% (Grossman and Leffell, 1997). In 
mammals, DNA repair of these lesions relies on nucleotide excision repair (NER) 
pathways (Thiagarajan et al., 2011). 
The importance of the NER pathway is demonstrated by the hereditary disorder 
xeroderma pigmentosum (XP), an autosomal recessive genetic disorder that arises from 
an impaired ability of epidermal cells to repair damaged DNA. Individuals with XP have 
a mutation in one of the several genes involved in the NER pathway, and are 
hypersensitive to UV radiation, exhibiting an increased risk of developing nonmelanoma 
skin carcinoma (Rezvani et al., 2011). The NER pathway can occur through either global 
genome NER (GG-NER), which repairs damage from the entire genome or through 
transcription-coupled NER (TC-NER), which generally repairs lesions when RNA 
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polymerase II is stalled on actively transcribed DNA strands (Figure 1.3) (Marteijn et al., 
2014). 
The first step in the NER pathway is recognition of damaged DNA. The damage sensor 
protein, XP complementation group C (XPC) forms a complex with UV excision repair 
protein Rad23 homolog (hHR23) and centrin 2 (Sugasawa et al., 1997; van der Spek et 
al., 1996a). When the XPC complex is recruited at the sites of DNA damage, hHR23 
dissociates from the complex. In the NER pathway, the hHR23 protein functions to 
recruit XPC to sites of DNA damage and promote nuclear accumulation of XPC by 
preventing its proteasomal degradation (Ng et al., 2003). At the damaged site, complex 
formation also occurs between DNA damage-binding protein-1 (DDB1, also known as 
the XPE-binding factor) and DDB2, the UV-DDB complex, which further facilitates 
subsequent binding of XPC (Reardon and Sancar, 2003). Lesion recognition is followed 
by verification of DNA damage by recruitment of transcription initiation factor IIH 
(TFIIH), composed of 10 protein subunits including XPA, XPB and XPD helicases. This 
complex verifies the presence of the lesion and unwinds approximately 20 base pairs (bp) 
around the damaged DNA site (Evans et al., 1997). This is followed by recruitment of 
XPG, XPF and excision repair cross-complementation group 1 (ERCC1) endonucleases 
by the XPA subunit to make a 3′ and 5′ incisions, respectively and excise 25-26 bp 
nucleotide strand surrounding the lesion site (Staresincic et al., 2009). In the final step, 
DNA gap-filling is completed by the proliferating cell nuclear antigen (PCNA), which 
recruits DNA polymerases and the repaired DNA is ligated by DNA ligases (Figure 1.3) 
(Moser et al., 2007; Ogi et al., 2010). 
  
  
 
 
 
 
Figure 1.3: Nuclear excision repair pathway. 
The two pathways, global genomic NER, and transcriptional coupled NER differ in the 
recognition of DNA damage but converge to a common mechanism from verification to 
DNA synthesis and ligation. In global genomic NER (left), the UV-DDB complex and 
the cullin 4A-regulator of cullins 1 (CUL4-ROC1) complex mediates XPC ubiquitylation 
to increase its binding affinity to damaged DNA and recruitment to lesion sites together 
with HR23 protein. Once XPC and centrin 2 (CETN2) is on lesion site, the UV-DDB 
complex is ubiquitylated and dissociates together with HR23, which is essential for the 
recruitment of TFIIH to verify the damaged site. In transcriptional couple NER (right), 
the stalled RNA polymerase II facilitates the recruitment of Cockayne syndrome protein 
(CSB) to sites of DNA damage. The recognition is followed by verification of DNA 
damage by TFIIH in both pathways. The XPC-CETN2 complex is ubiquitylated and 
targeted for degradation to enable binding of XPF-ERCC1 and XPG endonuclease to 
excise 20-25 nucleotide of the damaged DNA. In the final step, the gap is filled by DNA 
polymerase (DNA pol)  to synthesize new DNA and the nick is sealed by DNA ligase. 
Ub, ubiquitylation. 
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1.4 The Ubiquitin-proteasome system 
The ubiquitin-proteasome system (UPS) is a complex biological system that targets 
proteins for degradation in the cytosol, the nucleus, or within the endoplasmic reticulum 
of eukaryotic cells (Peters et al., 1994). The main function of the UPS is to degrade 
misfolded, denatured, or improperly translated proteins, as well as participating in normal 
protein turnover. Target proteins are first marked by ubiquitylation and the ubiquitylated 
protein is then recognized, unfolded and hydrolyzed by the proteasome. 
1.4.1 Ubiquitylation 
Ubiquitin is a small 8.5-kDa protein with 76 amino acid (a.a.) residues that functions as a 
protein degradation signal (Ciechanover et al., 1980). Ubiquitylation is also an inducible 
event activated by extracellular stimuli, phosphorylation or during DNA damage 
response (Hershko and Ciechanover, 1998). When a substrate protein is covalently linked 
to polyubiquitin chains, it is frequently targeted for degradation through the 26S 
proteasome. When the substrate protein in delivered to the proteasome, the ubiquitin is 
recycled by deubiquitylating enzymes (DUB). 
Ubiquitin is conjugated to a substrate in a three-step process catalyzed by specific E1, E2 
and E3 enzymes (Scheffner et al., 1995). The carboxyl-terminal (C-terminal) end of 
ubiquitin contains two glycine residues (Gly75-Gly76) that are activated by the E1 
enzyme in an ATP-dependent manner. This forms a covalent thioester linkage between 
ubiquitin and a cysteine residue of the E1 ubiquitin-activating enzyme. The activated 
ubiquitin is subsequently transferred to an E2 ubiquitin-conjugating enzyme, which acts 
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as a ubiquitin carrier protein. The E2 enzyme then transfers the ubiquitin to an active 
cysteine residue on the E3 ubiquitin-ligase bound to the substrate protein. Ubiquitin is 
subsequently transferred to the substrate protein through an amide isopeptide linkage 
between Gly76 of ubiquitin and the ε-amino group of a lysine residue on the substrate 
protein (Scheffner et al., 1995). A single ubiquitin molecule can be transferred to a lysine 
residue on the substrate protein, leading to monoubiquitylation or it can be attached to 
multiple lysine residues, which leads to multi-monoubiquitylation (Chan et al., 2006; 
Hoege et al., 2002). Additional ubiquitins can be added to a lysine residue of ubiquitin, 
resulting in the formation of polyubiquitin chains (Pickart, 2000). Ubiquitin has seven 
lysine residues, all capable of forming polyubiquitin chains (Figure 1.4). There are 
proteins with ubiquitin-binding domains (UBD) that interact with different types of 
ubiquitin linkages, leading  to numerous biological effects (Ravid and Hochstrasser, 
2008). For example, K63-linked polyubiquitylation binds UBD-containing endosomal 
sorting complex required for transport (ESCRT) proteins, and targets a substrate for 
endosomal trafficking to lysosomes (Erpapazoglou et al., 2012; Nathan et al., 2013). On 
the other hand, K11- and K48-linked polyubiquitin chains preferentially interact with 
ubiquitin-binding receptors, such as hHR23, and target a substrate for degradation 
(Bremm and Komander, 2011; Elsasser et al., 2004).  
1.5 hHR23 
The yeast Saccharomyces cerevisiae, Rad23 and its mammalian orthologue, hHR23 are 
evolutionary conserved scaffold proteins essential for NER and are also involved in  
  
 
 
 
 
Figure 1.4: Schematic of ubiquitin and types of ubiquitylation formed. 
The seven lysine residues on ubiquitin are shown. The K0 ubiquitin has all lysine 
residues substituted for an arginine, and therefore can only form mono-ubiquitin on one 
or more sites on proteins (multi-ubiquitylation). The K0 ubiquitin prevents the generation 
of polyubiquitin chains. The K11, K48, and K63 ubiquitins have all lysine substituted to 
an arginine expect for the indicated lysine residue. Therefore, K11, K48, or K63 ubiquitin 
can only form K11-, K48- or K63- linked polyubiquitin chains, respectively. Different 
ubiquitin linkages lead to different biological consequences, multi-ubiquitylation of 
substrate leads to endocytosis, K11- or K48-linked polyubiquitylation leads to substrate 
degradation through the proteasomal pathway, and K63-linked polyubiquitylation leads 
to DNA repair, endocytosis, or activation of kinase function. K, lysine; R, arginine; Ub, 
ubiquitylation. 
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modulating proteasomal degradation of variety of proteins (Dantuma et al., 2009; 
Masutani et al., 1994). Depending on the cellular context, hHR23 can bind to and escort 
polyubiquitylated proteins to the proteasome, increasing their degradation, or, 
paradoxically, protect XPC and other proteins from proteasomal degradation (Blount et 
al., 2014; Fang et al., 2013; Ng et al., 2003; Zhu et al., 2001).  
There are two homologs of the mammalian HR23: HR23A, and HR23B (Renaud et al., 
2011). XPC associates with hHR23B and hHR23A in vivo (Sugasawa et al., 1997; van 
der Spek et al., 1996a). mHR23A knockout mice are viable, develop normally and show 
no defects in NER, whereas inactivation of the gene that encodes mHR23B severely 
impairs the development of mice (Ng et al., 2003; Ng et al., 2002). This indicates 
mHR23A can only partially compensate for the loss of mHR23B, and mHR23B has 
additional important functions. Moreover, inactivation of both genes leads to embryonic 
lethality, suggesting a role in pathways other than NER, most likely linked to the UPS. 
Indeed, mHR23B associates with proteins involved in the UPS and knockout of mHR23B 
affects the proteasome function resulting in decreased cell proliferation (Bergink et al., 
2013). HR23 proteins are composed of an amino-terminal (N-terminal) ubiquitin-like 
(UbL) domain, two ubiquitin-associated domains (UBA1 and UBA2), and linking the 
UBA1 and UBA2 regions is the XPC domain (Jung et al., 2014). These four domains are 
connected through flexible linker regions ranging in length from 25 to 80 a.a. (Walters et 
al., 2003). 
The UbL domain of hHR23 consists of 80 a.a. and shares ~23% sequence similarity with 
ubiquitin (van der Spek et al., 1996b). The UbL domain interacts with the 26S 
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proteasome non-ATPase regulatory subunit 4 (PSMD4) (Chen and Madura, 2006; 
Hiyama et al., 1999). Deletion of the UbL domain of Rad23 leads to increased sensitivity 
to UV radiation, which indicates the importance of the interaction between UbL and the 
proteasome and its function to efficiently repair damaged DNA (Lambertson et al., 
2003). Indeed, the NER recognition protein, XPC is stabilized by hHR23 (Ng et al., 
2003). The interaction between the UbL domain of hHR23 and the proteasome inhibits 
the formation of multi-ubiquitin chains leading to increased protein stability (Ortolan et 
al., 2000).  
The UBA1 and UBA2 domains in hHR23 contain 48 a.a. and 44 a.a., respectively. Both 
UBA domains can interact with ubiquitin and multi-ubiquitin chains (Bertolaet et al., 
2001; Kang et al., 2006). The interaction between UBA and ubiquitin prevents the 
assembly and disassembly of multi-ubiquitin chains, and therefore can either inhibit or 
favor degradation, respectively (Chen et al., 2001; Raasi and Pickart, 2003). UBA1 and 
UBA2 domains mediate inhibition of proteolysis and the UbL domain is dispensable for 
inhibiting substrate proteasomal degradation. The UbL domain can interact with both 
UBA domains and PSMD4 (Kang et al., 2007; Lambertson et al., 1999). The interaction 
between PSMD4 and UbL changes the conformation of hHR23A, so that it prevents UbL 
from interacting with the UBA domain. The UBA domain can then interact with 
polyubiquitylated substrates. This tertiary structure mediates the delivery of ubiquitylated 
substrates to the proteasome for degradation where hHR23 act as an adaptor protein 
linking the proteasome with the substrate (Figure 1.5A). Through biochemical and 
structural analysis, many studies have proposed a working model for hHR23 proteins, 
where high levels of hHR23 leads to protein stability and lower levels of hHR23 promote   
  
 
 
 
 
 
Figure 1.5: Model of HR23 regulation in proteasome degradation of proteins. 
A. In the first model, HR23 interacts with ubiquitylated substrates through its UBA 
domain and the UbL domain mediates its interaction with PSMD4 of the proteasome. 
This tertiary complex delivers ubiquitylated proteins to the proteasome for degradation. 
In this model, HR23 functions as a bridging factor to facilitate protein turnover. B. In a 
second proposed model, HR23 functions as a negative regulator of proteasome 
degradation. HR23 prevents the assembly of more than four ubiquitins on a substrate, 
which is crucial for the degradation of ubiquitylated proteins through the proteasome. 
Secondly, an excess amount of HR23 proteins binds to ubiquitylated proteins and the 
proteasome separately preventing the formation of a tertiary structure. Ub, ubiquitylation. 
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degradation of ubiquitylated substrates (Figure 1.5B) (Brignone et al., 2004; Chen and 
Madura, 2002; Fang et al., 2013; Glockzin et al., 2003; Kim et al., 2004; Ng et al., 2003). 
Following UV-induced DNA damage, hHR23 stabilizes XPC and recruits it to DNA 
damage site in the presence of DNA lesions (Baron et al., 2012; Kumar et al., 1999; Ng 
et al., 2003). In humans, cells lacking either of these proteins are sensitive to UV 
radiation and are at an increased risk of transformation to nonmelanoma skin carcinoma. 
Thus, hHR23 and XPC are necessary to prevent loss of DNA integrity and inhibit 
accumulation of mutations leading to cancer. The signals that sense the damaged DNA 
will initiate cell cycle checkpoint signaling pathways to allow repair to occur, and 
constitute cellular surveillance strategies to coordinate DNA repair and cell cycle 
transitions. 
1.6 Cell Cycle Regulation 
A somatic cell can move through two phases, the mitosis phase (M) and interphase, 
which includes three sub-phases: Gap phase 1, (G1), DNA synthesis (S), Gap phase 2, 
(G2) (Figure 1.6A). Both intrinsic and extrinsic factors control cell division (van den 
Heuvel, 2005). However, when G1 cells pass a restriction point (R1), they are committed 
to go through the cell cycle. Cells can exit the cell cycle and enter the G0 quiescent phase. 
Exposure to growth factors promotes entry into the G1 phase where cells prepare for 
DNA replication in S phase. During S phase, the DNA is duplicated before cell division 
and in G2 phase, the cell ensures proper intracellular signals prior to entering into M 
phase where cells are divided into two daughter cells (van den Heuvel, 2005). Each of 
these cycles is tightly regulated by cyclins and cyclin-dependent kinases (CDK) (Figure  
  
 
 
 
 
 
Figure 1.6: Cell cycle regulation by CDK-cyclin complexes. 
A. The cell cycle is divided into four phases: G1, S, G2, and M phase. Different CDK-
cyclin complexes regulate each of these phases. When cells are not prepared to progress 
through the cell cycle, cells enters the G0 quiescent phase. The CDK interacting 
protein/Kinase inhibitory protein (CIP/KIP) family of CDK inhibitors involved in 
suppressing the activity of CDK are shown. B. CDK-cyclin is regulated through 
phosphorylation and dephosphorylation by membrane-associated tyrosine- and threonine-
specific cdc2-inhibitory kinase (Myt1) and cell division cycle 25 (Cdc25) to form an 
inactive and active complex, respectively. The CDK-activating kinase (CAK) also 
phosphorylates CDK to form an active CDK-cyclin complex. P, phosphorylation. 
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1.6). CDK are serine/threonine protein kinases activated by association with cyclins. The 
CDK-cyclin complex is inactivated through association with cyclin kinase inhibitors 
(CKI) and phosphorylation of CDK by membrane-associated tyrosine- and threonine-
specific cdc2-inhibitory kinase (Myt1). The inhibitor effect is lifted off when CKI are 
ubiquitylated and targeted for degradation and dephosphorylation of CDK by cell 
division cycle (Cdc25) phosphatase (Figure 1.6B). In order to ensure proper cell cycle 
progression, there are multiple cyclins and CDK governing each phase of the cell cycle. 
During early G1 phase the CDK4 and CDK6 form a complex with cyclins D1, D2, and 
D3. During transition and progression through S phase, CDK2-cyclin E/A are activated 
and in G2/M phase, the CDK2/CDK1 and cyclins A/B are involved (Figure 1.6A). One of 
the main functions of the CDK-cyclin complex is to phosphorylate the retinoblastoma 
(Rb) proteins to activate transcription of E2F-dependent genes required for S phase 
transition. 
1.6.1 Retinoblastoma family proteins 
There are three family members of the Rb proteins: pRb, p107, and p130 (DeCaprio et 
al., 1988; Dyson et al., 1989; Hannon et al., 1993; Mayol et al., 1993). Mutations in the 
RB gene lead to retinoblastoma (Knudson et al., 1975) and other cancers, including 
osteosarcomas, breast cancer, and lung cancer (Ceccarelli et al., 1998; Kelley et al., 
1995; Toguchida et al., 1988). pRb is phosphorylated during late G1 phase of the cell 
cycle and regulates G1 to S phase transition (DeCaprio et al., 1988). All three Rb family 
members interact with E2F to inhibit its transcriptional activity. 
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The Rb family of proteins are often referred to as "pocket proteins" owing to their highly 
conserved carboxyl-domain that interacts with E2F called the pocket domain. The pocket 
domain is subdivided into the A and B domains separated by a spacer region. The p107 
and p130 have two B domains. Many mutations on Rb proteins are found on the pocket 
domain (Giacinti and Giordano, 2006). The Rb family of proteins also contain an N-
terminal and C-terminal domain, sixteen phosphorylation sites, and a highly conserved 
LXCXE binding cleft to interact with proteins containing an LXCXE motif, such as 
histone deacetylases (HDAC) (Dahiya et al., 2000; Rubin, 2013). Mutations on the 
LXCXE binding cleft do not prevent Rb proteins to bind E2F family proteins but inhibit 
Rb proteins from recruiting repressor complexes to promoters of E2F target genes 
(Dahiya et al., 2000). In addition to binding of E2F1 to the pocket domain of pRb, E2F1 
binds pRb on a second site located at the end of the C-terminus of pRb (Dick and Dyson, 
2003). This interaction is unique to E2F1 and prevents E2F1-induced apoptotic events 
(Julian et al., 2008). Following DNA damage, the interaction of E2F1 to the pRb unique 
site is lost but the interaction with the pocket domain is enhanced (Dick and Dyson, 2003; 
Inoue et al., 2007). This complex formation not only represses transcription of genes 
required for cell cycle progression, but also transcriptionally activates proapoptotic genes 
(Inoue et al., 2007). 
1.6.2 The E2F family of transcription factors 
The E2F family of transcription factors regulates many functions including: proliferation, 
apoptosis, differentiation, metabolism and DNA repair. In mammals, the E2F family is 
composed of E2F 1-8 and three dimerization partners (DP), DP1, -2 and -4 (Figure 1.7). 
E2F1 through -6 have a DNA binding domain, a leucine zipper, a marked box domain,  
  
 
 
 
 
Figure 1.7: The mammalian E2F family of a transcription factor.  
E2F family of transcription factors are comprised of ten members and three polypeptide 
DP1, -2, and -4 to form a heterodimer. E2F family members share several homologous 
regions including the DNA binding domain and a dimerization domain. E2F1 through -3 
have a nuclear localization sequence and a CDK-cyclin binding domain in the N-
terminus; and a transcriptional activation domain and Rb proteins binding site 
(specifically interacts with pRb, p107 or p130) at the C-terminus. E2F4 and -5 lack a 
CDK-cyclin binding sequence but still contain a pocket protein binding domain 
(preferentially interact with the other Rb family proteins, p107 and p130). E2F4 and -5 
are exported out of the nucleus via their nuclear export signal. E2F6 shares only the DNA 
binding domain and the dimerization domain with the other E2F family members. Both 
E2F7 and -8 contain two conserved DNA binding domains allowing it to form 
heterodimer without DP proteins. E2F6 through -8 lack pRb-binding and a transcriptional 
activation domain. DP1, -2, and -4 proteins lack transcriptional activation domains and 
pRb-binding regions. 
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and a dimerization domain which associates with DP proteins to form a functional 
heterodimer complex. In E2F1, the marked box domain interacts with c-Jun activation 
domain-binding protein 1 (Jab1) to enhance E2F1-induced apoptosis and not proliferation 
(Hallstrom and Nevins, 2006).  E2F1 through -5 have a transactivation domain and an Rb 
protein-binding region. Rb family proteins can modulate the transcriptional activity of 
E2F proteins. E2F1 through -3 associate specifically with pRb, E2F4 preferentially 
interacts with p107 or p130 and E2F5 binds p130 (Beijersbergen et al., 1994; Hijmans et 
al., 1995; Ivey-Hoyle et al., 1993; Lees et al., 1993; Shan et al., 1992). The interaction 
between E2F and Rb family proteins represses the transcriptional activity of E2F1 
through -5 (Figure 1.8). E2F6 does not have a transactivation domain or an Rb-binding 
region. E2F1 through -3 are structurally similar and have a cyclin A-binding domain, 
which is not present on E2F4 and -5. E2F7 and -8 have two DNA binding domains but 
lack a dimerization domain. Thus, they are not dependent on DP proteins for functional 
activity. E2F7 and -8 can interact with each other to form homodimer complexes (Li et 
al., 2008).  
Binding of E2F family of proteins to hypophosphorylated Rb family proteins recruits 
histone deacetylases and DNA methyltransferases, such as HDAC1, suppressor of 
variegation 3-9 homolog 1 (Suv39H1) and SWItch/Sucrose Non-Fermentable (SWI/SNF) 
(Figure 1.8). This complex functions to inhibit transcription of E2F-responsive genes 
(Magnaghi-Jaulin et al., 1998; Nagl et al., 2007; Vandel et al., 2001). In an actively 
proliferating cell, Rb family proteins are sequentially phosphorylated by CDK4/6-cyclin 
D and CDK2-cyclin E complexes resulting in dissociation from E2F, rendering E2F 
activators transcriptionally active to target genes required for G1/S phase progression   
  
 
 
 
 
 
Figure 1.8: Cell cycle regulation of E2F family of transcription factors. 
The activity of different E2F-DP-Rb protein complexes during each phase of the cell 
cycle are shown. E2F1 through -3 function as activators during late G1 to initiation S 
phase progression and G2 phase to promote activation of genes required for mitosis. E2F6 
through -8 are involved in repressing E2F-target genes during S phase. E2F1 through -5 
are involved in repressing E2F-dependent transcription during cell cycle arrest (G0 
phase). pRb is preferentially phosphorylated by CDK4/6-cyclin D during late G1 phase 
which leads to subsequent phosphorylation at multiple sites on pRb by CDK2-Cyclin E 
causing full inactivation of pRb and dissociation with E2F1 through -3 to promote G1 to 
S phase transition. P, phosphorylation. 
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(Ezhevsky et al., 1997; Lundberg and Weinberg, 1998). The E2F family members 
function as both transcriptional repressors and activators, depending on cellular context. 
E2F1 through -3 can switch from being transcriptional activators in proliferating cells to 
repressors in cells committed to differentiate and in response to DNA damage (Chong et 
al., 2009a; Ianari et al., 2009). 
The best-characterized function of E2F1 through -3 is the activation of gene transcription 
to promote G1/S phase transition leading to proper cellular proliferation (Wu et al., 2001). 
Constitutive expression of E2F1 through -3 induce S phase entry of quiescent cells and 
triple knockout lead to defects in proliferation and increased cell death (Chong et al., 
2009a; Johnson et al., 1993; Wu et al., 2001). During G2 phase, E2F1 through -3 activate 
transcription of genes required for G2/M progression (Zhu et al., 2004). The E2F3 locus 
encodes two gene products, E2f3a and E2f3b, through the use of alternate promoters. 
While E2F3a expression is highest during S phase, E2F3b is expressed constitutively 
throughout the cell cycle (Leone et al., 2000). Both E2F3 isoforms can function as 
activators or repressors of E2F target genes (Chong et al., 2009b).  
E2F4 and -5 function as transcriptional repressors by forming a complex with p107 or 
p130, which recruits chromatin remodeling proteins to repress E2F target genes and 
prevent G1/S phase transition (Takahashi et al., 2000). E2F6 acts as a transcriptional 
repressor to inactivate E2F-responsive genes and inhibit S phase entry by forming a 
repressor complex with enhancer of polycomb (Attwooll et al., 2005; Cartwright et al., 
1998; Trimarchi et al., 1998). E2F7 and -8 delay cell cycle progression during S phase 
functioning as transcriptional repressors (Logan et al., 2005). E2F7 and -8 repress the 
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expression of E2F1 and their expression is dependent on E2F1 (Moon and Dyson, 2008). 
This negative feedback loop serves to maintain E2F1 balance during cell cycle 
progression. 
1.7 Other functions of E2F factors 
Inactivation of E2f genes in mice has demonstrated the existence of multiple roles for 
these proteins. They include tumour formation in mice lacking the E2f1, E2f2 or E2f3 
gene (Olson et al., 2007; Paulson et al., 2006; Scheijen et al., 2004), fetal erythrocyte 
maturation defects in mice lacking the E2f4 gene (Kinross et al., 2006), prenatally lethal 
hydrocephalus upon inactivation of the E2f5 gene (Lindeman et al., 1998), and 
embryonic lethality with widespread apoptosis, vascular dilation and hemorrhage upon 
joint inactivation of the E2f7 and E2f8 genes (Li et al., 2008).  
1.7.1 Role of E2F in apoptosis 
E2F1 through -6 play a role in activating apoptotic events in cultured cells and transgenic 
mouse models (Chang et al., 2000; Chen et al., 2013; Johnson and Degregori, 2006; 
Martinez et al., 2010; Yang et al., 2007). The involvement of E2F1 in activating 
apoptosis has been extensively studied. Expression of E2F1 induces p53-dependent and -
independent apoptosis. E2F1 increases p53 expression levels by transcriptionally 
activating the p14ARF gene. The p14ARF protein negatively regulates mouse double 
minute 2 homolog (Mdm2), an E3 ubiquitin ligase, essential for ubiquitylating p53 and 
targeting it for degradation. Deregulated Mdm2 stabilizes p53 protein levels followed by 
activation of genes required for apoptosis, such as TAp73, Fas, Bax, and Noxa (Haupt et 
al., 2003). E2F1 also stimulates expression of ataxia-telangiectasia mutated (ATM), 
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checkpoint kinase 1 (Chk1), and Chk2, which leads to p53 phosphorylation and 
stabilization. Moreover, E2F1 up regulates transcription of several p53 co-factors, 
including Aspp1, Aspp2, Jmy, and TP53inp, which are essential for induction of the pro-
apoptotic p53 target gene, Bax.  
E2F1 can also stimulate apoptosis by inducing TAp73 expression (Wu et al., 2008). 
Similarly, E2F1 is found on the promoter of genes important for the apoptotic pathway, 
such as the Bcl-2 family of proteins, apoptotic protease-activating factor 1 (Apaf1), 
caspase 3, and caspase 7 (Moroni et al., 2001; Wu et al., 2009). E2F1 is also involved in 
transcriptionally inactivating genes important for cell survival, by disrupting the NF-κB 
signaling pathway through down regulation of TNF receptor-associated factor 2 (TRAF2) 
(Ginsberg, 2002).  
1.7.2 Role of E2F in DNA damage 
E2F1 up regulates expression of genes required for the initiation of the DNA damage 
response (Polager et al., 2002). Some of these genes function in the mismatch repair 
pathway, such as DNA mismatch repair protein 2 (MSH2), MSH6, mismatch repair 
endonuclease (PMS2). Others include uracil-DNA glycosylase (UNG), flag structure-
specific endonuclease (Fen1), and PCNA, which participate in the base excision repair 
(BER) pathway. E2F1 also induces the expression of genes involved in the NER 
pathway, such as DDB2/XPE (Prost et al., 2007), and XPC (Lin et al., 2009). By acting 
as a transcriptional repressor, E2F1 forms a complex with pRb, C-terminus-binding 
protein (CtBP), and CtBP interacting protein (CtIP) corepressor to mediate transcriptional 
inactivation of zinc finger and BRCA1-interacting protein with a KRAB domain 1 
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(ZBRK1) (Liao et al., 2010). ZBRK1 negatively regulates growth arrest and DNA-
damage-inducible alpha (GADD45A), an important DNA repair response protein that 
functions to stimulate cell cycle arrest following DNA damage (Zheng et al., 2000).  
Treatment with DNA damaging agents including UV or ionizing radiation, actinomycin 
D, adriamycin, neocarzinostatin or etoposide increases E2F1 through -3 transcript and 
protein levels (Castillo et al., 2015; Hofferer et al., 1999; Martinez et al., 2010; Meng et 
al., 1999). Both transcriptional and post-translational modifications are required for the 
induction of E2F1 through -3 in response to DNA damage. E2F1 and E2F3 are 
phosphorylated at Ser364 and Ser124, respectively by Chk1/2 to activate transcription of 
pro-apoptotic genes, such as TAp73 and Apaf1 (Martinez et al., 2010; Pediconi et al., 
2003; Stevens et al., 2003). E2F1 is also phosphorylated at Ser31 by ATM and/or ataxia 
telangiectasia and Rad3-related (ATR) proteins following drug-induced DNA damage 
(Lin et al., 2001). This leads to E2F1 stabilization and transcriptional activation of TAp73 
and Apaf1. This residue is also necessary for E2F1's interaction with DNA topoisomerase 
IIβ-binding protein I (TopBP1) to repress transcriptional activity of E2F1 by recruiting 
Brahma (BRM) and Brahma-related gene 1 (BRG1), subunits of the SWI/SNF 
chromatin-remodeling complex and to activate replication checkpoint surveillance 
following DNA damage (Liu et al., 2003; Liu et al., 2004). UV-induced DNA damage 
also phosphorylates E2F1, however under these circumstances, phosphorylation at Ser31 
facilitates E2F1 recruitment to sites of UV-induced DNA damage or DNA double strand 
breaks (DSB). Ser31 of E2F1 is also required for the recruitment of XPA, XPC, GCN5, 
and accumulation of H3K9 acetylation at sites of UV-induced DNA damage but is 
dispensable for E2F-dependent transcriptional activity and induction of apoptosis 
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(Biswas et al., 2014; Guo et al., 2011; Guo et al., 2010). Therefore, the stabilization of 
E2F1 through phosphorylation at Ser31 could either increase its transcriptional activity or 
promote non-transcriptional functions of E2F1 (Biswas and Johnson, 2012).  
1.8 Mechanisms of E2F1 Regulation 
1.8.1 Post-translational modifications 
E2F1 can be modified by acetylation, citrullination, methylation, neddylation, 
ubiquitylation, and phosphorylation (Figure 1.9). E2F1 can be acetylated at Lys117, 
Lys120, and Lys125 by the p300/CREB-binding protein (CBP) or by p300/CBP-
associated factor (P/CAF) acetyltransferase (Martinez-Balbas et al., 2000; Marzio et al., 
2000). Acetylation of E2F1 allows for stabilization and increase in transcriptional 
activation of E2F1 target genes (Farhana et al., 2002; Martinez-Balbas et al., 2000). 
Ectopic expression of P/CAF or p300/CBP increases E2F1 ubiquitylation and it is 
dependent on Lys117, Lys120, and Lys125 following DNA damage (Galbiati et al., 
2005). This could indicate that DNA damaging signals may prevent ubiquitylated E2F1 
to be targeted for degradation through the proteasomal pathway (Galbiati et al., 2005). 
Acetylation of E2F1 also promotes its interaction with bromodomain-containing protein 4 
(BRD4). This interaction is dependent on E2F1 citrullination at Arg109, Arg111, 
Arg113, and Arg127 by protein arginine deiminases 4 (PDA4) and enhances E2F1 
binding to the promoter region of inflammatory genes tumor necrosis factor–α (TNFα) 
and interleukin-1β (IL-1β) (Ghari et al., 2016).  
Methylation of E2F1 can occur at Lys185 by histone-lysine N-methyltransferase 
(SETD7), and demethylated by lysine-specific histone demethylase 1A (KDM1A) in  
  
 
 
 
 
 
 
 
Figure 1.9: Post-translational modifications on E2F1. 
The protein kinases involved in modifying the residues on E2F1 is shown. Ac, 
acetylation; Ci, citrullination; Me, methylation; NE, NEDDylation; P, phosphorylation. 
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vitro and in cultured cells (Kontaki and Talianidis, 2010; Xie et al., 2011a). 
Demethylation stabilizes E2F1 and up regulates the transcription of TAp73 in response to 
DNA damage. Importantly, methylation of E2F1 impairs its acetylation and 
phosphorylation at Ser364, targeting E2F1 for ubiquitylation and degradation (Kontaki 
and Talianidis, 2010). Methylation of E2F1 at Lys185 promotes E2F1 neddylation (also 
at Lys185) and subsequent down regulation of E2F1 transcriptional activity and increases 
turnover of E2F1 (Loftus et al., 2012). E2F1 can also be methylated at arginine residues. 
Asymmetric arginine methylation of E2F1 at Arg109 by protein arginine 
methyltransferase 1 (PRMT1) stabilizes E2F1 and symmetric arginine methylation at 
Arg111 and Arg113 by PRMT5 promotes E2F1 ubiquitylation and degradation (Cho et 
al., 2012; Zheng et al., 2013). In response to DNA damage, the interaction between E2F1 
and PRMT1 is enhanced with concomitant increase in asymmetric arginine methylation 
and this prevents PRMT5 binding and symmetric arginine methylation of E2F1. 
Together, the E2F1-PRMT1 complex favors E2F1-induced apoptosis. On the other hand, 
when E2F1 is methylated by PRMT5, the binding of E2F1 with PRMT1 is inhibited and 
cell proliferation is stimulated (Zheng et al., 2013). 
 E2F1 regulation can also be controlled through ubiquitylation. Targeting of E2F1 for 
ubiquitylation can occur through the C-terminal activation domain. The physical 
association between pRb and E2F1 stabilizes E2F1 by protecting it from ubiquitylation 
(Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996). At the 
S/G2 boundary, E2F1 is regulated through ubiquitylation by S-phase kinase-associated 
protein-2 (Skp2), the F-box protein of the Skp1–Cullin–F-box protein (SCF) E3 ubiquitin 
ligase complex (Marti et al., 1999). Skp2 functions as a substrate recognition component 
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to specifically recognize phosphorylated substrates resulting in subsequent ubiquitylation 
and proteasomal degradation of the targeted protein (Tsvetkov et al., 1999). E2F1 
interaction with 14-3-3τ (Wang et al., 2004) or Mdm2 (Zhang et al., 2005) displace Skp2 
from E2F1 thereby inhibiting E2F1 ubiquitylation and degradation. Both 14-3-3τ and 
Mdm2 enhance E2F1 transcriptional activity (Martin et al., 1995; Wang et al., 2004). 
During mitosis, the interaction between E2F1 and activator cell division cycle20 (Cdc20) 
of the anaphase-promoting complex/cyclosome (APC/C) complex regulates E2F1 
stability (Budhavarapu et al., 2012). Cdc20 homolog 1 (Cdh1), another activator subunit 
of the APC/C complex that preferentially interacts with destruction box (D-box) of 
substrates (Qin et al., 2016), specifically forms K11-linked polyubiquitin chains on E2F1 
to target it for degradation during late S phase (Budhavarapu et al., 2012) However, DNA 
damage does not prevent Cdh1 from ubiquitylating E2F1, but rather inhibits its 
degradation. E2F1 can also be ubiquitylated in vitro by the multi-subunit Cullin (CUL)-
RING E3 ligase (CRL) independent of Skp2 and phosphorylation of E2F1 (Ohta and 
Xiong, 2001). The presence of multiple E3 ligases that interact with and mediate 
degradation of E2F1 enables orderly control of E2F1 expression under different 
circumstances.  
E2F1 can also be de-ubiquitylated by deubiquitylase 26S proteasome non-ATPase 
regulatory subunit 14 (PSMD14) and Ubiquitin carboxyl-terminal hydrolase isozyme L5 
(UCHL5). PSMD14 stabilizes E2F1 by cleaving K11- and K63- linked polyubiquitin 
chains, which lead to increased expression of E2F1-induced pro-survival genes (Wang et 
al., 2015). UCHL5 is not involved in the stability of E2F1 but the cleavage of K63-linked 
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polyubiquitin chains lead to enhanced E2F1 transcriptional activity following DNA 
damage (Mahanic et al., 2015).  
E2F1 is phosphorylated at multiple sites at the N- and C-terminus in vitro and in vivo by 
a number of kinases, and most of these phosphorylation sites are conserved between 
human and mouse orthologues. E2F1 phosphorylation at Ser332 and Ser337 residues by 
CDK4-cyclin D attenuates E2F1-pRb association and phosphorylation of these residues 
indirectly regulates E2F1 ubiquitylation (Fagan et al., 1994). E2F1 is also phosphorylated 
by CDK2-cyclin A on Ser375 and reduces DNA binding (Dynlacht et al., 1994; Krek et 
al., 1995; Xu et al., 1994). During S phase, E2F1 is also phosphorylated at Ser403 and 
Thr433 by TFIIH-CDK7, which targets E2F1 for degradation (Vandel and Kouzarides, 
1999). Disruption of the cyclin A binding domain or the TFIIH-CDK7 binding domain of 
E2F1 increases its stability and can lead to apoptosis, emphasizing the importance of tight 
regulation of E2F1 by both CDK2-cyclin A and TFIIH kinases (Krek et al., 1995; Vandel 
and Kouzarides, 1999). The Ser403 and Thr433 of E2F1 are also phosphorylated in vitro 
by p38β-MAPK. Activation of p38β-MAPK triggers E2F1 nuclear export and 
degradation allowing for proper keratinocyte differentiation (Ivanova et al., 2009).  
As mentioned earlier, E2F1 is phosphorylated at Ser31 and Ser364 residues by ATM and 
Chk1/2, respectively, in response to DNA damage, and phosphorylation mediates E2F1 
stabilization (Lin et al., 2001; Stevens et al., 2003). The Ser31 of E2F1 resides within the 
Skp2 binding domain and has been suggested to modulate E2F1 degradation by inhibiting 
Skp2 binding. It also mediates interactions with 14-3-3τ, which interfere with 
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ubiquitylation (Wang et al., 2004). Phosphorylation of E2F1 at Ser364 increases E2F1 
transcriptional activity (Stevens et al., 2003).  
1.8.2 E2F1 subcellular localization 
E2F regulation can also be modulated by its subcellular localization (Verona et al., 1997). 
The N-terminal domain of E2F1 through -3 has a nuclear localization signal (NLS) 
(Muller et al., 1997). Differentiation leads to E2F1 nuclear export and degradation in 
keratinocytes (Ivanova and Dagnino, 2007). E2F1 has a nuclear export sequence (NES), 
which allows chromosomal maintenance-1 (CRM1)-dependent export and is involved in 
nucleocytoplasmic shuttling in a variety of cells (Ivanova et al., 2007). Conversely, E2F4 
and -5 are expressed predominantly in the cytoplasm owing to the presence of NES 
(Magae et al., 1996). Both E2F4 and -5 are localized to the nucleus through their 
interactions with DP or p107/p130. However, the N-terminus of E2F5 has an intrinsic 
nuclear localization signal, which is required for its nuclear import independent of 
interactions with DP or p130 (Apostolova et al., 2002). 
1.8.3 Protein-protein interactions 
In addition to pRb and DP factors, E2F1 associates with other proteins. E2F1 interactions 
with transcription intermediary factor 1-β (TRIM28) (Wang et al., 2007), MDM4 
(Strachan et al., 2003), and neural proliferation differentiation and control protein 1 
(NPDC1) (Sansal et al., 2000) reduces DNA binding and hence E2F1 transcriptional 
activity. On the other hand, E2F1 binding with poly [ADP-ribose] polymerase 1 (PARP1) 
(Simbulan-Rosenthal et al., 2003), host cell factor 1 (HCF1) (Tyagi et al., 2007), and 
chromodomain-helicase-DNA-binding protein 8 (CHD8) (Subtil-Rodriguez et al., 2014)  
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promotes cell cycle progression by recruiting chromatin remodeling proteins to E2F1 
target promoter regions. 
1.9 The role of E2F in the epidermis 
The E2F family of transcription factors modulate many cellular processes involved in 
epidermal homeostasis, including cell proliferation, apoptosis, differentiation, DNA 
replication, DNA damage response and DNA repair (Dicker et al., 2000; Hong et al., 
2008; Ivanova et al., 2009; Stevens and La Thangue, 2004; Wang et al., 2004).  One of 
the events that contribute to the abnormal regulation of proliferation and differentiation is 
the disruption of the pRb/E2F pathway, which is common in most cancers, including 
NMSC (Ebihara et al., 2004; Yamazaki et al., 2005).  
The members of the E2F family of transcription factors are differentially expressed in the 
epidermis. The E2f1 through -4 transcripts are expressed in the basal layer, whereas E2f5 
transcripts are abundant in the suprabasal layers (Dagnino et al., 1997). Moreover, the 
expression levels of E2F1 through -3 decrease following keratinocyte differentiation, 
with an increase in E2F5 protein levels (D'Souza et al., 2001; Wong et al., 2003). 
E2F1 maintain normal proliferation in undifferentiated keratinocytes and modulates 
keratinocyte differentiation (Ivanova et al., 2009; Wong et al., 2003). In undifferentiated 
keratinocytes E2F1 localizes to the nucleus, but differentiation induces E2F1 export to 
the cytoplasm, where it is degraded through the proteasomal pathway. The signaling 
pathways involved in E2F1 turnover during Ca2+-induced keratinocyte differentiation 
involve the activation of PKCη and PKCδ. PKCη and PKCδ subsequently activate p38β, 
which appears to phosphorylate E2F1 at Ser403 and Thr433 (Figure 1.10). E2F1 nuclear  
  
 
 
 
 
 
Figure 1.10: Regulation and signaling pathway of E2F1 in differentiated 
keratinocytes. 
In keratinocytes, E2F1 shuttles between the nucleus and cytoplasm. Upon keratinocyte 
differentiation through external stimuli, such as Ca2+, it triggers signaling events that lead 
to activation of protein kinase C eta and delta which phosphorylates p38β. p38β appears 
to phosphorylate E2F1 at Ser403 and Thr433. This leads to E2F1 nuclear export through 
the chromosome region maintenance 1 (CRM1)-nuclear protein export pathway with 
concurrent ubiquitylation of E2F1 and degradation through the proteasomal pathway. The 
sequence of events involving E2F1 phosphorylation, ubiquitylation, nuclear export, and 
subsequent degradation are required for proper keratinocyte differentiation. Ub, 
ubiquitylation; P, phosphorylation. 
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export is dependent on chromosome region maintenance 1 (CRM1) and requires E2F1 
Ser403 and Thr433. When differentiated keratinocytes are exposed to a specific inhibitor 
of CRM1-nuclear export,leptomycin B (LMB), E2F1 accumulates in the nucleus and is 
stable. Further, forced nuclear retention by engineering an additional NLS protects E2F1 
from degradation. This indicates that E2F1 nuclear export is required for its proteasomal 
degradation during keratinocyte differentiation. The sequence of events involving E2F1 
phosphorylation, ubiquitylation, nuclear export, and subsequent degradation are therefore 
required for proper keratinocyte differentiation. In cultured keratinocytes, substitution of 
Ser403 and Thr433 to Ala (hereafter termed ST/A) generated a mutant protein defective 
in nuclear export, and more stable than wild-type E2F1 following Ca2+-induced 
keratinocyte differentiation. Exogenous expression of the ST/A in cultured keratinocytes 
caused defects in differentiation (Ivanova et al., 2009). Abnormal increases in E2F1 
expression and activity can lead to epidermal tumor formation by inducing proliferation-
specific genes and suppressing squamous differentiation-specific genes (Dicker et al., 
2000). Constitutive expression of E2F1 in basal keratinocytes results in hyperkeratosis 
and contributes to tumor development (Pierce et al., 1998b). Inactivation of the E2f1 gene 
results in impaired keratinocyte migration, proliferation and significant delay in wound 
healing (D'Souza et al., 2002).  
1.10 Rationale and Aims of this Study 
The E2F1 transcription factor regulates expression of key genes involved in cell cycle 
progression and cell survival. The levels of E2F1 are tightly regulated during the cell 
cycle, when keratinocytes and other cells differentiate, as well as in response to DNA 
damage. Despite the fact that the regulation of E2F1 has been extensively studied, major 
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questions remain to be addressed. First, E2F1 is necessary for recruitment of XPC to 
damaged sites, however the recognition of DNA damage by XPC is dependent on 
hHR23. This begs the question: does E2F1 co-operate with hHR23 to recruit XPC and 
subsequent recruitment of XPA to DNA damage sites? Second, E2F1 degradation is 
necessary for proper keratinocyte differentiation. E2F1 Ser403 and Thr433 are required 
for its degradation, but whether other sites on E2F1 are necessary for proper keratinocyte 
differentiation is not known. Third, it is currently unclear whether mechanisms that 
regulate E2F1 stability during cell cycle progression also regulate E2F1 stability 
following DNA damage or differentiation. The objective of this study is to further 
understand the regulation of E2F1 in epidermal keratinocytes. I hypothesize that the 
regulation of E2F1 protein turnover plays a critical role during epidermal keratinocyte 
DNA repair and differentiation. To test the hypothesis, I addressed the following aims: 
Specific Aims: 
1) Characterize the role of E2F1 and hHR23 following UV-induced DNA damage in 
keratinocytes. 
2) Identify residues essential for E2F1 stability following drug-induced DNA damage in 
keratinocytes. 
3) Investigate the mechanisms of E2F1 degradation following keratinocyte 
differentiation. 
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Chapter 2  
2 Materials and Methods 
2.1 Reagents and materials 
The materials used in this study are listed in Table 2.1. The reagents and, where 
applicable, the concentrations used in this study are listed in Table 2.2. The composition 
of routinely used solutions and the final concentrations of each reagent are presented in 
Table 2.3.  
Table 2.1: List of materials and catalogue numbers. 
Materials Source Catalogue number 
3-µm pore polycarbonate 
membrane EMD Millipore, Billerica, MA TSTP02500 
8×10 inch Blue Ray Film Endoch Inc. Concord, ON, CA 810UPB 
Amicon Ultra-15 columns EMD Millipore, Billerica, MA UFC903024 
Amersham Hybond-N+ Nylon 
membrane 
GE Healthcare, Mississauga, 
ON RPN203B 
Falcon® 70 µm cell strainers Corning Incorporated, Corning, NY 352350 
Grade 703 Blotting paper VWR International, Radnor, PA 28298-020 
PD10 desalting column GE Healthcare, Mississauga, ON 17-0851-01 
Poly-L-lysine-coated glass 
coverslips 12 mm 
Neuvitro Corporation, 
Vancouver, WA NEU-GG-12-PLL 
Immu-mount mounting media Thermo Scientific, Waltham, MA 9990402 
Polyvinylidene difluoride 
membranes (PVDF) EMD Millipore, Billerica, MA IPVH00010 
Ultra Cruz autoradiography film Santa Cruz Biotechnology, Santa Cruz, CA SC-201697 
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Table 2.2: Reagents, the catalogue number, and the final concentration used. 
Reagents Source Catalogue Number Concentration 
0.25% trypsin with 
ethylenediaminetetraacetic 
acid (EDTA) 
Gibco, Burlington, 
ON 25200-056 0.25% 
2.5% Trypsin Gibco, Burlington, ON 15090-046 0.25% 
Agar BioShop, Burlington, ON AGR001 1.5% 
Albumin, Bovine Serum 
(BSA) 
BioShop, 
Burlington, ON ALB001 2% 
Amersham ECL Prime 
Western Blotting detection 
reagent 
GE Healthcare, 
Mississauga, ON RPN2232 N/A 
Aprotinin BioShop, Burlington, ON APR200 1 µg/ml 
Betaine Sigma, St Louis, MO B2629 1 M 
Bradford protein 
quantification solution 
Bio-Rad, 
Mississauga, ON 500-0006 20% 
Ca2+-free Eagle’s 
minimum essential 
medium (EMEM) 
Lonza, 
Walkersville, MD 06-174G N/A 
Chelex 100 resin (100-200 
dry mesh size, 150–300 
µm wet bead size) 
Bio-Rad, 
Mississauga, ON 1422832 80 mg/ml 
Cholera toxin Sigma, St. Louis, MO C8052 9.5 ng/ml 
Cycloheximide (CHX) Sigma, St Louis, MO C7698 100 µg/ml 
Dimethyl sulfoxide 
(DMSO) 
Caledon Labs Ltd. 
Georgetown, ON 
4100-1 N/A 
Dispase II Roche Diagnostics, Indianapolis, IN 4942078001 8 mg/ml 
Epidermal growth factor 
(EGF) 
Sigma, St Louis, 
MO E4127 5 ng/ml 
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FBS for keratinocytes Thermo Scientific, Waltham, MA 12483-020 8% 
Fetal bovine serum (FBS) Gibco, Burlington, ON 12483 4% 
Etoposide Sigma, St Louis, MO E1383 150 µM 
Glutathione Sepharose™ 
4B 
GE Healthcare, 
Mississauga, ON 17-0756-01 50% 
Hoechst 33342 Thermo Scientific, Waltham, MA H1399 1 µg/ml 
Hydrocortisone Sigma, St. Louis, MO H4001 74 ng/ml 
HyQ-Dulbecco’s Modified 
Eagle Medium-Reduced 
Serum (HyQ-DMEM-RS) 
Thermo Scientific, 
Waltham, MA SH3056501 N/A 
Imidazole Thermo Scientific, Waltham, MA 03196-500 Varies 
Insulin Sigma, St. Louis, MO H4001 
5 µg/ml, pH 
3.0 
Isopropyl β-D-1-
thiogalactopyranoside 
(IPTG) 
BioShop, 
Burlington, ON 
 
IPT001.5 
0.5 mM 
Leptomycin B (LMB) Enzo life sciences, Plymouth, PA ALX-380-100 5 ng/ml 
Leupeptin BioShop, Burlington, ON LEU001 1 µg/ml 
L-Glutathione reduced Sigma, St. Louis, MO G4251 10 mM 
Lipofectamine 2000 
Transfection Reagent  
 Thermo Scientific, 
Waltham, MA 11668029 15 µg 
N-ethylmaleimide (NEM) Sigma, St. Louis, MO E3876 10 mM 
Ni-NTA agarose slurry Qiagen, Louisville, KY 30210 50% 
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Paraformaldehyde (PFA) Thermo Scientific, Waltham, MA AC416780030 4% 
Penicillin-Streptomycin, 
100× liquid 
Gibco, Burlington, 
ON 15140-122 
100 U/ml, 
(Pen) 100 
µg/ml (Strep) 
Pepstatin A BioShop, Burlington, ON PEP605 1 µg/ml 
Phenylmethylsulfonyl- 
fluoride (PMSF) 
BioShop, 
Burlington, ON PMS123 1 mM 
Pierce protein A/G 
magnetic beads 
Thermo Scientific, 
Waltham, MA 88803 
400 µg or       
250 µg 
Polyethylenimine (PEI, 25 
kDa linear) 
Polysciences, 
Warrington, PA 23966 
1 mg/ml,      
pH 5.0 (Stock) 
Poly-L-lysine 
hydrobromide 
Sigma, St. Louis, 
MO A00013 1 mg/ml 
Rat tail collagen type I BD Biosciences, Bedford, MA 354236 20 µg/cm
2 
SimpleBlue™ Safe Stain Thermo Scientific, Waltham, MA LC6060 100% 
Sodium Pyrophosphate 
tetrabasic decahydrate 
(Na₄P₂O₇·10H2O) 
Sigma, St. Louis, 
MO S9515 10 mM 
Sodium Azide (NaN3) 
BDH Inc. Dubai, 
UAE B30111 10 mM 
Sodium Deoxycholate Sigma, St. Louis, MO D6750 0.5% 
Sodium Fluoride (NaF) Sigma, St. Louis, MO S-6521 10 mM 
Sodium Orthovanadate 
(Na₃VO₄) 
BioShop, 
Burlington, ON SOV664-10 1.2 mM 
Triiodothyronine (T3) Sigma, St. Louis, MO T6397 6.7 ng/ml 
Z-Leu-Leu-Leu-al (MG-
132) 
Sigma, St. Louis, 
MO C2211 10 µM 
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Table 2.3: Composition of routinely used solutions and media. 
Name Composition 
1× Sodium dodecyl sulfate 
(SDS) 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
1× Laemmli loading buffer 50 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol, 100 mM DTT 
1× Phosphate Buffered 
Saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KaH2PO4, pH 7.4 
1× Tris-acetate-EDTA (TAE) 40 mM Tris, 5 mM NaAc, 1 mM EDTA, 20 mM HAc 
1× Tris-Buffered Saline 
(TBS) 25 mM Tris-HCl, 137 mM NaCl, 5 mM KCl, pH 7.4 
1× Tris-Glycine Transfer 
Buffer 39.2 mM glycine, 48.1 mM Tris, 20% (v/v) methanol 
2× Yeast extract and 
Tryptone (2× YT) broth 
2% (w/v) bacto-tryptone, 1% (w/v) yeast extract, 85 
mM NaCl2, 17 mM MgSO4 
Guanidine hydrochloride-
based (GnHCl) stripping 
solution 
6 M GnHCl, 0.2% (v/v) Nonidet P-40 (NP-40), 20 mM 
Tris-HCl pH 7.5 
Luria Bertani (LB) Broth 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl2 
Low pH stripping buffer 25 mM glycine pH 2.0, 1% (w/v) SDS 
LB Agar LB + 1.5% (w/v) Agar 
Modified 
radioimmunoprecipitation 
assay (RIPA) Buffer 
50 mM Tris-HCl pH 7.4, 150 mM  NaCl, 0.1% (v/v) 
NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) 
SDS, 1 µg/ml aprotinin, leupeptin, pepstatin A, 1 mM 
PMSF, 10 mM sodium pyrophosphate, 10 mM sodium 
fluoride, 1.2 mM sodium orthovanadate 
Mouse tonicity phosphate-
buffered saline (MTPBS) 150 mM NaCl, 4 mM NaH2PO4, 16 mM Na2HPO4 
Super Optimal Broth (SOB) 
medium 
2% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 
TBST TBS, 0.1% (v/v) Tween-20 
Transformation buffer (TB) 
solution 
10 mM PIPES, 15 mM CaCl2, 250 mM KCl, adjust to 
pH 6.7 with KOH, then add MnCl2 (final concentration, 
55mM) 
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2.2 Antibodies, enzymes and kits 
The antibodies used in the study are listed in Table 2.4. Table 2.5 shows the list of 
restriction endonucleases, DNA polymerases, and other modifying enzymes. Table 2.6 
shows the list of commercially available kits used in this study. For immunoblotting, 
primary antibodies were diluted in TBST unless stated otherwise, and secondary 
antibodies were diluted in TBST containing 5% (w/v) non-fat milk. For 
immunofluorescence microscopy, primary antibodies were diluted in PBS containing 5% 
(v/v) goat serum, and secondary antibodies were diluted in PBS containing 1% (w/v) 
non-fat milk and 5% (v/v) goat serum. 
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Table 2.4: Antibodies and dilutions used. 
Antibodies Source Catalogue Number Dilution*  
Primary antibodies    
Anti-FZR1 [DH01 (DCS-
266)]  
Abcam, Cambridge, 
UK ab3242 IB: 1:2500 
Anti-c-Myc (9E10) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
SC-40 IB:1:1000 
Anti-CPD (Clone TMD-2) CosmoBio Co. Tokyo, Japan NMDND001 
IB: 1:5000 
IF: 1:1000 
Anti-dsDNA Abcam, Cambridge, UK Ab27156 IB: 1:1000 
Anti-E2F1 
OriGene 
Technologies, 
Rockville, MD 
TA308764 IB: 1:1000  IP: 3 µg 
Anti-E2F1 (C-20) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
SC-193 IB: 1:500 
Anti-FLAG (Rabbit) Sigma, St. Louis, MO F7425 IP: 3 µg 
Anti-FLAG M2 Sigma, St. Louis, MO F1804 IB: 1:5000 
Anti-GAPDH Assay Designs, Ann Arbor, MI CSA-335 IB: 1:10 000 
Anti-HA (Y-11) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
SC-805 
IB: 1:5000 
IP: 3 µg     
IF: 1:1000 
Anti-Lamin A/C Cell Signaling, Danvers, MA 2032S IB: 1:2500 
Anti-Rad23A (D-6) 
Santa Cruz 
Biotechnology, 
Santa Cruz, CA 
SC-365669 IB: 1:1000 
Anti-V5 (Chicken) Abcam, Cambridge, UK Ab9113 IF: 1:1000 
Anti-V5 (Mouse) Thermo Scientific, Waltham, MA R960-25 
IB: 1:5000 
IP: 3 µg     
IF: 1:1000 
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Anti-β-Tubulin Hybridoma Bank, University of Iowa 
E7 
RRID:AB_2315513 IB: 1:50 
Anti-γ-Tubulin Sigma, St. Louis, MO T6557 IB: 1:50 000 
AlexaFluor™ 488-
Phalloidin 
Thermo Scientific, 
Waltham, MA A12379 IF: 1:100 
AlexaFluor™ 564-
Phalloidin 
Thermo Scientific, 
Waltham, MA A12381 IF: 1:100 
AlexaFluor™ 647-
Phalloidin 
Thermo Scientific, 
Waltham, MA A22287 IF: 1:100 
ChromPure Mouse IgG 
Whole molecule 
Jackson 
ImmunoResearch, 
West Grove, PA 
015-000-003 IP: 3 µg 
AffiniPure Goat anti-
Rabbit IgG [H+L] 
Jackson 
ImmunoResearch, 
West Grove, PA 
111-005-045 IP: 3 µg 
Secondary antibodies    
AlexaFluor™ 488-
conjugated Goat anti-
Rabbit IgG 
Thermo Scientific, 
Waltham, MA A11008 IF: 1:1000 
AlexaFluor™ 594-
conjugated Goat anti-
Chicken IgG 
Thermo Scientific, 
Waltham, MA A11042 IF: 1:1000 
AlexaFluor™ 594-
conjugated Goat anti-
Mouse IgG 
Thermo Scientific, 
Waltham, MA A11005 IF: 1:1000 
AlexaFluor™ 647-
conjugated Goat anti-
Mouse IgG 
Thermo Scientific, 
Waltham, MA A21235 IF: 1:1000 
AlexaFluor™ 647-
conjugated Goat anti-
Rabbit IgG 
Thermo Scientific, 
Waltham, MA A21244 IF: 1:1000 
HRP-conjugated Goat anti-
Mouse IgG 
Jackson 
ImmunoResearch, 
West Grove, PA 
115-035-146 IB: 1:5000 
HRP-conjugated Goat anti-
Rabbit IgG 
Jackson 
ImmunoResearch, 
West Grove, PA 
111-035-003 IB: 1:5000 
*IB: immunoblot, IP: immunoprecipitation; IF: immunofluorescence. 
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Table 2.5: Enzymes for molecular biology experiments. 
Enzymes Source Catalogue number 
ApaI New England BioLabs Inc, Whitby, ON R0114 
HindIII-HF New England BioLabs Inc, Whitby, ON R3104 
λ Protein Phosphatase New England BioLabs Inc, Whitby, ON P0753S 
NotI-HF New England BioLabs Inc, Whitby, ON R3189 
PerfeCTa® qPCR SuperMix Quanta Biosciences, Gaithersburg, MD 95064-100 
Platinum™ Taq DNA 
polymerase 
Thermo Scientific, Waltham, 
MA 10966-018 
SuperScript™ II Reverse 
Transcriptase 
Thermo Scientific, Waltham, 
MA 18064-014 
T4 DNA ligase New England BioLabs Inc, Whitby, ON M0202 
XhoI New England BioLabs Inc, Whitby, ON R0146 
 
Table 2.6: List of kits used in this study. 
Kits Source Catalogue Number 
RNeasy Mini Kit Qiagen, Louisville, KY 74104 
DNeasy® Blood & Tissue Kit Qiagen, Louisville, KY 69506 
QIAprep Spin Miniprep Kit Qiagen, Louisville, KY 27106 
EndoFree Plasmid Maxi Kit Qiagen, Louisville, KY 12362 
QIAquick Gel Extraction Kit Qiagen, Louisville, KY 28704 
NE-PER™ Nuclear and 
Cytoplasmic Extraction Kit 
Thermo Scientific, Waltham, 
MA 78833 
NucleoBond® Xtra Maxi Kit Macherey-Nagel, Düren, Germany 740414 
QIAquick PCR Purification 
Kit Qiagen, Louisville, KY 28104 
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2.3 Vectors 
Table 2.7: Plasmids used in this study. 
Plasmid References or source 
pCDNA 3.1 Thermo Scientific, Waltham, MA                         catalogue number V790-20 
pCDNA 3.1 hHR23A-FLAG 
Dr. Christine Blattner, Institute of Toxicology 
and Genetics, Karlsruher Institut für Technologie, 
Germany (Glockzin et al., 2003) 
pCDNA 3.1 hHR23A-HA 
pCDNA 3.1 hHR23A-HA UBA2 
pCDNA 3.1 hHR23A-HA ΔUBA2 
pCDNA 3.1 hHR23A-HA ΔUbL 
pCDNA 3.1 hHR23B-FLAG 
pCDNA 3.1 V5-E2F1 
K117R/K120R/K125R (KTR)  
 
 
 
 
 
 
 
This study 
 
 
 
 
 
 
 
 
 
pCDNA 3.1 V5-E2F1 K185R 
pCDNA 3.1 V5-E2F1 
R111K/R113K (RDK) 
pCDNA 3.1 V5-E2F1 S31A 
pCDNA 3.1 V5-E2F1 S332A 
pCDNA 3.1 V5-E2F1 S337A 
pCDNA 3.1 V5-E2F1 S364A 
pCDNA 3.1 V5-E2F1 S375A 
pCDNA 3.1 V5-E2F1 S403D 
pCDNA 3.1 V5-E2F1 T433D 
pCDNA 3.1 V5-E2F1 
S403D/T433D (ST/D) 
pCDNA 3.1 V5-E2F1 WT-NES 
pCDNA 3.1 V5-E2F1 ST/A-NES 
62 
 
 
pEGFP-C1 hHR23A-HA WT  
 
 
 
 
 
This study 
 
pEGFP-C1 hHR23A-HA UBA1 
pEGFP-C1 hHR23A-HA UBA2 
pEGFP-C1 hHR23A-HA XPC-
UBA2 
pEGFP-C1 hHR23A-HA ΔUBA1 
pEGFP-C1 hHR23A-HA ΔUBA2 
pEGFP-C1 hHR23A-HA ΔUbL 
pEGFP-C1 hHR23A-HA ΔXPC 
pET32b-TRX-hHR23A-FLAG 
pCDNA 3.1 V5-E2F1 WT 
Dr. Iordanka A. Ivanova, Western University, 
London, Ontario (Ivanova et al., 2007) 
pCDNA 3.1 V5-E2F1 T433A 
pCDNA 3.1 V5-E2F1 S403A 
pCDNA 3.1 V5-E2F1 
S403A/T433A (ST/A) 
pCDNA 3.1 FLAG-Cdh1 Dr. Daniele Guardavaccaro, Hubrecht Institute, 
Utrecht, Netherlands (Ping et al., 2012) pCDNA 3.1 FLAG-Cdc20 
pCMV2 FLAG-Skp2 Dr. Wenyi Wei, Harvard Medical School 
Boston, MA (Wei et al., 2004) 
pCMV2 FLAG-Ubc13 
Addgene, Cambridge, MA, deposited by Dr. 
Dong-Er Zhang, plasmid #12460 (Zou et al., 
2005) 
pCS2-Myc-hEmi1 Dr. Peter K. Jackson, Stanford University School of Medicine, Stanford, CA (Hsu et al., 2002) 
pEGFP-C1 Clontech Laboratories, Inc, Mountain View, CA, catalogue number 6084-1 
pET32b-TRX Novagene®, EMD Millipore, Billerica, MA catalogue number 69016 
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pGEX-4T-1 Amersham Pharmacia Biotech, Piscataway, NJ catalogue number 28-9545-49 
 
pGEX-GST-E2F1 
 
Dr. Paul Hamel, University of Toronto, Toronto, 
Ontario 
pBluescriptSK--HA-Ubiquitin-WT Dr. David Litchfield, Western University, London, Ontario (Treier et al., 1994) 
pRK-HA-Ubiquitin-K11 Addgene, Cambridge, MA, deposited by Sandra Weller, plasmid #22901 (Livingston et al., 2009) 
pRK-HA-Ubiquitin-K0 Plasmid #17603  
Addgene, Cambridge, 
MA, deposited by Dr. 
Ted Dawson (Lim et al., 
2005) 
pRK-HA-Ubiquitin-K48 Plasmid #17605   
pRK-HA-Ubiquitin-K63 Plasmid #17606  
pRK-HA-Ubiquitin-WT Plasmid #17608  
 
2.4 Molecular cloning 
2.4.1 Generation of vectors encoding E2F1 and hHR23A mutants 
All E2F1 mutants were generated using a three-step site-directed mutagenesis strategy, as 
summarized in Figure 2.1. This approach allowed for introduction of mutations in the 
central regions of the E2F1 cDNA while simultaneously maintaining good amplicon 
yields, which proved challenging because the E2F1 cDNA has several GC-rich regions 
that interfered with optimal polymerase-chain reaction (PCR) amplification. The plasmid 
encoding V5-tagged wild type E2F1 was used as a template (Table 2.7). For each V5-
tagged E2F1 mutant, the N- and the C-terminal halves were amplified separately. For the 
N-terminal half, a forward primer containing a HindIII site for subsequent cloning, 
together with sequence encoding the V5 tag. In these reactions, the reverse primer 
contained the mutated nucleotide(s). For the C-terminal half, a forward primer containing  
  
 
 
 
 
Figure 2.1: Schematic representation of the three-step PCR protocol used for site-
directed E2F1 mutagenesis. 
A three-step PCR amplification procedure was used to generate fragments F’, R’ and FL. 
Two complementary primers to the E2F1 cDNA, as indicated by a and d (primers E2F1 
V5 WT Fwd and Rev, see Table 2.8) including, respectively HindIII and NotI sequences, 
together with primers containing the desired point mutations (red circle) were designed to 
generate the vectors encoding E2F1 mutants used in this thesis. For each mutant 
construct, fragment F’ was amplified using primers a and c (PCR 1), and fragment R’ 
was amplified using primers b and d (PCR 2). Amplicons F’ and R’ contain overlapping 
sequences, which allowed them to be used as templates for the third, and final PCR 
reaction to synthesize full-length  FL fragments , using primes a and d (PCR 3). All FL 
fragments were digested with HindIII and NotI and cloned into pCDNA3.1. 
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the same mutated nucleotide(s) paired with a reverse primer containing the STOP codon 
(TGA) and a NotI site for subsequent cloning (Figure 2.1). The N- and C- terminal 
amplicons were then combined and served as templates in a third PCR reaction, which 
generated full-length V5-tagged E2F1 cDNAs, using the HindIII-V5-tag forward and 
STOP-NotI reverse primer (primers a and d, Figure 2.1). Full-length E2F1 mutant 
cDNAs thus obtained (1500 bp) were cloned into the expression plasmid pCDNA3.1 
(4500bp) at the HindIII and NotI sites. The sequences of all the primers used to generate 
mutant E2F1 cDNAs are shown in Table 2.8. 
To add a NES to the E2F ST/A mutant, the simian virus 40 (SV40) large T antigen NES 
(LPPLERLTL) was inserted at the C-terminus of E2F1 ST/A by PCR. The sequences of 
all mutant constructs generated were verified by dideoxy sequencing at the Robarts 
Research Institute sequencing facility. 
To generate vectors encoding GFP-tagged hHR23A forms, cDNAs corresponding to wild 
type hHR23A and the deletion mutants ∆UbL, ∆UBA1, ∆UBA2, ∆XPC, XPC-UBA2, 
UBA1 and UBA2 were amplified by PCR using reverse primers that included sequences 
corresponding to the HA tag (AGCATAATCAGGAACATCATA) at the C-terminus 
(Table 2.9). The templates used for these reactions were vectors encoding the 
corresponding HA-tagged hHR23A proteins, which were generous gifts from Dr. 
Christine Blattner (Glockzin et al., 2003). Amplicons thus generated were cloned into the 
XhoI and ApaI sites of pEGFP-C1. The sequences of all mutant constructs generated 
were verified by dideoxy sequencing at the Robarts Research Institute sequencing 
facility. 
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Table 2.8: Forward (Fwd) and reverse (Rev) primers used to generate E2F1 point 
mutants. 
Primers Sequence* 
E2F1 V5 WT 
Fwd: 5'-CTTaagcttCCATGGGTAAGCCTATCCCTAACCCTCTCC 
TCGGTCTCGATTCTACGGCCTTGGCCGGGGCCCCTGCGGGC
GGCCCA-3' 
Rev: 5'-AATAATgcggccgcTCAGAAATCCAGGGGGGTGAGGT 
CCCCAAAGTCACAGTCG-3' 
E2F1 S31A 
Fwd: 5'-CGGCTGCTCGACTCCGCGCAGATCGTCATCATC-3' 
Rev: 5'-GATGATGACGATCTGCGCGGAGTCGAGCAGCCG-3' 
E2F1 S332A 
Fwd:5'-CTGCCACCATAGTGGCACCACCACCATCATC-3' 
Rev: 5'-GATGATGGTGGTGGTGCCACTATGGTGGCAG-3' 
E2F1 S337A 
Fwd: 5'-CACCACCACCATCAGCTCCCCCCTCATCCC-3' 
Rev: 5'-GGGATGAGGGGGGAGCTGATGGTGGTGGTG-3' 
E2F1 S364A 
Fwd:5'-GTTGTCCCGGATGGGCGCCCTGCGGGCTCCCGTG-3' 
Rev: 5'-CACGGGAGCCCGCAGGGCGCCCATCCGGGACAAC-
3' 
E2F1 S375A 
Fwd: 5'-GACGAGGACCGCCTGGCCCCGCTGGTGGCGG-3' 
Rev: 5'-CCGCCACCAGCGGGGCCAGGCGGTCCTCGTC-3' 
E2F1 K185R 
Fwd: 5'-GCCAAGAAGTCCAGGAACCACATCCAGTGG -3' 
Rev: 5'- CCACTGGATGTGGTTCCTGGACTTCTTGGC -3' 
E2F1 
K117R/K120R/K
125R 
Fwd:5'- CCATCCAGGAAGAGGTGTGAGATCCCCGGGGGAG 
AGGTCACGCTATG -3' 
Rev: 5'- CATAGCGTGACCTCTCCCCCGGGGATCTCACACCT 
CTTCCTGGATGG -3' 
E2F1 
R111K/R113K 
Fwd: 5'-CCAGCTCGGGGCAAAGGCAAGCATCCAGGAAAAG 
GTGTG-3' 
Rev: 5'- CACACCTTTTCCTGGATGCTTGCCTTTGCCCCGAG 
CTGGC-3' 
E2F1 S403D 
Fwd: 5'-CCTGAGGAGTTCATCAGCCTTGACCCACCCCACGA 
GGCCC-3' 
Rev: 5'-GGCCTCGTGGGGTGGGTCAAGGCTGATGAACTCCT 
CAGG-3' 
E2F1 T433D Rev: 5'- CGAgcggccgcTCAGAAATCCAGGGGGTCGAGGTCC CCAAAGTCACAGTCG-3' 
E2F1 ST/A NES Rev: 5'-gcggccgcTCAAAGAGTAAGTCTCTCAAGCGGTGGTA GG AAATCCAGGGGGGCGAGGTCCCC 3' 
*Mutated nucleotides are underlined and shown in bold characters; the nucleotide 
sequence for the V5 tag is italicized. The HindIII and NotI sequences are written in lower 
case characters. 
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Table 2.9: Forward (Fwd) and reverse (Rev) primers used for deletion mutations in 
hHR23A. 
Primers Sequence* 
hHR23A WT 
Fwd: 5'-CCATACGACGTCCCAGActcgagAGGGATCCATGGCC 
GTCACC-3' 
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACTCGT 
CATCAAAGTTCTG-3' 
hHR23A UbL 
Fwd: 5'-CCATACGACGTCCCAGActcgagAGGGATCCATGCAG 
GG TACC-3' 
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATAGGCAG 
GTGGGGGATGGG-3' 
hHR23A UBA2 
Fwd: 5'-CATACGACGTCCCAGActcgagAGGGATCCATGGCGT 
ACCCATAC-3' 
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACTCGT 
CATCAAAGTTCTG-3' 
hHR23A UBA1 
Fwd: 5'-CCCAGActcgagAGGGATCCATGGCCAGAGAGGACA 
AG-3' 
Rev: 5'-GgggcccTTAAGCATAATCAGGAACATCATACGGCT 
GCTCCGATACCTGG-3' 
hHR23A ∆UBA1 
Fwd:5'-GCCAGAGAGGACAAGAGCGCCACGGAAGCAGCAG 
G-3' 
Rev: 5'-GCTCTTGTCCTCTCTGGCGGCAGGTGGGGGATGGG-
3' 
hHR23A ∆XPC 
Fwd: 5'-GAGCAGCCGGCCACGCAGGTGACGCCGCAG-3' 
Rev: 5'-CGTGGCCGGCTGCTCCGATACCTGGCTCTC-3' 
*The HA-tag is bolded and underlined; The XhoI and ApaI nucleotides are written in 
lower case characters. 
To generate the construct encoding the thioredoxin (TRX) fusion protein of hHR23A for 
bacterial expression, a cDNA containing the FLAG tag sequence at the C-terminus was 
amplified by PCR using the following primers: Forward 5’-CCCAGAAAGCTTGCCGT 
CACCATCACGCTC-3’ and reverse 5’-CCGTCTGGCGGCCG CTCATATGTCGTAA-
3’. The amplicon was digested with HindIII and NotI and cloned into the corresponding 
sites of the bacterial expression vector pET32b-TRX. 
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2.4.2 Polymerase chain reaction (PCR) 
All PCR reactions were carried out using Platinum™ Taq DNA polymerase (Qiagen) in a 
50-µl reaction containing 150 ng of DNA, 300 nM each forward and reverse primers, 200 
µM dNTP mix, 1× PCR buffer (20 mM Tris-HCl pH 8.4 and 50 mM KCl), 1 M Betaine, 
2 mM MgCl2, and 5 U Platinum™ Taq DNA polymerase. The reactions were conducted 
in a PCR thermal cycler (Eppendorf Mastercycler EP Gradient S, Hauppauge, NY) under 
the following cycling parameters: one cycle at 95ºC for 2 min, followed by 30 cycles of 
denaturation at 94ºC for 30 sec, annealing at 58ºC for 30 sec, and elongation at 72ºC for 
50 sec. The final step involved a post-elongation cycle at 72ºC for 7 min, followed by 
cooling to 4ºC until sample retrieval from the thermal cycler. All PCR products were 
analyzed on 1× TAE agarose gels.  
2.4.3 Isolation and purification of DNA and PCR products 
The PCR products were purified from agarose gels using gel purification kits (Qiagen), 
following the manufacturers’ instructions. After gel purification, amplicons were digested 
with the appropriate restriction enzymes and purified with PCR cleanup kits (Qiagen), 
followed by ligation into appropriate vectors previously digested with the appropriate 
restriction enzymes and gel purified. 
2.4.4 DNA ligation 
All ligation reactions were performed in 10-µl reaction volumes containing 1:3 molar 
reactions of vector to insert, and using T4 DNA ligase. Ligation reactions were incubated 
at 22ºC for 1 h before transformation into Escherichia coli (E. coli).  
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2.4.5 Preparation of competent DH5α and BL-21 (DE) cells 
E. coli DH5α or BL-21(DE) cells were streaked on an LB agar plate and cultured for 16 h 
at 37ºC. Immediately afterwards, a single colony from the streak was used to inoculate 5 
ml of LB medium and cultured for 16 h at 37ºC with shaking (250 rpm). The following 
day, bacteria were subcultured into 250 ml of SOB medium at a ratio of 1:3. The culture 
was incubated at 18ºC with shaking at 250 rpm. When the culture reached an optical 
density at 600 nm (OD600) of 0.6, it was cooled on ice for 10 min and centrifuged at 
2500×g for 10 min at 4ºC. After removing the supernatant, cell bacterial pellets were 
resuspended in 80 ml ice-cold TB and incubated on ice for 10 min. The bacteria were 
then collected by centrifugation (2500×g, 10 min, 4ºC). The bacterial pellets were gently 
resuspended in 20 ml ice-cold TB and DMSO was added to a final concentration of 7% 
(w/v). Two hundred-µl aliquots of competent cells were freeze using liquid nitrogen, and 
stored at -80ºC. The competence of the bacteria was determined by transforming 100 pg 
of DNA, and calculated using the following equation: 
Number of colonies obtained  ×  106pg   ×  1000 µl total transformation volume  × DF   
100 pg transformed DNA               µg           100 µl plated 
= Number of colony-forming-units (cfu) per µg plasmid DNA 
The transformation efficiency following this protocol was routinely > 1 × 106 cfu/µg 
supercoiled plasmid DNA. 
2.4.6 Bacterial transformation 
Plasmids were transformed into E. coli DH5α, to prepare vectors used for mammalian 
cell transfection. For bacterial expression of recombinant proteins, E. coli BL-21(DE) 
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was used because this strain generally attains higher yields of recombinant proteins. For 
transformation, a 250-µl aliquot of competent bacteria was thawed on ice and mixed with 
10 ng of purified plasmid DNA or 2 µl from a 10-µl ligation reaction. The bacterial 
suspension was incubated on ice for 30 min with intermittent mixing, followed by heat 
shock at 42ºC for 45 sec. Seven-hundred and fifty ml of LB medium were quickly added 
and the bacteria were incubated at 37ºC for 1 h with shaking at 250 rpm. The 
transformation mixture was centrifuged (3000×g, 3 min, 22ºC). The bacterial pellet was 
resuspended in 100 µl LB and plated on LB agar plates containing 100 μg/ml ampicillin 
or 50 µg/ml kanamycin, according to the antibiotic resistance associated with the plasmid 
transformed, and the plates were incubated at 37ºC for 16ºC to allow for colony 
formation.  
2.5 Recombinant Protein Purification 
2.5.1 GST fusion protein expression 
Glutathione S-transferase (GST) fusion proteins were purified as described (Apostolova 
et al., 2002; Ivanova et al., 2007) with slight modifications. GST and GST-E2F1 
expression plasmids were transformed into E. coli BL-21(DE). A single colony was used 
to inoculate 5 ml of 2× YT medium containing 200 µg/ml ampicillin, and cultured for 16 
h at 37ºC with shaking at 250 rpm. One ml of this overnight culture was used to inoculate 
200 ml of fresh 2× YZ with 200 µg/ml ampicillin, and was cultured at 37ºC until the 
OD600 was 0.6 (approximately 4 h). To induce protein expression, isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to the bacterial culture to a final concentration 
of 0.5 mM, and incubation continued at 18ºC for 18 h. Bacteria were harvested by 
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centrifugation (6000×g, 15 min, 4ºC) and resuspended in MTPBS buffer (Section 2.1, 
Table 2.3) containing 1% (v/v) Triton X-100, 1 mM PMSF, 1 µg/ml each aprotinin, 
leupeptin, and pepstatin A. The cells were lysed through a French-pressure cell press 
(American instrument Co In, Silver Spring MD) twice at a pressure of 10,000-11,000 psi. 
The lysate was then centrifuged (14000×g, 15 min, 4ºC) to remove cell debris.  The 
supernatant was incubated in 50% (v/v) slurry of GST sepharose beads rinsed with lysis 
buffer prior to use. Incubation proceeded for 30 min at 4ºC with gentle mixing. The 
sepharose beads were washed three times with MTPBS, and bound GST or GST fusion 
proteins were eluted with 50 mM Tris-HCl pH 8.0 containing 10 mM reduced L-
glutathione. The purified GST fusion proteins were desalted using PD10 columns, and 
concentrated to a final volume of about 500 µl, using Amicon Ultra-15 columns. The 
protein concentrations in the eluates were determined using Bradford assays, and 
recombinant proteins were stored in single-use 20-µl aliquots at -80ºC. 
2.5.2 TRX fusion protein expression 
His-TRX and His-TRX-hHR23A-FLAG proteins were induced as described in Section 
2.5.1 and purified as described (Ho et al., 2009), with the following exceptions. 
Harvested bacterial pellets were resuspended in lysis buffer containing imidazole (10 mM 
imidazole, 300 mM NaCl, 50 mM NaH2PO4 (pH 8.0), 1% (v/v) Triton X-100, 1 mM 
PMSF, 1 µg/ml each aprotinin, leupeptin, and pepstatin A), homogenized using a French-
press, and cleared by centrifugation as above. Supernatants were mixed with 50% (v/v) 
slurry of Ni-NTA agarose previously rinsed with lysis buffer. Agarose slurry mixtures 
incubated for 30 min at 4ºC with gentle rocking, washed three times with wash buffer (40 
mM imidazole, 300 mM NaCl, 50 mM NaH2PO4 (pH 8.0)), and eluted with wash buffer 
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containing 250 mM imidazole. The purified TRX fusion proteins were desalted using 
PD10 columns, and concentrated to a final volume of about 500 µl, using Amicon Ultra-
15 columns. The protein concentrations in the eluates were determined using Bradford 
assays, and recombinant proteins were stored in single-use 20-µl aliquots at -80ºC. 
2.6 Preparation of glass coverslips for cultured cells 
Glass coverslips were washed in 1 N HCl at 60ºC for 4 h, and subjected to 2-3 washes in 
double distilled H2O (ddH2O) at 50-60°C. The glass coverslips were allowed to cool to 
room temperature, and were then rinsed with 95% (v/v) ethanol and allowed to air dry. 
Dry coverslips were incubated in a sterile poly-L-lysine (PLL) solution (1 mg/ml) for 1 h 
at 22°C, with gentle rocking. PLL-coated coverslips were washed with sterile ddH2O and 
allowed to air dry under sterile conditions in a tissue culture biosafety cabinet. Sterile 
PPL-coated coverslips were then stored at 22ºC until needed. Prior to use to culture 
mammalian cells, PPL-coated coverslips were further coated with collagen type I as 
described (Nakrieko et al., 2008). Briefly, the coverslips were rinsed with 70% (v/v) 
ethanol, washed with PBS, and incubated in a solution of rat tail collagen type I (20 
µg/cm2) dissolved in 0.02 N acetic acid for 4 h at 37°C. These coverslips were then 
washed three times with sterile PBS, and placed in tissue culture plates. 
2.7 Cell culture and transfection 
2.7.1 Isolation of primary epidermal keratinocytes 
All experiments that involved the use of mice were approved by the University of 
Western Ontario Animal Care Committee (Protocol No. 2015-021), in accordance with 
regulations and guidelines from the Canadian Council on Animal Care. Primary mouse 
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keratinocytes were isolated from 2d-old CD-1 mice and cultured in keratinocyte growth 
medium (Ca2+-free EMEM supplemented with 100U/ml penicillin, 100μg/ml 
streptomycin, 74 ng/ml hydrocortisone, 5 μg/ml insulin, 9.5 ng/ml cholera toxin, 5 ng/ml 
EGF, 6.7 ng/ml T3 and 8% (v/v) FBS pre-treated with chelex resin) (Dagnino et al., 
2010; Ivanova et al., 2006; Ivanova et al., 2009). Mice were euthanized by CO2/O2 
inhalation and placed in 70% (v/v) isopropyl alcohol for sterilization. The limbs, tail and 
head were removed, and a longitudinal incision was made along the back, starting at the 
base of the skull. The skins were harvested using two forceps, washed with PBS, spread 
epidermis side up on 10-cm bacterial culture plates containing freshly diluted 0.25% (v/v) 
trypsin, and incubated for 16 h at 4°C. The trypsin was then removed by aspiration, and 
replaced with fresh 0.25% (v/v) trypsin, and the tissues were incubated at 37ºC for 15 
min. The epidermis was mechanically separated from the dermis, and placed in 5 ml of 
keratinocyte growth medium. The epidermis was minced very finely with scissors, and 30 
ml of keratinocyte growth medium was added. The minced epidermis was incubated with 
gentle rocking at 37ºC for 30-40 min. The cell suspension was filtered through a 70-μm 
nylon mesh to remove the cornfield envelope, and the cell density in the suspension was 
determined using a haemocytometer. Keratinocytes were plated at a density 1.6 × 105 
cells/cm2. For microscopy experiments, cells were seeded on PPL- and collagen-coated 
sterile glass coverslips (Section 2.5). The day after plating, keratinocytes were washed 
once with PBS and cultured in fresh growth medium, which was subsequently replaced 
every other day. Keratinocyte differentiation was induced by in culture by adding growth 
medium containing 1 mM CaCl2 (“High-Ca2+ medium”) for at least 24 h. Keratinocytes 
were transfected 3 days after plating. 
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2.7.2 Culture of tumour cell lines 
HeLa cervical carcinoma and RPMI-7951 human melanoma cells were purchased from 
the American Type Culture Collection. These cells were cultured in HyQ Reduced Serum 
DMEM, supplemented with 4% (v/v) FBS at 37ºC in a humidified 5% (v/v) CO2 
atmosphere.  When cells reached a confluence of ~ 90%, they were subcultured at a ratio 
of 1:4, and the growth medium was replaced 2-3 times per week. All experiments were 
conducted with cells that had reached less than 80% confluence, and had been passaged 
for 10 generations or less. 
2.7.3 Cell transfection and drug treatments 
Cells were transfected with PEI solution (Section 2.1, Table 2.2), as previously described 
(Dagnino et al., 2010). Cells were transfected at a ratio of 1 µg of DNA per 3 µl PEI, 
adjusted to 100 µl (24-well plates), 200 µl (6-well plates), 300 µl (6-cm plates), or 500 µl 
(10-cm plates) with sterile 150 mM NaCl. The DNA/PEI mixture was vortexed, followed 
by a pulse centrifugation, incubated at 22ºC for 10 min, and added dropwise onto the 
culture medium, swirling gently to ensure thorough mixing. The cells were cultured in 
the presence of DNA/PEI mix for 4 h, at which time they were washed twice with Ca2+-
free PBS and cultured with fresh growth medium. Where indicated, transfected 
keratinocytes were induced to differentiate by culturing in growth medium containing 1 
mM CaCl2 for a total of 24 h, which was initiated 4 h after transfection. For experiments 
with proteasome inhibitors, cells were treated with MG132 (10 µM) for 6 h prior to 
harvesting. Where indicated, LMB (5 ng/ml) was added 24 h after transfection and cells 
were harvested 6 h later. To induce single strand DNA damage, etoposide (150 µM) was 
added 24 h after transfection and cells were harvested 8 h later. For steady-state E2F1 
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protein levels, CHX was added to keratinocyte cultures 24 h after transfection for 30 min 
prior to replacing the culture medium with growth medium containing either low Ca2+ or 
high Ca2+ in the presence of CHX, and cell lysates were prepared 2.5 h later. For E2F1 t½ 
experiments, CHX (100 µg/ml) was added 24 h after transfection to keratinocytes 
cultured in low Ca2+ or high Ca2+ for 4 h. Cell lysates were prepared at timed intervals 
following CHX addition and protein abundances were measured by immunoblot analysis 
(Section 2.9).  
2.8 RNA isolation and quantitative reverse-transcription 
PCR (qPCR) 
Total RNA was isolated from cultured cells or from tissues harvested from 2d-old CD-1 
mice, using RNeasy mini-kits (Qiagen), and following the manufacturer’s instructions. 
Epidermis and dermis samples were obtained from skin treated with 8 mg/ml dispase for 
15 minutes at 37°C, as described (Judah et al., 2012). RNA concentration and quality 
were determined with an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). Only 
samples with RNA integrity numbers ≥8.5 were used. RNA (200 ng/sample) was reverse- 
transcribed using SuperScriptTM II RT, as per manufacturer’s protocol. qPCR reactions 
were conducted on a CFX384™ Real-Time PCR system (Bio-Rad) operated by CFX 
Manager™ software (version 1.6). cDNA samples corresponding to 20 ng of RNA were 
amplified using PerfeCTa® qPCR SuperMix and the following primers (400 nM, final): 
mHR23A forward 5’-AAGATCCGCATGGAACCTGA-3’ and reverse 5’-TGGTC 
ACCATGACAACCACAA-3’; mHR23B forward 5’-CTTAGGCACCATGCAGGTCA-
3’ and reverse 5’-CGGAAAGGCATCTTTCCCCT-3’. The results were normalized to 
the expression of the housekeeping genes Rpl6 and Rps29, which encode ribosomal 
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protein L6 and S29, respectively (de Jonge et al., 2007). Replicate cDNA samples were 
amplified for 40 cycles (98°C for 10 sec, and 58°C for 30 seconds per cycle). Primer 
specificity and amplicon sizes were confirmed, respectively, by analysis of melt curves 
conducted between 65°C and 95°C, in 0.5°C increments, and agarose gel electrophoresis. 
Relative mHR23A and mHR23B mRNA levels were calculated using the ΔΔCt method. 
2.9 Immunoblot analysis and immunoprecipitation 
Whole-cell lysates were prepared using a modified RIPA-lysis buffer (Section 2.1, Table 
2.3). To prepare nuclear and cytoplasmic fractions, primary keratinocytes were lysed 
using a NE-PER nuclear and cytoplasmic extraction kit, following the manufacturers’ 
protocol. For phosphatase treatments (Ivanova et al., 2009), cell lysates were prepared in 
duplicate. One of the samples was prepared in modified RIPA-lysis buffer, and the other 
in the same buffer, but without phosphatase inhibitors (Na3VO4, NaF and Na4P2O7). The 
lysates prepared in the absence of phosphatase inhibitors were further incubated with λ 
phosphatase (4 U/µg of lysate protein) at 30ºC for 30 min. In experiments assessing E2F1 
ubiquitylation, the lysis buffer also contained 25 mM NEM.  The protein concentration of 
lysates were measured using the Bio-Rad protein assay reagent (Table 2.2) on a DU®640 
spectrophotometer (Beckman Coulter Inc. CA, USA). Proteins in lysates (30 µg/sample) 
were resolved by denaturing polyacrylamide gel electrophoresis and transferred to PVDF 
membranes, which were probed with antibodies indicated in individual experiments. 
After antibody probing, protein signals were visualized using Amersham ECL Prime 
Western Blotting Detection Reagent. Keratinocytes exhibits contact inhibition and 
therefore to obtain 1.5 mg of protein, five 10-cm tissue culture dishes (9.6 × 106 cells, 
78 
 
 
 
~2.5 skins from 3-day-old mice per plate) per sample were used for immunoprecipitation 
assays. Cell lysates prepared as described above (1.5 mg protein/sample, for Figures 3.2, 
3.6, 3.14, 3.15, and 3.20 and 1 mg/protein/sample for Figures 3.4, 3.5, 3.21, and 3.23) 
were incubated with antibodies indicated in individual experiments (3 µg 
antibody/sample for Figures 3.2, 3.6, 3.14, 3.15, and 3.20 and 2 µg antibody/sample for 
Figures 3.4, 3.5, 3.21, and 3.23) for 16 h at 4°C, with rotation. The immune complexes 
were captured by incubation with 400 µg of A/G magnetic beads previously rinsed with 
PBS containing 0.05% (v/v) Tween-20 for 1 h at 22°C with rotation, followed by 5 
washes with PBS containing 0.05% (v/v) Tween-20, and elution in 1× Laemmli sample 
buffer (Table 2.3) for 10 min at 25°C. Immune complexes were resolved and analyzed by 
immunoblot, as described above. Protein signals were visualized with either a 8×10 inch 
Blue Ray Film and quantified using ImageJ (Schneider et al., 2012) or with a VersaDoc-
3000 imager (Bio-Rad Laboratories) and quantified with Quantity One software (Bio-Rad 
Laboratories). In all experiments, E2F1 and hHR23A band intensities were normalized to 
γ-Tubulin or GAPDH. For E2F1 turnover experiments, E2F1 to γ-Tubulin band intensity 
ratio for each time point was normalized to t=0. The apparent t½ of E2F1 protein was 
calculated by plotting the percentage of band intensity setting T=0 at 100% against time 
(min) following CHX treatment and determined using GraphPad Prism software (version 
5.00 for Windows, San Diego, CA) setting Y=0 at 100.0 and plateau at 0.0.  
2.10 Indirect immunofluorescence microscopy 
Twenty-four hours after transfection, cells were fixed and processed for microscopy, as 
previously described (Ivanova and Dagnino, 2007). Cells were fixed with 4% (w/v) PFA 
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on ice for 15 min and permeabilized with PBS containing 0.1% (v/v) Triton X-100 at 
22ºC for 10 min. After washing with PBS buffer, cells were incubated with 1% (w/v) 
non-fat milk and 5% (v/v) goat serum diluted in TBST for 1 h at 22ºC, and then 
incubated with primary antibodies for 16 h at 4ºC (Table 2.4). Cells were washed three 
times with 1× PBS and incubated with the appropriate AlexaFluor-conjugated secondary 
antibody (Table 2.4) for 1 h at 22ºC. DNA was visualized using Hoechst 33342 (1 µg/ml, 
final; Table 2.2). The fraction of cells with nuclear or cytoplasmic E2F1 or hHR23A was 
determined from the analysis of at least 100 cells per experiment in replicates. To 
visualize CPD, cells were fixed in freshly diluted 4% (w/v) PFA in 1× PBS, followed by 
incubation in 0.2N HCl for 30 min at 22°C, to denature nuclear DNA. The cells were 
washed 5 times with PBS and incubated with primary antibodies, as described (Ivanova 
and Dagnino, 2007). All photomicrographs shown are representative of experiments 
conducted on duplicate samples, and scoring > 100 transfected cells per experiment. 
Images were obtained with a Leica DMIRBE fluorescence microscope equipped with an 
Orca-ER digital camera (Hamamatsu Photonics, Hamamatsu City, Japan), using Volocity 
6.1.1 software (Improvision-PerkinElmer, Waltham, MA).  
2.11 In vitro binding assays 
For in vitro protein binding assays, 2 µg of each recombinant protein indicated were 
mixed in a final volume of 250-µl of PBS containing 1 mM PMSF, and 1 µg/ml each 
aprotinin, leupeptin, and pepstatin A. Protein mixtures were incubated at 4ºC for 16 h, 
followed by incubation in 50% (v/v) slurry of pre-equilibrated Ni-NTA agarose or GST 
sepharose beads at 4ºC for 30 min. Protein complexes captured by the resins were washed 
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5 times with PBS containing 0.05% (v/v) Tween-20 and eluted in 1× Laemmli sample 
buffer for 10 min at 70°C. The samples were resolved by electrophoresis, using 
polyacrylamide gels as described in Section 2.9.  
2.12 UV damage and repair assays 
The co-localization of proteins to sites of UVC radiation-induced DNA damage was 
conducted as described (Guo et al., 2011; Guo et al., 2010), with minor modifications. 
Keratinocyte monolayers were rinsed once with PBS, leaving a thin PBS layer. A sterile 
3-µm pore polycarbonate membrane was gently placed onto the cells, followed by 
irradiation with 254 nm UVC light (200 J/m2), using a Bio-Rad GS Gene Linked UV 
Chamber. The membrane was removed and normal growth medium was added to the 
cells, which were processed for immunofluorescence microscopy 2 h later, as described 
in Section 2.10. 
Repair of UV-induced DNA damage was assessed as described (Guo et al., 2011), with 
some modifications.  HeLa or RPMI-7951 cells seeded in 10-cm culture dishes were 
transfected with vectors encoding E2F1 and/or hHR23A. Sixteen hours after transfection, 
the cells were trypsinized, re-seeded in quadruplicate 35-mm culture dishes, and cultured 
for an additional 16-h interval to allow attachment. Duplicate samples were then mock-
irradiated or subjected to UVB treatment (302 nm, 100 J/m2), using a UVM-28 EL 
series8-watt lamp (UVP, Upland, CA). At timed intervals following UVB irradiation, 
genomic DNA was purified with DNeasy® Blood & Tissue kits (Qiagen) and denatured 
by boiling at 95ºC for 5 min. Replicate 200 ng samples were spotted onto Hybond N+ 
membranes (Amersham, NJ), which were baked at 80ºC for 1 h, and placed onto filter 
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paper pre-wetted with 0.4 N NaOH for 20 min. The membranes were blocked for 16 h at 
4°C in 5% (w/v) non-fat milk diluted in TBST. After two TBST washes, membranes 
were incubated for 2 h at 22°C with anti-CPD antibodies. To normalize for DNA content, 
the membrane was blocked for 1 h at 22ºC in 2% (w/v) BSA diluted in TBST and probed 
with anti-dsDNA antibodies diluted in TBST containing 2% (w/v) BSA. CPD and 
dsDNA signals were visualized with a VersaDoc-3000 imager (Bio-Rad Laboratories) 
and quantified with Quantity One software (Bio-Rad Laboratories).  
2.13 Cdh1 silencing by RNA interference 
Primary keratinocytes were transfected 2 d after plating onto 60-mm culture dishes with a 
non-targeting Silencer Negative Control siRNA #1 (AM4611, Ambion® ThermoFisher 
Scientific, Waltham, MA) or Cdh1-targeting siFZR1 siGENOME SMARTpool (M-
065289-00, Dharmaco™ GE Healthcare, Lafayette, CO) using Lipofectamine 2000 
transfection reagent according to manufacturer's instruction. Specifically, 15 µl of 
Lipofectamine 2000 (1 µg/µl stock) mixed with 1 ml of serum-free (SF) and Ca2+-free 
EMEM were combined with 200 pmoles of siRNA that had been mixed with 1 ml SF and 
Ca2+-free EMEM. The samples were vortexed and incubated at 22ºC for 5 min. This 
solution was then used to replace the culture medium of the keratinocytes, which had 
been previously rinsed once with Ca2+-free PBS. The cells were incubated at 37ºC for 4 h 
prior to the addition of 3 ml of keratinocyte growth medium (Ca2+-free EMEM 
supplemented with growth additives and 8% (v/v) FBS pre-treated with chelex resin). 
The cells were cultured for 24 h, at which time they were washed twice with Ca2+-free 
PBS and cultured with fresh growth medium for 72 h. The cells were transfected with 
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vectors encoding V5-tagged E2F1, as described in section 1.7.3, and cultured for 21 
additional hours. Keratinocytes were then treated with CHX as described in section 1.7.3 
prior to lysis and protein analysis (Section 1.9). 
2.14 Statistical analyses 
Data are expressed as mean ± SEM or mean ± SD, as indicated in individual experiments. 
Student’s t-tests were used for comparisons between two groups. One-way analysis of 
variance (ANOVA) with Newman-Keuls post-hoc test was used for comparisons among 
multiple groups and one variable. Two-way ANOVA with Bonferroni post-hoc test was 
used for comparisons among multiple groups and two variables. Statistical analyses were 
conducted with GraphPad Prism software (version 5.00 for Windows, San Diego, CA), 
and significance was set at P<0.05. The results shown in all figures are representative of 
3-8 experiments, each conducted with independent cell isolates. 
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Chapter 3  
3 Results 
3.1 Interaction of hHR23A and E2F1 
The mammalian orthologues of yeast Rad23 (HR23) proteins play dual roles in DNA 
NER and modulation of ubiquitin-mediated protein degradation (Dantuma et al., 2009). 
To begin to address the role of these proteins in the epidermis, their expression levels in 
mouse tissues were first assessed. Quantitative polymerase chain reaction (qPCR) 
analysis revealed the presence of transcripts encoding mHR23A and mHR23B in the 
epidermis and the dermis, at levels comparable to those found in a variety of other tissues 
(Figure 3.1A).  Further, mHR23A and mHR23B mRNA species were also detected in 
primary cultured epidermal keratinocytes, irrespective of whether they were 
undifferentiated or had been induced to differentiate (Figure 3.1A). mHR23A protein was 
detected at low levels in mouse epidermis and in cultured keratinocytes, whereas it was 
substantially more abundant in various human epithelial cell types and mouse tissues, 
including the dermis (Figure 3.1B, 3.1C).  
hHR23A and mHR23A proteins participate in NER processes through the formation of 
multiprotein complexes that recognize sites of DNA damage (Dantuma et al., 2009). The 
ability of the E2F1 transcription factor to recognize sites of DNA damage induced by UV 
radiation and to promote NER (Guo et al., 2010) prompted me to investigate the 
possibility that E2F1 and hHR23A might associate. To this end, exogenous V5-tagged 
E2F1 together with FLAG-tagged hHR23A were expressed in primary mouse  
  
 
 
 
 
 
Figure 3.1: Expression of mHR23 and hHR23 proteins.  
A. mRNA was isolated from primary undifferentiated (Undiff. KT) or differentiated 
(Diff. KT) 3-day keratinocyte cultures, or from the indicated tissues harvested from 2-d-
old CD-1 mice. mHR23A and mHR23B mRNA levels were assessed by qPCR, and 
normalized to the abundance of Rpl16 and Rps29 transcripts. The results are expressed as 
the mean + SEM (n=3), relative to mRNA abundance in undifferentiated keratinocytes, 
which is set to 1.0. The asterisks indicate P<0.05, relative to abundance in 
undifferentiated keratinocytes (ANOVA). B, C. The abundance of mHR23A or hHR23A 
was determined in protein lysates from the tissues harvested in (A) or from the indicated 
cultured cells. Glyceraldehyde-3-phosphatase (GAPDH) was used to normalize for 
protein loading. MEK and HEK indicate, respectively, primary cultures of 
undifferentiated mouse and human epidermal keratinocytes. Blot exposure times and the 
amount of protein on the blots (in μg) are indicated, to better illustrate differences in 
protein abundance (n=3). 
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keratinocytes that had been maintained undifferentiated, or had been induced to 
differentiate by 24 h of culture in medium containing 1 mM Ca2+ (High-Ca2+ medium).  
When hHR23A immune complexes were isolated, V5-tagged E2F1 was detected, 
irrespective of the differentiation status of the keratinocytes (Figure 3.2A). Reciprocally, 
hHR23A fused to green fluorescent protein (GFP) and hemagglutinin (HA) tags was 
readily detected in V5-E2F1 immune complexes (Figure 3.2B). The larger molecular 
mass of the GFP-tagged hHR23A species avoided the interference of IgG heavy chains in 
this analysis. It was also found that endogenous E2F1 could associate with hHR23A 
proteins (Figure 3.2C), but I was unable to detect mHR23A in E2F1 immune complexes, 
likely due to its very low abundance in primary keratinocytes. 
hHR23 proteins can function as scaffolds between ubiquitylated substrates and the 
proteasome. To determine if hHR23A interactions with E2F1 required ubiquitylation of 
the latter, I examined if bacterially produced hHR23A and glutathione (GST)-tagged 
E2F1 were able to interact. I readily detected hHR23A in GST-E2F1 immune complexes, 
indicating that interactions between these two proteins do not require the presence of 
post-translational modifications (Figure 3.2D). These observations do not exclude the 
possibility that binding of hHR23A to E2F1 also occurs through ubiquitylated residues on 
the latter. Bacterially produced hHR23A or GST-E2F1 could also interact with 
exogenously expressed V5-tagged E2F1 or HA-tagged hHR23A from mammalian cell 
lysates respectively (Figure 3.2E, 3.2F).  
  
  
 
 
Figure 3.2:  Association of hHR23A and E2F1.  
A, B. Primary keratinocytes were transfected with vectors encoding V5-tagged E2F1 
with or without FLAG-tagged hHR23A or HA- and GFP-tagged hHR23A and cultured 
for 24 h after transfection in Low Ca2+ or in High Ca2+ medium, to induce differentiation. 
Cell lysates were prepared and immunoprecipitated with anti-FLAG or anti-V5 
antibodies, as indicated, or an irrelevant IgG. Immune complexes were resolved by 
denaturing gel electrophoresis, transferred to membranes, and the blots were probed with 
the indicated antibodies. Samples of lysates used for immunoprecipitation show 
expression levels of exogenous proteins. γ-Tubulin was used to normalize for protein 
loading, and the asterisks indicate a non-specific band. n=3. C. Lysates prepared from 
transfected keratinocytes as in (A, B), were immunoprecipitated with anti-E2F1 
antibodies, to isolate endogenous and/or exogenous E2F1 immune complexes. Replicate 
lysate samples were also analyzed to show expression levels of endogenous and 
exogenous proteins. n=3. D. Bacterially produced GST, GST-E2F1, as well as His- and 
FLAG-tagged hHR23A (2 μg each) were used in immunoprecipitation experiments with 
anti-GST or anti-His antibodies, as indicated. The immune complexes were further 
analyzed by immunoblot, using anti-FLAG or anti-E2F1 antibodies. The lanes labelled 
“Input” contain 100 ng each of the indicated recombinant proteins. n=3. E. GST fusion 
E2F1 from bacterial extracts were incubated with cell lysates prepared from 
undifferentiated keratinocytes transfected with HA-tagged hHR23A for 16 h at 4ºC. The 
protein mixtures were subjected for GST pull down and immunecomplexes were 
analyzed by immunoblot with anti-HA antibodies, to detect hHR23A. n=3. F. His fusion 
FLAG-tagged hHR23A from bacterial extracts were incubated with cell lysates prepared 
from keratinocytes transfected with V5-tagged E2F1. The protein complexes were 
subjected for His pull down and analyzed by immunoblot using anti-V5 antibodies, to 
detect E2F1. Samples of the lysates were also analyzed by immunoblot with the indicated 
antibodies. n=3.  
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3.2 Modulation of hHR23A subcellular localization by E2F1 
Given that hHR23 proteins and their orthologues are involved in both proteasomal 
degradation and DNA repair, the subcellular localization of exogenously expressed 
hHR23A in undifferentiated keratinocytes was investigated. I observed that hHR23A 
exhibited cytoplasmic distribution in about 90% of the cells (Figure 3.3A). This pattern 
markedly differs from that observed in transformed HeLa cells, which show nuclear 
concentration of hHR23A (Figure 3.3B).  
In many cell types, including undifferentiated keratinocytes, E2F1 is predominantly 
found in the nucleus, although it exhibits nucleocytoplasmic shuttling (Ivanova et al., 
2007) (Figure 3.3A). Significantly, the joint expression of hHR23A and E2F1 resulted in 
the co-localization of both proteins in the nucleus of almost all keratinocytes (Figure 
3.3A).  Induction of differentiation in keratinocytes promotes E2F1 nuclear export and 
degradation (Ivanova and Dagnino, 2007). Thus, it was of interest to investigate if the 
presence of cytoplasmic E2F1 in these cells was associated with loss of nuclear pools of 
hHR23A. Keratinocytes were cultured in medium containing either 0.12 mM or 1.0 mM 
Ca2+, and found that in both culture conditions, when E2F1 was cytoplasmic, hHR23A 
was also excluded from the nucleus (Figure 3.3C). These observations are consistent with 
the concept that E2F1 is capable of modulating hHR23A subcellular localization and 
recruitment into the nucleus, possibly mediated via complex formation between these two 
proteins. 
  
  
 
 
 
 
 
Figure 3.3: Modulation of hHR23A subcellular distribution by E2F1.  
A. Primary keratinocytes or B. HeLa cells were transfected with vectors encoding the 
indicated proteins, and 24 h later were processed for immunofluorescence microscopy 
using the indicated antibodies. The histograms represent the average fraction of cells with 
nuclear (N) or cytoplasmic (C) protein distribution + SEM (n=4). At least 100 transfected 
cells per condition were scored in each experiment. The asterisks indicate P<0.05, 
relative to cells transfected with single vectors (ANOVA). F-actin and DNA were 
visualized, respectively, with phalloidin and Hoechst 33342. Bar, 25 μm. C. Subcellular 
distribution of hHR23A and E2F1 in differentiated keratinocytes. Keratinocytes were 
transfected with vectors encoding the indicated proteins, and 4 h after transfection cells 
were induced to differentiate by culture in growth medium with the indicated Ca2+ 
concentration. The cells were processed for immunofluorescence microscopy using anti-
V5 and anti-HA antibodies to detect, respectively, E2F1 and hHR23A. DNA was 
visualized with Hoechst 33342. Bar, 25 μm. 
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3.3 hHR23A domains involved in binding to E2F1 
To begin to understand the biological significance of E2F1 binding to hHR23A, I next 
undertook an analysis of the protein domains involved in these interactions. As a scaffold 
protein, hHR23A has several functionally important domains that mediate interactions 
with ubiquitin and/or various ubiquitin-unrelated proteins (Dantuma et al., 2009). To 
identify which of those regions are important for E2F1 binding, I exogenously expressed 
several GFP- and HA-tagged hHR23A deletion mutants (Figure 3.4A). The use of GFP-
tagged hHR23A allowed for the confirmation that the GFP moiety did not affect the 
ability of hHR23A to bind E2F1 (Figure 3.4B, 3.4C), and allowed for efficient expression 
of small hHR23A domains for analysis. The N-terminal ubiquitin-like domain (UbL) in 
hHR23A mediates binding to the proteasome, and is important for protein-protein 
interactions. The deletion of this domain (∆UbL hHR23A) did not affect the ability of 
hHR23A to interact with E2F1 (Figure 3.4B, 3.4C). hHR23A has two ubiquitin-
associated domains, UBA1 and UBA2, which mediate interactions with ubiquitin 
moieties conjugated to various proteins.  When I exogenously expressed two hHR23A 
fragments corresponding to UBA1 or UBA2, I observed that only the former was able to 
associate with E2F1 (Figure 3.4B). Thus, the contribution of UBA2 to hHR23A binding 
to E2F1 is likely negligible, if any. In a complementary approach, I also investigated the 
consequences of deleting UBA1 or UBA2 in the context of the entire hHR23A protein 
(hHR23A ∆UBA1 or ∆UBA2), and observed efficient binding of these mutants to E2F1 
(Figure 3.4B). This suggests that, in addition to UBA1, other hHR23A regions likely 
contribute to its association with E2F1.  hHR23 proteins bind the  XPC via their XPC 
  
 
 
 
 
 
 
Figure 3.4: hHR23A domains involved in E2F1 binding.  
A. Schematic of GFP- and HA- doubly tagged hHR23A proteins analyzed for their ability 
to bind E2F1. B. and C. Primary keratinocytes were transfected with vectors encoding 
V5-tagged E2F1 and the indicated hHR23A proteins. Twenty-four hours after 
transfection, cell lysates were prepared and hHR23A immune complexes were isolated 
and analyzed by immunoblot with the indicated antibodies, and γ-Tubulin was used to 
normalize for protein loading. A portion of the lysates from cells co-expressing wild type 
(WT) hHR23A and V5-tagged E2F1 were also used for immunoprecipitation with an 
unrelated IgG control. n=4. 
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 domain (Dantuma et al., 2009).  To determine if the XPC region contributes to E2F1 
binding, an hHR23A mutant composed of only the XPC and UBA2 domains was 
expressed (hHR23A XPC-UBA2). I reasoned that this mutant would provide information 
on the role of the XPC domain in this process, given our previous observation that UBA2 
does not bind E2F1. I found that this hHR23A form was still able to bind E2F1 fairly 
efficiently (Figure 3.4B, 3.4C). However, the XPC region appears to be sufficient, but not 
indispensable for E2F1 binding, given that an hHR23A mutant lacking these sequences 
(∆XPC) also associates with E2F1 (Figure 3.4C). Together, my observations implicate 
the UBA1 and XPC domains in the association of hHR23A with E2F1.   
I undertook a similar analysis to determine the regions in E2F1 involved in binding to 
hHR23A. The N-terminal domain in E2F1 mediates protein-protein interactions, such as 
binding to cyclin A, and contains the nuclear localization and export domains responsible 
for nucleocytoplasmic shuttling (Ivanova et al., 2007). A mutant, constitutively 
cytoplasmic E2F1 protein lacking these sequences (E2F1 126-437) associated with 
hHR23A (Figure 3.5A, 3.5B), indicates that nuclear localization of E2F1 is not required 
for this interaction. The C-terminus in E2F1 contains the transcriptional activation 
domain, and mediates protein-protein interactions with other proteins, including those in 
the retinoblastoma family (reviewed in (Meng and Ghosh, 2014)), but it was also 
dispensable for hHR23A binding (Figure 3.5B). Similarly, E2F1 proteins incapable of 
both cyclin A and retinoblastoma binding also formed complexes with hHR23A (Figure 
3.5B). Of note, E2F1 contains 14 lysine residues that can potentially be modified by  
  
 
 
 
 
 
 
 
Figure 3.5: Regions in E2F1 involved in binding to hHR23A. 
A. Schematic of V5-tagged E2F1 proteins analyzed. B. Primary keratinocytes were 
transfected with vectors encoding wild type hHR23A and the indicated V5-tagged E2F1 
proteins. Twenty-four hours after transfection, cell lysates were prepared and hHR23A 
immune complexes were isolated using anti-HA antibodies. The immune complexes were 
resolved by denaturing gel electrophoresis, and analyzed with the indicated antibodies. γ-
Tubulin was used to normalize for protein loading. Lysates from cells co-expressing 
E2F1 and wild type (WT) hHR23A were used for immunoprecipitations using anti-HA 
antibodies, or an unrelated, control IgG. n=3. 
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ubiquitylation and, given that the ubiquitin-binding UBA1 domain in hHR23A 
participates in the interaction between these two proteins, it is conceivable that no single 
region in E2F1 is indispensable. 
3.4 Inhibition of E2F1 degradation by hHR23 proteins 
E2F1 ubiquitylation includes K11-, K48- and K63-linked polyubiquitin chains, which can 
promote its proteasomal degradation (Wang et al., 2015). To begin to characterize the 
functional significance of the interactions between hHR23 proteins and E2F1, 
keratinocytes were exogenously expressed with V5-tagged E2F1 and HA-tagged wild 
type ubiquitin, in the presence or absence of hHR23 proteins. Next, HA-containing 
immune complexes were isolated and investigated therein the presence of E2F1. This 
approach examined the effects of hHR23 on the abundance of ubiquitylated E2F1. In the 
absence of exogenous hHR23 proteins, and consistent with previous reports (Ivanova et 
al., 2006), low levels of ubiquitylated E2F1 in both undifferentiated and differentiated 
keratinocytes were detected, likely because it efficiently undergoes proteasomal 
degradation (Figure 3.6A, 3.6B). The presence of either hHR23A or hHR23B 
substantially increased the abundance of ubiquitylated E2F1, irrespective of the 
differentiation status of the keratinocytes. Thus, hHR23 proteins appear to protect E2F1 
from degradation, although this effect does not appear to involve interference with E2F1 
ubiquitylation per se (Figure 3.6A, 3.6B). Next, the effect of proteasomal inhibition on 
modulation by hHR23A of polyubiquitylated E2F1 was determined. To this end, I 
exogenously expressed V5-tagged E2F1 together with HA-tagged wild type ubiquitin and 
FLAG-tagged hHR23A as before, and assessed the effect of proteasomal inhibition by  
  
 
 
 
 
 
Figure 3.6: Modulation of ubiquitylated E2F1 degradation by hHR23 proteins.  
A. Primary undifferentiated keratinocytes were transfected with vectors encoding V5-
tagged E2F1 and HA-tagged ubiquitin, in the presence or absence of hHR23-encoding 
vectors, as indicated. The cells were cultured for 24 h in Low Ca2+ (undifferentiated 
keratinocytes) or High Ca2+ medium (differentiated keratinocytes) in the absence of 
MG132. Cell lysates were prepared and ubiquitylated proteins were immunoprecipitated 
with anti-HA antibodies. HA immune complexes were analyzed with anti-V5 antibodies, 
to detect ubiquitylated E2F1 in the immune complexes. The asterisk indicates a lower 
mobility non-specific band. n=3. B. Primary undifferentiated keratinocytes were 
transfected with a vector encoding V5-tagged E2F1 and either wild type (WT) ubiquitin, 
or a ubiquitin mutant lacking all Lys residues (K0), in the presence or absence of FLAG-
tagged hHR23A. Keratinocytes were treated with vehicle (dimethylsulfoxide) or MG132 
(10 μM) for 6 h, and cell lysates were prepared, immunoprecipitated with anti-HA 
antibodies and analyzed for the presence of ubiquitylated V5-E2F1, as in (A). n=3. 
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MG132 on the abundance of E2F1. A robust increase in polyubiquitylated E2F1 in the 
presence of hHR23A was slightly enhanced in MG132-treated cells (Figure 3.6B), 
indicating that exogenous expression of hHR23A does not impair proteasomal activity 
but interferes with the ability of the proteasome to target E2F1 for degradation.  
The UBA domains of hHR23A exhibit maximum affinity for chains composed of 4-6 
ubiquitin residues (Raasi et al., 2004). Cellular proteins can be modified by polyubiquitin 
chains linked through isopeptide bonds between the terminal glycine (G76) in ubiquitin 
and one of the seven Lys residues on another ubiquitin moiety. To determine whether the 
stabilizing effect of hHR32A required the presence of polyubiquitin chains on E2F1, I co-
expressed V5-tagged E2F1, FLAG-tagged hHR23A and an HA-tagged mutant ubiquitin 
form lacking all lysine residues (K0). This mutant is presumably incapable of forming 
polyubiquitin chains, although it can still contribute to monoubiquitylation (Lim et al., 
2005).  In the absence of MG132, I found negligible E2F1 immunoreactivity in ubiquitin-
K0 immunoprecipitates (Figure 3.6B). Significantly, proteasomal inhibition was 
associated with the presence of abundant poly-ubiquitylated E2F1 species (Figure 3.6B). 
These observations suggest that hHR23A preferentially modulates the degradation of 
poly-ubiquitylated E2F1, although monoubiquitin modification of the latter on one or 
more Lys residues likely also takes place in keratinocytes, without precluding its 
proteasomal degradation. 
The outcomes of hHR23 modulation of proteasome-mediated proteolysis are complex.  In 
some cases, they deliver polyubiquitylated substrates to the proteasome for destruction 
(Verma et al., 2004). In others, they impede the interaction of bound proteins with the 
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proteasome, thus suppressing their degradation (Blount et al., 2014). First, I assessed the 
effect of increasing amount of hHR23A on the stability of E2F1 and showed that E2F1 
levels gradually increased with increasing amount of hHR23A (Figure 3.7A). To further 
confirm that hHR23 negatively modulates E2F1 turnover, I used cycloheximide chase 
assays to determine E2F1 apparent half-life (t½) in undifferentiated keratinocytes 
expressing wild type or mutant hHR23A proteins (Figure 3.7B).  The apparent t½ of V5-
E2F1 was 77±8 min, which was increased 3- and 2-fold, respectively, in the presence of 
similar levels of wild type hHR23A and hHR23B. Thus, although both hHR23 forms are 
able to stabilize E2F1, the effect of hHR23A would appear to be more pronounced.  
Similar to full-length hHR23A, ∆UbL GFP-hHR23A, which can efficiently bind E2F1, 
increased its apparent t½ 3-fold to 185±5 min. In contrast, expression of UBA2 GFP-
hHR23A did not significantly alter E2F1 t½, consistent with the notion that the 
stabilizing effect of hHR23A requires its association with E2F1, and that UBA2 does not 
associate with this transcription factor. Although the UBA2 domain does not participate 
in binding to or stabilizing E2F1, it is critical for the ability to hHR23A to escape 
proteasomal degradation itself, and its deletion markedly increases hHR23A turnover 
(Heinen et al., 2011). Consistent with these characteristics, I observed that, whereas the 
apparent t½ of wild type hHR23A was > 6 h, the apparent t½ of ∆UBA2 GFP-hHR23A 
was only about 4 h (Figure 3.7B).  Further, ∆UBA2 GFP-hHR23A was without effect on 
E2F1 apparent t½, suggesting that insufficient pools of the former protein may have been 
available to protect exogenous E2F1 from degradation. 
  
  
 
 
 
 
Figure 3.7: Modulation of E2F1 t½ by hHR23 proteins.  
A. Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged 
E2F1 with the indicated DNA concentration of FLAG-tagged hHR23A. Cell lysates were 
prepared 24 h later and analyzed by immunoblot with the indicated antibodies. The 
histograms represent quantification of E2F1 proteins (mean + SEM, n=3), relative to 
E2F1 abundance in the absence of exogenous hHR23A, which is set at 100%. The 
asterisks indicate P<0.05 relative to E2F1 levels in cells cultured in Low Ca2+ medium in 
the absence of exogenous hHR23A proteins (ANOVA). B. Primary undifferentiated 
keratinocytes were cotransfected with vectors encoding V5-tagged E2F1 and the 
indicated FLAG- or HA-tagged hHR23 proteins. Twenty-four hours after transfection, 
cycloheximide (CHX, 100 μg/ml, final) was added to the culture medium, and cell lysates 
were prepared at the indicated time intervals thereafter. The lysates were analyzed by 
immunoblot with the indicated antibodies, and γ-Tubulin was used to normalize for 
protein loading. The graphs represent the mean ± SD of E2F1 levels quantified in 
replicate immunoblots generated from lysates prepared from three independent cell 
isolates, and were used to calculate E2F1 apparent t½ (mean ± SD, n=3) in the presence 
of each hHR23 protein, as summarized in the chart. The asterisks indicate P<0.05 relative 
to E2F1 t½ in the absence of any exogenous hHR23 protein (ANOVA). 
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3.5 Modulation of DNA damage repair by hHR23A and 
E2F1 
Following DNA damage, hHR23A participates in NER processes, whereas E2F1 is 
stabilized, either promoting apoptosis or stimulating DNA repair (Biswas et al., 2014). 
Given that a major source of DNA damage in keratinocytes is UV radiation, I examined 
the responses of these two proteins to UV-induced DNA damage.  I observed that 
endogenous E2F1 levels are increased by UVB radiation or by expression of hHR23A, 
and the presence of exogenous hHR23A further increased E2F1 levels in UVB-treated 
keratinocytes (Figure 3.8A). The kinetics of exogenous E2F1 and hHR23A proteins were 
also examined following UVB radiation. A time course of post- irradiation was carried 
out at 0, 3 and 6 h.  The protein levels of hHR23A did not change 6 h post-irradiation, 
whereas E2F1 showed increased protein levels at 6 h (Figure 3.8B). Interestingly, when 
E2F1 and hHR23 were co-expressed, the expression levels of both proteins peaked at 3 hr 
and returned to control levels by 6 hr (Figure 3.8B). Next, I determined if hHR23A 
subcellular localization was regulated by DNA damage in primary keratinocytes, using 
filtered UV radiation coupled with immunofluorescence microscopy (Guo et al., 2010; 
Mone et al., 2001). Cells were irradiated with UV light through a filter (3-µm pore size), 
and nuclear regions containing UV-induced photoproducts were identified with an 
antibody specific for CPD. UVB radiation penetrated through the entire filter, giving rise 
to CPD-positive nuclei, rather than discrete CPD-positive areas with DNA damage 
(Appendix 1A). UVC radiation did not penetrate through the entire filter, and was 
transmitted down the nuclear DNA only through the pores (Appendix 1B). This allowed  
  
 
 
 
 
 
 
 
Figure 3.8: Effect of UVB radiation on E2F1 levels in keratinocytes.  
Primary keratinocytes expressing HA-tagged hHR23A and/or V5-tagged E2F1 was 
exposed to A. 250 J/m2 of UVB, and whole cell lysates were prepared 24 h after 
irradiation, n=3 or B. 100 J/m2 of UVB, and cell lysates were prepared at indicated time 
point post-irradiation to analyze levels of the indicated proteins. GAPDH levels were 
used to normalize for protein loading. The graphs in (B) represent the mean ± SD (n=3) 
of hHR23A (left) and E2F1 (right) levels quantified in replicate immunoblots generated 
from lysates prepared from three independent cell isolates.  
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detection of discrete CPD-positive DNA damaged foci. Therefore, I used light in the 
UVC spectrum for these experiments. Although, UVC light does not reach the earth 
surface because it is absorbed by the ozone layer, both UVB and UVC radiation induce 
the same type of DNA damage and activate the same DNA repair pathways, making the 
use of UVC irradiation physiologically relevant. It was observed that UV treatment of 
keratinocytes induced cytoplasm-to-nucleus translocation of hHR23A (Figure 3.9). In the 
majority of cells expressing exogenous E2F1, E2F1 was substantially enriched in nuclear 
areas that exhibited CPD immunoreactivity (Figure 3.9). Significantly, when E2F1 and 
hHR23A were co-expressed, both proteins concentrated in CPD-positive regions, 
indicating that E2F1 promotes enrichment of hHR23A at sites of UV-induced DNA 
damage in primary keratinocytes (Figure 3.9).  
Next, I investigated if the increased localization of hHR23A to DNA photolesions in the 
presence of E2F1 was associated with changes in DNA repair.  To this end, I transfected 
cells with vectors encoding hHR23A and/or E2F1, subjected the cells to 100 J/m2 UVB 
radiation, and measured CPD abundance in genomic DNA (indicative of NER) as a 
function of time. Because UVB treatment of transfected primary keratinocytes resulted in 
variable proportions of transfected cell death among different cell isolates, I conducted 
this experiment on HeLa cervical carcinoma cells, in which no such variability was 
observed. CPD levels in control cells transfected with empty vector decreased by about 
30%-40% of initial values 3 h after UVB treatment, and did not decrease substantially 
further 6 h after UVB treatment (Figure 3.10A). CPD levels in cells expressing E2F1 or 
hHR23A had decreased by about 20%-25% 6 h after UVB treatment. In contrast, in cells  
  
 
 
 
 
 
 
 
Figure 3.9: Co-localization of E2F1 and hHR23 at DNA damage sites following UV 
radiation.  
Keratinocytes were transfected with vectors encoding the indicated proteins, and 24 h 
later were subjected to UVC irradiation through 3-μm polycarbonate isopore filters, and 
cultured for 2 h. The cells were processed for immunofluorescence microscopy to detect 
cyclobutane pyrimidine dimers (CPD), V5-tagged E2F1 and HA-tagged hHR23A. 
Nuclear DNA was visualized with Hoechst 33342. Bar, 25 μm. n=3 
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Figure 3.10: Increased repair of UV-induced DNA damage by E2F1 and hHR23A. 
A. HeLa or B. RPMI 7951 human melanoma cells transfected with plasmids encoding the 
indicated proteins were subjected to UVB irradiation (100 J/m2). Genomic DNA was 
isolated at the indicated times after UVB treatment, and analyzed for the presence of 
CPD as described in “Materials and Methods”. CPD levels were normalized to the 
amount of dsDNA. The histograms show the fraction of normalized CPD signal 
remaining after 3 or 6 h, relative to CPD 0.1 h after irradiation (set to 100%), for each 
transfection group. The results are expressed as the mean + SD (n=3), and the asterisks 
indicate P<0.05 (ANOVA). 
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co-expressing E2F1 and hHR23A, CPD levels steadily decreased by about 40% and 60%, 
respectively, 3 h and 6 h following UVB exposure. Similar results were observed in 
RPMI 7951 human melanoma cells (Figure 3.10B). Thus, the joint expression of E2F1 
and hHR23A accelerates CPD removal and DNA repair following UVB damage. 
3.6 Amino acid residues in E2F1 that contributes to its 
stabilization following drug-induced DNA damage 
E2F1 accumulates in mouse embryonic fibroblasts (MEF) and cancer cell lines when 
treated with various chemotherapeutic drugs (Lin et al., 2001).  Several residues on E2F1 
are essential for its stabilization following DNA damage. They include Ser31, Arg111, 
Arg113, Lys117, Lys120, Lys125, Lys185, Ser403, and Thr433 (Cho et al., 2012; 
Kontaki and Talianidis, 2010; Lin et al., 2001; Pediconi et al., 2003; Real et al., 2010; 
Xie et al., 2011b). The importance of these residues has been established by site-directed 
mutagenesis studies in transformed cell lines. However, their importance in primary cells 
treated with DNA damaging agents has not been studied. Therefore, to better understand 
the role of each residue on E2F1 in response to DNA damage, the following constructs 
were made: a single mutant with Ser to Ala substitution on a.a. site 31 (S31A); a single 
mutant with Lys to Arg substitution on a.a. site 185 (K185R); a triple mutant with Lys to 
Arg substitution on a.a. sites 117, 120, and 125 (KTR); a double mutant with Arg to Lys 
substitution on a.a. sites 111 and 113 (RDK); and a double mutant with Ser to Ala 
substitution on a.a. sites 403 and 433 (ST/A). The various E2F1 mutants were 
exogenously expressed in primary mouse keratinocytes and subsequently DNA double 
strand breaks was induced by treating the cells with 150 µM etoposide. 
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Consistent with previous studies on transformed cell lines and MEFs, the protein levels of 
wild-type E2F1 increased and the E2F1-S31A mutant failed to accumulate following 
etoposide treatment in undifferentiated and differentiated keratinocytes (Figure 3.11). 
The KTR triple E2F1 mutant also showed impaired induction following treatment with 
etoposide in differentiated keratinocytes (Figure 3.11). These results indicate that 
modifications at Ser31, Lys117, Lys120, and Lys125 play an essential role in stabilizing 
E2F1 in response to DNA damage not only in transformed cell lines but also in primary 
mouse keratinocytes. However, in undifferentiated keratinocytes, the KTR triple E2F1 
mutant protein levels increased following etoposide treatment (Figure 3.11). This 
indicates that multiple mechanisms contribute to E2F1 induction in response to DNA 
damage. On the other hand, the K185R, RDK, or ST/A E2F1 mutant increased following 
etoposide treatment in undifferentiated and differentiated keratinocytes (Figure 3.11). 
This indicates that these residues are not essential for E2F1 accumulation and 
stabilization following DNA damage. 
3.7 Identification of E2F1 amino acid residues required for 
nuclear export and stabilization in differentiated 
keratinocytes 
Following Ca2+-induced keratinocyte differentiation, E2F1 is exported to the cytoplasm 
and substitutions of Ser403 and Thr433 to Ala (ST/A) generated a mutant protein that is 
defective in nuclear export and is more stable than WT-E2F1 (Ivanova and Dagnino, 
2007; Ivanova et al., 2009). Whether other amino acid residues on E2F1 are required for 
its nuclear export and stabilization is yet to be elucidated. First, residues shown to be 
required for the interaction between E2F1 and pRb were examined. During the cell cycle,  
  
 
 
 
 
 
 
Figure 3.11: Changes in E2F1 levels in response to etoposide. 
Vectors encoding V5-tagged wild type (WT) E2F1 or the indicated mutants were 
transfected in undifferentiated keratinocytes. Fours after transfection, the cells were 
cultured in Low (-) or High (+) Ca2+ medium, and 24 h later, they were incubated in the 
absence or presence of etoposide (150 µM). Cell lysates were prepared 8 h later and 
analyzed by immunoblot, using anti-V5 antibodies or GAPDH as loading control. The 
histograms represent normalized densitometric quantification of each E2F1 protein (mean 
+ SEM, n=3), and are expressed as percentage of a given E2F1 form relative to its 
abundance in Low Ca2+ medium, which is set at 100%. The asterisks indicate P<0.05, and 
# indicate P<0.05 relative to the corresponding E2F1 mutant protein levels in cells 
cultured in Low Ca2+ medium in the absence of etoposide (ANOVA). 
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E2F1 is specifically regulated by associating with pRb. The interaction between pRb and 
E2F1 protects E2F1 from ubiquitylation; therefore, events that affect the association 
between pRb and E2F1 could regulate E2F1 stability. Phosphorylation at Ser332 and 
Ser337 is required for the dissociation of E2F1 from pRb (Fagan et al., 1994), whereas 
phosphorylation at Ser375 favors pRb binding to E2F1 (Peeper et al., 1995). To test 
whether the association with pRb plays a role in E2F1 nuclear export and degradation, 
three E2F1 single mutants with serine to alanine substitutions at sites 332 (S332A), 337 
(S337A), or 375 (S375A) were generated and expressed in keratinocytes. These three 
mutant E2F1 showed no apparent defect in nuclear export and were efficiently degraded 
in differentiated keratinocytes in a similar manner as wild-type E2F1 (WT-E2F1), which 
is significantly different from the ST/A mutant E2F1 protein (Figure 3.12, 3.13). These 
findings indicated that the residues known to promote the association or dissociation 
between E2F1 and pRb may not be essential for the Ca2+-induced nuclear export and 
degradation of E2F1 in keratinocytes. 
As mentioned earlier, during DNA damage, E2F1 is post-translationally modified, which 
contributes to its increased stability. Thus, residues involved in the stabilization of E2F1 
were examined. The triple KTR E2F1 mutant showed increased cytoplasmic localization 
(Figure 3.12) and decreased E2F1 abundance following Ca2+-induced keratinocyte 
differentiation (Figure 3.11, 3.13), similar to that observed with WT-E2F1. This indicates 
that these three lysine residues are dispensable for regulation of E2F1 abundance upon 
keratinocyte differentiation. Similarly, S31A, K185R, RDK and S364A E2F1 mutants 
also showed increased nuclear export (Figure 3.12) and decreased E2F1 protein levels   
  
 
 
 
 
 
 
Figure 3.12: Ser403 and Thr433 are required for E2F1 nuclear export during 
keratinocyte differentiation.  
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild 
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the 
culture medium was replaced with Low or High Ca2+ medium, and the cells were 
processed for immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA 
was visualized with Hoechst 33342. The photomicrographs represent three replicas, and 
100 cells per experiment were analyzed. The values in the histograms represent the 
percentage of cells (mean + SEM, n=5) that exhibited nuclear (N, green bar) or 
cytoplasmic (C, yellow bar) E2F1 distribution. The asterisks indicate P<0.05 relative to 
values in the corresponding subcellular compartments in Low Ca2+ medium (ANOVA). 
Bar, 16 μm. KTR: K117R/K120R/K125R; RDK: R109K/R113K; ST/A: S403A/T433A. 
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Figure 3.13: Ser403 and Thr433 mediate E2F1 degradation during keratinocyte 
differentiation.  
Vectors encoding V5-tagged wild type (WT) or the indicated E2F1 mutants were 
transfected in undifferentiated keratinocytes. Twenty-four hours after transfection, cells 
were treated with cycloheximide (CHX, 100 μg/ml) and 30 min later the culture medium 
was replaced with Low or high Ca2+ medium supplemented with CHX. Cell lysates were 
prepared 2.5 h later and analyzed by immunoblot for the indicated proteins, using anti-V5 
antibodies, or γ-Tubulin as loading control. The histograms represent normalized 
densitometric quantification of each E2F1 protein (mean + SEM, n=3), and are expressed 
as percentage of a given E2F1 form relative to its abundance in Low Ca2+ medium, which 
is set at 100%. The asterisks indicate P<0.05 (ANVOA). KTR: K117R/K120R/K125R; 
RDK: R109K/R113K; ST/A: S403A/T433A. 
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following Ca2+ induction, as seen with WT-E2F1 (Figure 3.11, 3.13). Therefore, these 
data indicate that residues involved in the regulation of E2F1 levels following DNA 
damage are not major contributors to E2F1 stability, whereas Ser403 and Thr433 are 
involved in E2F1 nuclear export and degradation following Ca2+-induced differentiation. 
3.8 Nuclear export is not the only mechanism required for 
E2F1 ubiquitylation and degradation following keratinocyte 
differentiation 
E2F1 nuclear export and ubiquitylation are both required for the degradation of E2F1 
following Ca2+-induced keratinocyte differentiation. When differentiated keratinocytes 
are exposed to a specific inhibitor of CRM1-mediated nuclear export, LMB, E2F1 
accumulates in the nucleus and its stability increases (Ivanova and Dagnino, 2007). This 
indicates that E2F1 nuclear export is required for E2F1 degradation following 
keratinocyte differentiation. However, whether nuclear export could inhibit E2F1 
ubiquitylation has yet to be elucidated. First, the subcellular compartment of E2F1 
ubiquitylation was assessed by exogenously expressing V5-tagged E2F1 and HA-tagged 
wild type ubiquitin in keratinocytes. Subsequently, cells were treated with ethanol or 
LMB to prevent nuclear export and lysates were harvested from whole cell, nuclear, and 
cytoplasmic fractions. HA-containing immune complexes were isolated and the presence 
of E2F1 was investigated. In differentiated keratinocytes, the abundance of ubiquitylated 
E2F1 was indistinguishable in the presence or absence of LMB (Figure 3.14). Further, the 
presence of polyubiquitylated E2F1 species was detected in both nuclear and cytoplasmic 
fractions (Figure 3.14). These results indicate that nuclear export is not required for E2F1 
ubiquitylation, and the ubiquitin enzymes that promote E2F1 ubiquitylation are present in  
  
 
 
 
 
 
 
Figure 3.14: E2F1 is polyubiquitylated in the nucleus and in the cytoplasm when 
keratinocytes are induced to differentiate with Ca2+.   
Undifferentiated keratinocytes were transfect with vectors encoding V5-tagged wild type 
(WT) E2F1 and HA-tagged ubiquitin. Twenty-four hours later, MG132 (10 µM) was 
added to the culture medium, followed 3 h later by leptomycin B (LMB, 10 ng/ml) or 
ethanol (vehicle). Cultures were incubated in the presence of both drugs for 30 min, at 
which time the Ca2+ concentration was adjusted to 1.0 mM. Lysates containing whole-
cell (T), nuclear (N), and cytoplasmic (C) fractions were prepared 2.5 h later, HA-
ubiquitin immunecomplexes were isolated, resolved by denaturing gel electrophoresis, 
and analyzed with anti-V5 antibodies to detect ubiquitylated V5-tagged E2F1. Antibodies 
against β-Tubulin and Lamin A/C were used to verify the purity of the fractionated 
extracts and as loading controls. n=3. 
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the nucleus and in the cytoplasm. The increase in stability of the ST/A mutant E2F1 
protein could be due to alterations in E2F1 ubiquitylation. Therefore, the importance of 
these residues for E2F1 ubiquitylation was examined. Consistent with previous accounts 
(Ivanova and Dagnino, 2007), the abundance of polyubiquitylated WT- E2F1 species was 
increased following Ca2+ induction (Figure 3.15). Interestingly, the ST/A E2F1 mutant 
was polyubiquitylated in undifferentiated keratinocytes and differentiation increased the 
abundance of the polyubiquitylated ST/A E2F1 mutant species (Figure 3.15). This 
indicates that ST/A is still ubiquitylated but not degraded as seen with the WT-E2F1.   
The increase in stability of the ST/A mutant suggested that nuclear export is essential for 
degradation in differentiated keratinocytes (Ivanova et al., 2009). If nuclear export is the 
only mechanism involved in E2F1 degradation, it is predicted that sequestrating the ST/A 
mutant E2F1 to the cytoplasm should induce its degradation in differentiated 
keratinocytes. To test this, an ST/A mutant containing a.a. encoding for the NES present 
in Simian Virus 40 (SV40) large T antigen, which directs CRM1-mediated nuclear 
export, was generated. The addition of NES to wild-type E2F1 (WT-E2F1-NES) 
produced a protein that is 100% cytoplasmic in both undifferentiated and differentiated 
keratinocytes (Figure 3.16A), and its protein levels decreased upon Ca2+-induced 
differentiation (Figure 3.16B). Similarly, the addition of NES sequences to E2F1 ST/A 
(ST/A-NES) also produced a protein that is 100% cytoplasmic in both undifferentiated 
and differentiated keratinocytes (Figure 3.16A). However, the protein levels of ST/A-
NES remained the same in differentiated keratinocytes (Figure 3.16B). This indicates 
nuclear export is not the only mechanism involved in the turnover of E2F1 in 
differentiated keratinocytes. 
  
 
 
 
 
 
Figure 3.15: Ubiquitylation of E2F1 is not affected by mutation of E2F1 at Ser403 
and Thr433 in keratinocytes.  
Undifferentiated keratinocytes were transfected with vectors encoding HA-tagged 
ubiquitin and V5-tagged wild type (WT) or ST/A E2F1. Four hours after transfection, the 
cultured medium was replaced with Low (-) or High (+) Ca2+ medium, and 24 h later, 
they were incubated in the presence of MG132 (10 µM). Cell lysates were prepared 6 h 
later, HA or unrelated IgG immunecomplexes were isolated and analyzed by immunoblot 
with anti-V5 antibodies. The abundance of exogenous E2F1 protein in lysates was 
analyzed by immunoblot, using γ-Tubulin as loading control. The asterisk indicates IgG 
heavy chain. n=5. 
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Figure 3.16: Effect of constitutive nuclear export on E2F1 abundance in 
differentiating keratinocytes.  
A. Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild 
type (WT) or  the indicated E2F1 mutant proteins. Four hours after transfection, the 
culture medium was replaced with Low or High Ca2+ medium, and the cells were 
processed for immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA 
was visualized with Hoechst 33342. The photomicrographs are representative of three 
indepenent cell isolates, and 100 cells per experiment were analyzed. Bar, 16 μm. n=3. B. 
Cells transfected as described in (A) were cultured for 24 h in Low Ca2+ medium. 
Cycloheximide (100 μg/ml) was added, and 30 min later the cells were cultured for 2.5 h 
in Low or High Ca2+ medium supplemented with cycloheximide. Cell lysates prepared 
and analyzed by immunoblot with antibodies against V5 or γ-Tubulin used as loading 
control. The histograms represent normalized densitometric quantification of E2F1 
protein level, and are expressed as the percentage of each E2F1 protein (mean + SEM, 
n=3), and are expressed as the percentage of a given E2F1 form relative to its abundance 
in Low Ca2+ medium, which is set to 100%. The asterisks indicate P<0.05. NES: nuclear 
export sequence. 
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3.9 Role of E2F1 pseudo-phosphorylation at Ser403 and 
Thr433 
To further understand the role of E2F1 Ser403 and Thr433, three E2F1 mutants with 
serine and/or threonine substituted for aspartic acid at sites 403 and/or 433 (S403D, 
T433D, and ST/D) were generated and expressed in keratinocytes. The E2F1 S403D, 
T433D, and ST/D proteins are phospho-mimetic mutants, where the aspartic acid adds a 
negative charge, which mimics phosphorylation of a protein. First, their subcellular 
localization was assessed in the absence or presence of Ca2+. As shown in Figure 3.15, 
WT-E2F1 shows nuclear localization in 90% of undifferentiated keratinocytes and Ca2+ 
treatments leads to a change in E2F1 localization to the cytoplasm in 40% of cells. The 
S403D, T433D, and STD E2F1 mutants also showed 50-55% of cells with cytoplasmic 
localization in differentiated keratinocytes compared to only 20% of cells with 
cytoplasmic localization in undifferentiated keratinocytes (Figure 3.17). The result 
suggests that the presence of Ca2+ contributes to the nuclear export of E2F1 and 
phosphorylation at Ser403 and Thr433 is required for this to occur. 
To further characterize the contribution of Ser403 and Thr433 to overall E2F1 
phosphorylation in keratinocytes, the mobility pattern in lysates from undifferentiated 
and differentiated keratinocytes of WT-E2F1, S403A, T433A, ST/A, S403D, T433D, and 
ST/D was examined. The results showed at least three species of E2F1 with different 
mobility, which collapsed into a single band when treated with λ phosphatase in lysates 
from both undifferentiated and differentiated keratinocytes (Figure 3.18). This indicates 
that E2F1 is phosphorylated in keratinocytes. The S403A and S403D E2F1 mutants had a 
single predominant species that migrated at the same level as the unphosphorylated form  
  
 
 
 
 
 
 
Figure 3.17: Subcellular localization of pseudophosphorylated E2F1 mutant 
proteins in keratinocytes. 
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild 
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the 
culture medium was replaced with Low or High Ca2+ medium and  processed for 
immunofluorescence microscopy 24 h later, using anti-V5 antibodies. DNA was 
visualized with Hoechst 33342. The values in the histograms represent the precentage of 
cells (mean + SEM, n=3) that exhibited nuclear (N) or cytoplasmic (C) E2F1 distribution. 
The asterisks indicate P<0.05 relative to values in the corresponding subcellular 
compartments in Low Ca2+ medium (ANOVA).Bar, 16 μm.  
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Figure 3.18: Ser403 and Thr433 are critical contributors to E2F1 phosphorylation. 
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild 
type (WT) or the indicated E2F1 mutant proteins. Four hours after transfection, the 
culture medium was replaced with Low (Top) or High (Bottom) Ca2+ medium. After 24 
h, cell lyates were prepared and incubated in the presence or absence of λ phosphatase (4 
U/mg lysate protein), resolved by denaturing polyacrylamide gels, and analyzed by 
immunoblot, with antibodies against V5 or γ-Tubulin, used as loading control. n=3. 
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of E2F1, indicating that Ser403 likely contributes to the overall phosphorylation status of 
E2F1. The T433A and T433D E2F1 mutants showed a similar banding pattern as WT-
E2F1 and treatment with λ phosphatase led to an increase in mobility. This suggests that 
other Ser/Thr residues on E2F1 can be phosphorylated when Thr433 is mutated (Figure 
3.18). Finally, the ST/A and ST/D E2F1 mutants behaved similarly to S403A and S403D, 
and these E2F1 mutants migrated with a mobility that was indistinguishable from that 
observed in lysates treated with λ phosphatase (Figure 3.18). This indicates that Ser403 
and to a lesser extent Thr433 are critical contributors to E2F1 phosphorylation in 
keratinocytes. 
3.10 Differentiation-specific role of Ser403 and Thr433 in 
E2F1 degradation 
To determine whether phosphorylation at Ser403 and Thr433 sites has a role in the 
turnover of E2F1 following Ca2+ induction in keratinocytes, the apparent t½ of the 
Ser403 and Thr433 phosphorylation site mutants was examined. In undifferentiated 
keratinocytes, the apparent t½ of E2F1 was 74±0.4 min (Figure 3.19A) and following 
Ca2+ induction, the apparent t½ of E2F1 was 63±3.5 min (Figure 3.19B). In the half-life 
experiments, keratinocytes were treated with Ca2+ for 4 h prior to cycloheximide chase 
assay, by 4 h the steady-state level of E2F1 protein had decreased by 30% (Figure 3.13). 
Therefore, when the cycloheximide chase assay was performed, the change in E2F1 
apparent t½ may not have been apparent. Interestingly, the apparent t½ of S403D 
(124±27 min) and T433D (104±2.3 min) E2F1 was higher than WT-E2F1 in 
undifferentiated keratinocytes (Figure 3.19A), and following Ca2+ induction, the apparent 
t½ were similar to WT-E2F1 (Figure 3.19B), but S403D and T433D E2F1 apparent t½  
  
 
 
 
 
 
Figure 3.19: Ser403 and Thr433 regulated E2F1 protein half-life in differentiated 
keratinocytes. 
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged wild 
type (WT) or the indicated E2F1 mutant proteins. Twenty-four hours after transfection, 
the culture medium was replaced with A. Low or B. High Ca2+ medium, followed by 
addition of cycloheximide (100 µg/ml). Cell lysates were prepared from replicate 
samples at the indicated times thereafter, and analyzed by immunoblot using anti-V5 
antibodies, to detect E2F1, or γ-Tubulin used as loading control. Representative blots of 
each E2F1 protein are shown. The graphs represent the densitometric quantification of 
E2F1 protein levels (mean + S.D., n=3) calculated from experiments conducted on three 
independent keratinocyte isolates, and are expressed as a percentage of levels measured 
at t=0, set to 100%. Decay curves were used to calculate the apparent half-life of each 
E2F1 protein (t½), summarized in the chart. The asterisks indicates P<0.05 relative to t½ 
of a given E2F1 form proteins cultured in Low Ca2+ medium and # indicates P<0.05 
relative to t½ of wild type E2F1 (ANOVA). 
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decreased by 2- and 1.6-fold, respectively, compared to undifferentiated keratinocytes. 
Further, the apparent t½ of ST/D E2F1 was found to be similar to WT-E2F1 in 
undifferentiated keratinocytes (76±15 min). In differentiated keratinocytes, the apparent 
t½ of ST/D E2F1 decreased by 1.6-fold as compared to WT-E2F1 and by 1.8-fold as 
compared to undifferentiated keratinocytes (Figure 3.19). Thus, although the phospho-
mimetic mutants have a similar t½ as WT-E2F1 in undifferentiated keratinocytes, Ca2+ 
induction decreased the t½ of phospho-mimetic E2F1 mutants, suggesting that they are 
subjected to degradation at a higher rate. In contrast, the t½ of ST/A E2F1 was 59±8.9 
min, which was increased by >10-fold in the presence of Ca2+ (Figure 3.19). This 
suggests that E2F1 phosphorylation at Ser403 and Thr433 is required for E2F1 
degradation in Ca2+-induced keratinocyte differentiation. 
3.11 K11- and K48-linkages on E2F1 promotes its 
degradation in differentiated keratinocytes 
The mechanisms of protein ubiquitylation are complex. They involve sequential catalytic 
reactions to transfer ubiquitin onto a substrate protein, and a single ubiquitin monomer 
can then be further ubiquitylated to form polyubiquitin chains through any of the seven-
lysine residues present in ubiquitin. Different ubiquitin linkages can lead to different 
biological outcomes. For example, K48-linked polyubiquitin targets substrates for 
degradation, whereas K63-linked polyubiquitylation targets substrates for changes in 
subcellular localization or endocytosis. Since ST/A is ubiquitylated (Figure 3.15), the 
different types of ubiquitin linkages were examined on WT-E2F1 and E2F1 ST/A mutant 
in undifferentiated and differentiated keratinocytes. Keratinocytes were transfected with 
vectors encoding V5-tagged WT-E2F1 or ST/A and HA-tagged mutant ubiquitin in 
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which all Lys residues were mutated to Arg except for one (K11, K48, or K63) or a 
mutant in which all Lys residues were mutated to Arg (K0). In undifferentiated and 
differentiated keratinocytes, the presence of WT-E2F1 immunoreactivity was detected in 
ubiquitin-K0, -K11, -K48, and -K63 HA-immunoprecipitates (Figure 3.20A, 3.20B). 
Similar to WT-E2F1, ST/D-E2F1 is detected in HA-containing immune complexes when 
cells were exogenously expressing K11-, K48-, or K63-ubiquitin (Figure 3.20C). Further, 
I found robust ubiquitylation of ST/A-E2F1 in undifferentiated keratinocytes when K11- 
or K48- ubiquitin was expressed (Figure 3.20A). This indicates that K11- and K48-
polyubiquitylation of ST/A-E2F1 can occur in keratinocytes. Strikingly, in differentiated 
keratinocytes, E2F1 ST/A ubiquitylation through K11- and K48-linkages was barely 
detectable, but K63-associated modifications were readily detected (Figure 3.20B). These 
results suggest that phosphorylation at Ser403 and/or Thr433 is required for K11- and 
K48-linked ubiquitylation and targeting of E2F1 to the proteasome for degradation when 
keratinocytes are induced to differentiate with Ca2+.   
3.12 Cdh1 regulates E2F1 degradation in keratinocytes 
Three different E3 ubiquitin ligases, Skp2, Cdh1 and Cdc20, are known to ubiquitylate 
E2F1 during S phase, late S phase, and mitosis, respectively (Budhavarapu et al., 2012; 
Marti et al., 1999; Peart et al., 2010). In a high-throughput microarray analysis of the 
keratinocyte transcriptome during differentiation, SKP2 and CDC20 transcripts were 
reportedly down regulated, whereas FZR1 transcripts, which encode Cdh1, were up 
regulated (Toufighi et al., 2015). This indicates that Skp2 and Cdc20 might not be 
involved in regulating E2F1 ubiquitylation and that, potentially, Cdh1 may play a role in 
  
 
 
 
 
 
 
Figure 3.20: Ser403 and Thr433 regulate K11- and K48-linked ubiquitylation of 
E2F1 in differentiated keratinocytes.  
Keratinocytes cultured in Low Ca2+ medium were transfected with vectors encoding the 
indicated V5- tagged and HA-tagged ubiquitin proteins. After 4 h, the cultured medium 
was replaced with A. Low or B. C. High Ca2+ medium, and cells were cultured for 18 h, 
followed by incubation in the presence of MG132 (10 µM) for 6 h. Cell lysates were 
prepared and HA immunecomplexes were isolated and analyzed by immunoblot with 
anti-V5 antibodies. The abundance of exogenous E2F1 and HA-ubiquitin-containing 
proteins in the lysates was analyzed by immunoblot, using γ-Tubulin as loading control. 
n=3. 
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E2F1 turnover in differentiating mouse keratinocytes. 
To test this hypothesis, I exogenously expressed V5-tagged E2F1 in the presence of 
FLAG-tagged -Cdh1 and -Skp2. I then examined E2F1 levels in undifferentiated 
keratinocyte extracts and in extracts isolated from keratinocytes induced to differentiate 
by incubation in High Ca2+ medium for 24 h. Expression of Skp2 had a negligible effect 
on E2F1 protein levels, whereas the presence of exogenous Cdh1 decreased E2F1 
abundance in undifferentiated and in differentiated keratinocytes (Figure 3.21). These 
data suggest that Cdh1 is likely involved in E2F1 degradation in keratinocytes.  
I next conducted experiments to confirm the role of Cdh1 in E2F1 degradation using two 
complementary approaches to interfere with Cdh1 function. First, Cdh1 activity was 
repressed by exogenously expressing the human early mitotic inhibitor 1 (hEmi1), a 
Cdh1 inhibitor (Hsu et al., 2002). To this end, keratinocytes were transfected with vectors 
encoding E2F1 in presence of hEmi1 and/or Cdh1. The cells were maintained 
undifferentiated or induced to differentiate by culture in High Ca2+ medium for 3 h in the 
absence of de novo protein synthesis. This allowed me to assess changes in E2F1 protein 
levels specifically associated with degradation during the early stages of Ca2+ induction 
of differentiation. Exogenous expression of hEmi1 induced a two-fold increase in the 
abundance of E2F1 in undifferentiated keratinocytes (Figure 3.22). Notably, hEmi1 
prevented the decrease in E2F1 levels associated with differentiation, and E2F1 
abundance in cells cultured in High Ca2+ medium was indistinguishable from that in 
undifferentiated keratinocytes (Figure 3.22).  Exogenously expressed hEmi1 was also 
able to interfere with the reduction in E2F1 levels in both undifferentiated and  
  
 
 
 
 
 
 
Figure 3.21: Cdh1 and not Skp2 reduce the abundance of E2F1 protein in 
keratinocytes.   
Primary epidermal keratinocytes cultured in Low Ca2 medium were transfected with 
vectors encoding the indicated FLAG-tagged ubiquitin ligases in the presence of V5-
tagged E2F1 at a ratio of 1:5 (E2F1 and each ubiquitin ligase). Four hours after 
transfection, the culture medium was replaced with Low (-) or High (+) Ca2+ medium and 
continued to culture for 24 h. Cell lysates were prepared and analyzed by immunoblot 
with the indicated antibodies. n=3. 
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Figure 3.22: Inhibition of Cdh1 activity with hEmi1 increases E2F1 protein levels. 
Undifferentiated keratinocytes were transfected with vectors encoding V5-tagged E2F1 
in the presence or absence of vectors encoding FLAG-tagged Cdh1 and myc-tagged 
hEmi1, as indicated. Twenty-four hours later, the cells were treated with cycloheximide 
(100 μg/ml) and the cultured medium was replaced 30 min later with Low (-) or High (+) 
Ca2+ medium. Keratinocyte lysates were prepared 3 h later and analyzed by immunoblot 
with the indicated antibodies. The histograms represent quantification of E2F1 proteins 
(mean + SEM, n=3), relative to E2F1 abundance in Low Ca2+ medium in the absence of 
exogenous Cdh1 and hEmi1, which is set at 100%. The asterisks indicate P<0.05 relative 
to E2F1 levels in cells cultured in Low Ca2+ without other exogenous proteins except 
where otherwise indicated (ANOVA).  
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differentiated keratinocytes observed upon overexpression of Cdh1. In a complementary 
approach, I silenced Cdh1 using RNA interference. A three-fold increase in E2F1 levels 
in undifferentiated keratinocytes treated with Cdh1-targeting siRNA was observed, which 
was unaffected by induction of differentiation following Ca2+ treatment (Figure 3.23). 
Together, these observations indicate that Cdh1 plays key roles in decreasing E2F1 
abundance in differentiating keratinocytes.  
The E2F1 ST/A mutant is stable in differentiated keratinocytes, therefore I determined 
whether Cdh1 could associate and promote the degradation of ST/A E2F1 in 
keratinocytes. FLAG-tagged Cdh1 was co-transfected with V5-tagged WT-E2F1, ST/D, 
or ST/A in undifferentiated keratinocytes, or in cells induced to differentiate by 24 h of 
culture in medium containing 1.0 mM Ca2+. FLAG-Cdh1 immune complexes were 
isolated and analyzed for the presence of E2F1. In these complexes, V5-tagged WT-
E2F1, STD, or ST/A were readily detected, irrespective of the differentiation status of the 
keratinocytes (Figure 3.24A, 3.24B). Unexpectedly, I observed similar decreases in all 
three E2F1 forms (WT, ST/D, or ST/A) in the presence of exogenous Cdh1 (Figure 
3.24A, 3.24B). These results suggest that phosphorylation of E2F1 at Ser403 and/or 
Thr433 is not essential for its interaction with Cdh1, and that a high level of Cdh1 is able 
to target the very stable ST/A E2F1 mutant for degradation. The results presented in 
section 3.11 show that E2F1 ST/A mutant is not defective in forming K11- and K48-
linkages in undifferentiated keratinocytes, but following Ca2+-induced differentiation, 
little or no detectable K11- and K48-associated modifications were observed. Since Cdh1 
could interact with E2F1 ST/A, the lack of K11- and K48-linkages is not likely due to its 
inability to interact with the ubiquitin ligase, but other aspects of the degradation process.  
  
 
 
 
 
 
 
 
Figure 3.23: Cdh1 promotes E2F1 degradation in differentiating keratinocytes. 
Undifferentiated keratinocytes were sequentially transfected with control, non-targeting 
(NC) or Cdh1-targeting siRNAs, followed by transfection with vectors encoding V5-
tagged E2F1, as described in Materials and Methods (Chapter 2, Section 2.13). Cells 
were treated with cycloheximide (100 μg/ml) and the cultured medium was replaced 30 
min later with Low (-) or High (+) Ca2+ medium. Keratinocyte lysates were prepared 3 h 
later and analyzed by immunoblot with the indicated antibodies. The histograms 
represent normalized densitometry quantification of E2F1 levels (mean + SEM, n=3), 
relative to those in cells cultured in Low Ca2+ medium transfected in the presence of NC 
siRNA, which is set to 100%. The asterisks indicate P<0.05 relative to cells transfected in 
the presence of NC siRNA, except where otherwise indicated (ANOVA). 
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Figure 3.24: E2F1 interacts with Cdh1 in keratinocytes. 
Primary epidermal keratinocytes cultured in Low Ca2+ medium were transfected with 
vectors encoding FLAG-tagged Cdh1 and the indicated V5-tagged E2F1 proteins. Four 
hours after transfection, the cells were cultured in Low (-) or High (+) Ca2+ medium for 
24 h. Cell lysates were prepared and subjected to immunoprecipitation with anti-FLAG. 
The immunecomplexes were analyzed by immunoblot with anti-V5 antibodies, to detect 
E2F1. Samples of the lysates were also analyzed by immunoblot with the indicated 
antibodies. n=3. 
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One likely possibility is that E2F1 ST/A associate with deubiquitylase that actively 
remove K11- and K48-linkages. Alternatively, substitution of S403 and T433 with non-
phosphorylatable alanine could specifically associate with ubiquitin ligases that favors 
K63-linkages and inhibits K11- and K48-modifications. 
3.13 E2 conjugating enzyme preferentially interacts with 
ST/A-E2F1 in differentiated keratinocytes  
Ubiquitin-conjugating enzyme 13 (UBC13) is the only known mammalian E2 ubiquitin 
enzyme that catalyzes the formation of K63-linked polyubiquitin chains (Hofmann and 
Pickart, 1999; Thorslund et al., 2015). Since K63-polyubiquitylation on E2F1 was 
observed, the interaction between UBC13 and all three forms of E2F1 (WT-E2F1, ST/A, 
or ST/D) was investigated. In undifferentiated keratinocytes, WT-E2F1, ST/A, and ST/D 
were able to efficiently interact with UBC13 (Figure 3.25A, 3.25B). However, following 
Ca2+ induction of differentiation, the interaction of WT-E2F1 and ST/D was no longer 
detected, whereas that of ST/A was maintained (Figure 3.25A, 3.25B). This indicates that 
modification at Ser403 and Thr433 (potentially phosphorylation) may prevent UBC13 
from interacting with E2F1 when differentiation pathways are activated in keratinocytes. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.25: E2F1 interaction with E2 UBC13 conjugating enzyme is modulated by 
Ser403 and Thr433 in differentiated keratinocytes. 
Undifferentiated keratinocytes were transfected with vectors encoding FLAG-tagged 
UBC13 and the indicated V5-tagged E2F1 proteins. After 4 h, the cells were cultured in 
Low (-) or High (+) Ca2+ medium for 24 h. Cell lysates were prepared and subjected to 
immunoprecipitation with anti-FLAG antibodies. The immunecomplexes were analysed 
by immunoblot with anti-V5 antibodies, to detect E2F1. Samples of lysates were also 
analyzed by immunoblot with the indicated antibodies. n=3. 
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Chapter 4  
4 Discussion 
Epidermal keratinocytes provide a barrier function to protect against environmental and 
physical damage. Keratinocytes undergo constant self-renewal to repair damaged tissues 
and replace old cells that have gone through the normal process of differentiation. 
Therefore, it is crucial to understand the regulation of repair mechanisms and the 
processes that control keratinocyte differentiation. In this thesis, I explored the function 
of E2F1 in these two processes and elucidated some of the mechanisms that regulate 
E2F1 stability and turnover following DNA damage or during differentiation. This study 
showed that the regulation of E2F1 stability plays a critical role during epidermal DNA 
repair and differentiation. First, I identified a novel interaction between E2F1 and 
hHR23A, whereby the stability of E2F1 is modulated by hHR23A. More importantly, I 
showed that following UV-induced DNA damage, E2F1 recruits hHR23A to damage 
sites, which leads to an increase in DNA repair efficiency. Secondly, I demonstrated that 
multiple mechanisms are involved in the degradation of E2F1 following Ca2+-induced 
keratinocyte differentiation, including nuclear export and ubiquitylation. This study 
further shows that Ser403 and Thr433 of E2F1 are likely major phosphorylation sites in 
keratinocytes, and appear to be essential for E2F1 turnover through the formation of K11- 
or K48-linked ubiquitin chains in differentiated keratinocytes. Finally, I showed that the 
ubiquitin ligase Cdh1 mediates E2F1 degradation in differentiated keratinocytes. 
Elucidating the events required for E2F1 turnover in keratinocytes, brings us one step 
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closer to understanding various epidermal diseases such as non-melanoma skin 
carcinoma. 
4.1 E2F1 regulation by hHR23 proteins in keratinocytes 
This study has uncovered a complex reciprocal regulation between hHR23 proteins and 
E2F1. Specifically, hHR23 proteins can bind E2F1 and protect it from proteasomal 
degradation. In turn, E2F1 can recruit hHR23A to the nucleus in the absence of DNA 
damage. Upon photodamage, E2F1 is stabilized and is recruited to DNA lesion sites, 
bringing hHR23A with it, and increasing the efficiency of DNA repair (Figure 4.1). 
hHR23A and the yeast orthologous protein Rad23 function as shuttle proteins that deliver 
ubiquitylated cargo to the proteasome for proteolysis (Chen and Madura, 2002). 
However, hHR23A can also associate directly with unmodified proteins. For example, 
the HIV-1 protein Vpr binds to the UBA2 and XPC domains of hHR23A (Jung et al., 
2014). Similarly, in vitro binding assays with bacterially produced proteins demonstrate 
that hHR23A also binds unmodified E2F1. The association of hHR23A and E2F1 in vivo 
is likely more complex, due to the presence of ubiquitylated E2F1 pools normally 
targeted for proteasomal degradation in mammalian cells. Domain mapping analysis 
clearly indicates that the UBA2 domain in hHR23A is neither necessary nor sufficient for 
E2F1 interaction. The data presented in this thesis further suggests that the UBA1 and 
XPC domains of hHR23A are important regions involved in E2F1 binding in 
keratinocytes. Whereas the XPC domain mediates binding to unmodified E2F1 residues, 
UBA1 also contacts ubiquitylated E2F1. An important area for future research will be to  
  
  
 
 
 
 
 
 
Figure 4.1: Proposed model for hHR23A and E2F1 regulation of DNA repair in 
undifferentiated keratinocytes 
A. In the absence of DNA damage, hHR23A remains mainly localized to the cytoplasm. 
E2F1 is known to undergo nucleocytoplasmic shuttling in these cells, with the 
equilibrium favouring nuclear concentration of this protein. Under these conditions, E2F1 
turnover is promoted by polyubiquitylation and proteasomal degradation. B. DNA 
photodamage induces hHR23A nuclear translocation and E2F1 recruitment to sites of 
DNA lesions, with potential involvement of factors that serve as a bridge between DNA 
and E2F1. E2F1 can form complexes with hHR23A at those sites, promoting DNA 
repair. In a coordinate fashion, E2F1 is also protected from degradation through various 
mechanisms, likely including association with hHR23 proteins. 
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determine which domains in hHR23A and E2F1 bind to each other, independent of 
ubiquitin modifications.  
The diversity of domains and possible modes of interaction of hHR23A and E2F1 imply 
that diverse cellular processes may be activated, depending on cell type, differentiation 
status and presence of DNA-related stresses. For example, under normal conditions 
hHR23A appears to be largely cytoplasmic in undifferentiated keratinocytes. 
Significantly, E2F1 is capable of modulating hHR23A subcellular localization, as its 
exogenous expression results in nuclear concentration of hHR23A in the absence of DNA 
damage in these cells. Reciprocally, hHR23A is able to reduce E2F1 turnover in 
undifferentiated keratinocytes. The ability of E2F1 to modulate hHR23A subcellular 
localization is further emphasized by the observation that both E2F1 and hHR23A remain 
cytoplasmic as a result of differentiation in keratinocytes. E2F1 is indispensable to 
maintain proliferative capacity in undifferentiated keratinocytes and for their activation 
during epidermal repair after injury (D'Souza et al., 2002). A potential role of hHR23A in 
these cells might be to stabilize E2F1 to ensure maintenance of a proliferative cell 
population. Further, it will be important to determine if hHR23A also plays a role in 
mediating the increases in E2F1 abundance observed in the regenerating epidermis. 
Similar stabilizing roles for hHR23A have been reported vis-à-vis p53 and ataxin-3 
(Blount et al., 2014; Glockzin et al., 2003).  
Because of their location at the skin surface, epidermal keratinocytes are uniquely 
exposed to UV-related damage, and have evolved several protective mechanisms, 
including the ability of these cells to repair damaged DNA through NER. The importance 
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of these pathways for epidermal homeostasis is underlined by the existence of 
dermatological diseases such as xeroderma pigmentosum, which is associated with skin 
photosensitivity. Individuals with this disorder exhibit hypersensitivity to solar UV light 
and frequent development of skin cancers (Cleaver, 1968). Several genetic abnormalities 
that cause XP have been identified, including alterations in XPC. In response to DNA 
damage, various signaling proteins are recruited to areas with altered bases. Under these 
conditions, hHR23 proteins play key roles facilitating recognition by XPC of DNA lesion 
sites, contributing to the repair of transcriptionally silent genome regions or of non-
transcribed strands of transcriptionally active genes (Bergink et al., 2012; Dantuma et al., 
2009). Given that E2F1 is most abundant in undifferentiated basal keratinocytes with 
proliferation potential (Dagnino et al., 1997), the cells of origin of nonmelanoma skin 
carcinoma, it is conceivable that a major role in vivo for the interaction between hHR23 
proteins and E2F1 is as a protective mechanism against DNA damage and malignant 
transformation of undifferentiated keratinocytes with proliferative potential in the 
interfollicular epidermis and hair follicles.  
The regulation of E2F1 in response to DNA damage is complex, depends on the 
damaging agent, and occurs through various mechanisms. The human ortholog of E2F1 is 
phosphorylated by the ATM and ATR kinases on Ser31 (Ser 29 in mouse E2F1) upon 
drug-induced DNA damage, promoting its binding to 14-3-3τ, which decreases its 
ubiquitylation and proteasomal degradation (Wang et al., 2004). Under these 
circumstances, stabilization of E2F1 leads to the transcriptional activation of its pro-
apoptotic targets TAp73 and Apaf1. E2F1 can also be acetylated on several Lys residues 
in response to chemicals that cause DNA double-strand breaks, with similar outcomes on 
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transcriptional activation of E2F pro-apoptotic targets (Galbiati et al., 2005; Pediconi et 
al., 2003). Efficient DNA repair in response to UV-induced DNA damage also requires 
E2F1, although different mechanisms appear to be involved. Under those conditions, 
E2F1 is also phosphorylated on Ser31 and stabilized (Berton et al., 2005; Pediconi et al., 
2003). Phospho-E2F1 can bind TopBP1, decreasing TAp73 and Apaf1 transcription. 
TopBP1 also mediates recruitment of E2F1 to DNA double-strand breaks, where it 
colocalizes with BRCA1, and promotes NER through mechanisms that appear to involve 
formation of complexes containing TopBP1, E2F1 and GCN5 (Guo et al., 2011). Indeed, 
E2F1-deficient cells are deficient in NER through mechanisms that involve impaired 
recruitment of DNA repair factors, such as GCN5, to sites of DNA damage. Further, a 
mouse E2F1 mutant protein lacking Ser29 is incapable of localizing to UV-induced sites 
of DNA damage, and epidermal keratinocytes expressing this protein exhibit increased 
susceptibility to UV-induced carcinogenic transformation (Biswas et al., 2014). This 
study identifies a novel mechanism that contributes to NER, involving interactions 
between hHR23 proteins and E2F1, and the recruitment of hHR23A by E2F1 to sites of 
DNA photodamage. Key issues for future research are to determine if E2F1- hHR23 
complexes also contain XPC, and to establish the relative importance of the E2F1-hHR23 
interaction to the overall capacity of keratinocytes to repair UV-induced DNA. This is a 
complex issue to address, given that individual depletion of hHR23 proteins or E2F1 
impair cellular repair capacity. The identification of E2F1 mutants incapable of binding 
to hHR23A may provide answers to this question.  
E2F1 is a well-established promoter of cell proliferation, but its roles in tumour formation 
and progression are complex, as it can either induce or suppress tumourigenesis. In the 
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context of the epidermis, E2F1 is necessary for normal wound healing (D'Souza et al., 
2002), and its overexpression leads to spontaneous tumour formation, exacerbated by the 
loss of p53 (Pierce et al., 1998b). Paradoxically, E2F1 also protects the epidermis from 
UV-induced transformation, and cooperates with the retinoblastoma protein, pRb, to 
prevent spontaneous carcinogenic transformation of hair follicle keratinocytes through 
modulation of β-catenin/Wnt pathways (Biswas et al., 2014; Costa et al., 2013). These 
studies now provide new insights on the role of E2F1 in maintenance of genomic 
stability, underlining the importance of this transcription factor in maintenance of 
epidermal homeostasis.  
4.2 E2F1 induction following genotoxic stress in 
keratinocytes 
This study revealed that the residues involved in the stability of E2F1 following 
genotoxic stress differ from the residues required for the degradation of E2F1 following 
keratinocyte differentiation. Moreover, residues identified previously to be required for 
E2F1 stability in response to DNA damage are similar in primary mouse keratinocytes 
and cancer cells. E2F1 response following DNA damage has been extensively studied 
over the years. Post-translational modifications on E2F1 lead to protein stability 
following genotoxic stress. For the first time, the importance of E2F1 post-translational 
modification in primary mouse keratinocytes has been analyzed and shows that a similar 
mechanism of E2F1 accumulation in cancer cells exists in primary mouse keratinocytes. 
Modifications at Ser31, Lys117, Lys120, and Lys125 are essential for the accumulation 
of E2F1 in response to genotoxic stress whereas Arg111, Arg113, and Lys185 are 
unmodified following DNA damage, which contributes to E2F1 accumulation. E2F1 
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plays a dual role in response to genotoxic insults, either leading to apoptosis or favoring 
cell survival (Poppy Roworth et al., 2015). In cancer cells, these modifications on E2F1 
promote an increase in apoptotic events leading to cell death (Cho et al., 2012; Kontaki 
and Talianidis, 2010; Lin et al., 2001; Pediconi et al., 2003). On the other hand, E2F1 
accumulates at DNA damage sites to stimulate NER pathway, which favors cell survival 
and resistance to genotoxic stress (Castillo et al., 2015; Guo et al., 2010). The increase in 
DNA repair is dependent on E2F1 residue Ser31 to favor recruitment of E2F1 at sites of 
DNA damage (Biswas et al., 2014). The Mer11 complex, containing Mer11, Nbs1, and 
Rad50, is recruited to sites of DNA DSB during DNA replication. Mer11 is methylated 
by PRMT1 and methylation favors the binding of Rad51 to damage sites (Yu et al., 
2012). E2F1 interacts with Mer11 at the replication fork to recruit Rad51 in the presence 
of DNA DSB (Maser et al., 2001). E2F1 is also methylated by PRMT1 at residue Arg109 
and increases E2F1 protein stability (Zheng et al., 2013). It will be of interest to 
determine whether Arg109 and other residues on E2F1 play a role in either accumulating 
E2F1 at DNA lesion sites or promoting E2F1-induced apoptosis in primary keratinocytes. 
4.3 Regulation of E2F1 turnover in differentiated 
keratinocytes 
The present study demonstrated multiple mechanisms of E2F1 degradation following 
Ca2+-induced keratinocyte differentiation. First, the stability of E2F1 is associated with 
E2F1 nuclear export through the CRM1-mediated pathway, as previously shown in our 
laboratory (Ivanova and Dagnino, 2007). Second, phosphorylation of E2F1 at Ser403 and 
Thr433 prevents the cleavage of K11- and K48- polyubiquitin chains in differentiated 
keratinocytes leading to recognition by the proteasome for degradation. Third, E2F1 
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protein stability is regulated through E3 ubiquitin ligase, Cdh1, in differentiated 
keratinocytes. 
The interaction between E2F1 and pRb plays an essential role in E2F1 transcriptional 
activity and stability (Helin et al., 1993; Martelli and Livingston, 1999). In my study, I 
established that modification at residues previously identified to be involved in the 
interaction between pRb and E2F1 do not prevent E2F1 degradation. Therefore, although 
pRb dissociation leads to increased transcription of genes through E2F1, this dissociation 
may not favour E2F1 degradation in primary mouse keratinocytes as seen in late S phase.  
E2F1 nuclear export plays an essential role leading to its degradation following Ca2+-
induced keratinocyte differentiation. However, this is not the only step necessary for 
E2F1 turnover under these circumstances. Modification at Ser403 and Thr433 of E2F1 
also appears to contribute significantly to E2F1 degradation. When Ser403 and Thr433 
are substituted for an alanine in a mutant also containing an NES to ensure proper 
CRM1-mediated nuclear export, this mutant E2F1 protein is cytoplasmic but still 
protected from degradation. The use of pseudo-phosphorylation mutants further 
confirmed the involvement of Ser403 and Thr433 in keratinocytes. The negative charge 
of aspartic acid can mimic phosphorylation of a protein. Notably, when E2F1 Ser403 and 
Thr433 are substituted for Asp, the half-life of this protein was significantly reduced in 
differentiated keratinocytes. Together, these findings strongly suggest that E2F1 can be 
phosphorylated at Ser403 and Thr433 and this post-translational event is required for its 
turnover in response to keratinocyte differentiation. The activity of p38β has been shown 
to be necessary for E2F1 degradation in keratinocytes, and in vitro kinase assays 
demonstrated that E2F1 Ser403 and Thr433 are substrates of p38β-MAPK 
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phosphorylation (Ivanova et al., 2009). However, whether E2F1 is phosphorylated by 
p38β-MAPK in cultured differentiating keratinocytes is yet to be determined.  
The regulation of E2F1 through ubiquitylation has been extensively studied. The APC/C 
complex plays a pivotal role in targeting E2F1 for degradation during cell cycle 
progression (Budhavarapu et al., 2012; Peart et al., 2010). E2F1 interacts with Cdh1, the 
activator of the APC/C complex during early G1 phase to down regulate E2F1 through 
K11 linked ubiquitin chain formation (Budhavarapu et al., 2012). My studies for the first 
time show phosphorylation-linked ubiquitylation and E2F1 degradation is modulated by 
Cdh1. In this thesis, I show that hEmi1-induced inhibition of Cdh1 and loss of Cdh1 
interfered with E2F1 down regulation in keratinocytes. Moreover, K11-, K48, and K63-
polyubiquitylation of E2F1 occur in response to keratinocyte differentiation, and the 
modification of E2F1 at Ser403 and Thr433 regulate K11- and K48-polyubiquitin 
linkages. These results could explain why the ST/A E2F1 mutant is more stable that wild 
type E2F1. Exogenous overexpression of Cdh1 can promote the degradation of ST/A 
E2F1 mutant protein as efficiently as wild type E2F1. This suggests that modification at 
Ser403 and Thr433 on E2F1 does not interfere with the ability of Cdh1 to target E2F1 for 
degradation. Moreover, phosphorylation of E2F1 also does not appear to directly 
interfere with the interaction with Cdh1, since all three forms of E2F1, WT, ST/A, and 
ST/D can interact with Cdh1 in keratinocytes. The absence of E2F1 post-translational 
modifications does not prevent its interaction with Cdh1 (Budhavarapu et al., 2012). 
Therefore, it was not surprising to observe the interaction between Cdh1 and all three 
forms of E2F1. If overexpressed Cdh1 can still interact with and mediate the degradation 
of ST/A E2F1, why does the ST/A mutant show decrease K11- and K48-linked 
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polyubiquitylation? One possibility is that under physiological conditions in 
differentiated keratinocytes, where Cdh1 is maintained at a normal level, both 
phosphorylated E2F1 and substitution of Ser403 and Thr433 with non-phosphorylatable 
alanine could interact with Cdh1 and catalyzes K11-linkage ubiquitin chain formation 
(Figure 4.2A). The phosphorylated E2F1 is then targeted for 26S proteasomal 
degradation. On the other hand, deubiquitylating enzymes (potentially ubiquitin-specific 
protease (USP) 37) could specifically interact with ST/A E2F1 and actively remove K11- 
or K48-linked ubiquitin molecules, thus protecting ST/A E2F1 from degradation (Figure 
4.2A). Ectopic expression of Cdh1 decreases endogenous USP37 protein levels (Huang et 
al., 2011). Therefore, in keeping with the notion that ST/A E2F1 could potentially be a 
target of USP37, when USP37 is down regulated, ST/A E2F1 is no longer 
deubiquitylated, thus could now be targeted for degradation (Figure 4.2B). Future study 
is warranted to identify whether E2F1 is a USP37 substrate. 
The increase in the half-life of E2F1-ST/A mutant and exclusive formation of K63-linked 
polyubiquitin chains in differentiated keratinocytes prompted me to investigate the 
possibility of interactions between E2F1 and the only known mammalian E2 ubiquitin 
conjugating enzyme, UBC13, which specifically generates K63-linked polyubiquitin 
chains. These studies identified a previously unrecognized interaction between E2F1 and 
UBC13. The phosphorylation state of E2F1 does not affect the ability of UBC13 to 
interact with E2F1 in undifferentiated keratinocytes. However, following Ca2+-induced 
differentiation, UBC13 preferentially interacts with E2F1-ST/A mutant and not with  
  
 
 
 
 
 
 
Figure 4.2: Proposed model of E2F1 phosphorylation-linked ubiquitylation 
modulated by ubiquitin ligases and deubiquitylating enzymes. 
A. Under normal conditions, Cdh1 and UBC13 interact with phosphorylatable E2F1 at 
Ser403 and Thr433 and non-phosphorylatable E2F1 (ST/A E2F1) to form specific K11- 
and K63-linked ubiquitin chains respectively. However, the K11-linkages on ST/A E2F1 
could be specifically cleaved by deubiquitylating enzymes (DUB, potentially by USP37) 
which lead to its stabilization. The phosphorylatable E2F1 is on the other hand targeted 
for degradation. B. The deubiquitylating enzyme, USP37 is targeted for degradation 
when Cdh1 is overexpressed. Under this circumstance, the ST/A E2F1 is likely no longer 
deubiquitylated by USP37 leading to its degradation via the 26S proteasome just like 
wild type E2F1. 
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E2F1 ST/D or wild type E2F1. Modifications on residues Ser403 and Thr433 do not 
appear to be necessary for UBC13 to interact with E2F1, but differentiation might alter 
E2F1 and/or UBC13 structure and thus prevent the physical interaction between 
phosphorylated E2F1 and UBC13. Therefore, one possibility of increased stability of the 
non-phosphorylated form of E2F1 mutant, ST/A could be due to its interaction with 
UBC13, which promotes the formation of K63-linked polyubiquitin chains that are 
modifications that likely regulate aspects of E2F1 function different from degradation 
(Figure 4.2A).  
Polyubiquitylation of protein through K63-linked ubiquitin chains is critical for recruiting 
DNA repair proteins upon DNA damage (Doil et al., 2009; Pinato et al., 2011; 
Ramachandran et al., 2010). Studies have shown that RNF168, an E3 ubiquitin ligase 
together with UBC13 catalyzes K63-linked ubiquitylation on the chromatin that 
surrounds DNA lesions. This follows by recruitment of RAP80-ABRA1-BRCA1 
complex to the damage sites (Stewart et al., 2009). RNF168 is able to ubiquitylate 
various histones and potentially other proteins found at sites of DNA damage to promote 
efficient DNA repair. E2F1 is important for recruitment of DNA repair proteins, such as 
XPC, XPA and hHR23 to sites of double strand breaks (Biswas et al., 2014; Chen et al., 
2011). Whether Ser403 and Thr433 play a role in favoring the accumulation of DNA 
repair proteins to lesion sites is yet to be determined. 
E2F1 activity is essential for keratinocyte proliferation and it is regulated through the 
pRb/E2F pathway. E2F1 down regulation is a prerequisite for keratinocytes to begin the 
differentiation process followed by entry into quiescence. The PKC-MAPK pathway is 
implicated in the epidermal differentiation process leading to E2F1 degradation (Ivanova 
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et al., 2006). This study has provided a mechanism of E2F1 turnover through 
phosphorylation-linked ubiquitylation mediated by ubiquitin ligase Cdh1. Following 
extracellular Ca2+ stimulation, the PLCγ enzyme is activated by PIP3, which hydrolyzes 
PIP2 to IP3 and DAG (Bikle et al., 2012). This leads to the release of Ca2+ from 
intracellular stores, and activation of PKC. The PKCη and PKCδ are specifically 
activated by DAG leading to activation of p38β-MAPK through the Ras-MEKK1-
MEK3/6 pathway (Denning et al., 1995; Efimova et al., 2002; Ivanova et al., 2006). In 
response to PKCδ activation, phosphorylated p38δ translocates into the nucleus (Efimova 
et al., 2004). Therefore, activation of p38β by phosphorylation could cause its 
translocation to the nucleus, where it could phosphorylate E2F1 at Ser403 and Thr433 
(Ivanova et al., 2009). Phosphorylation of E2F1 at these sites may prevent its 
deubiquitylation (likely occurring through USP37) and interaction with UBC13, which 
catalyzes specific K63-linkage ubiquitin chains. Together, the data favour a model where 
E2F1 degradation is mediated through its association with Cdh1 (Figure 4.3). 
Understanding the signaling events that lead to the degradation of E2F1 is vital as 
increased E2F1 expression in the epidermis results in hyperproliferation and hyperplasia 
(Pierce et al., 1998a). 
4.4 Future studies 
This study identified a novel interaction between E2F1 and hHR23A proteins. Together, 
these proteins promote DNA repair of UV-damaged keratinocytes. The proximal 
promoter region of Rad23A contains a consensus E2F1 binding site but putative binding 
sites for any of the other E2F family members were not detected. A future direction of  
  
 
 
 
 
 
 
Figure 4.3: Proposed model of E2F1 regulation and function in differentiated 
keratinocytes.  
The activation of phospholipase C γ (PLCγ) through binding of extracellular Ca2+ to cell 
surface receptor(s) catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Through DAG, 
novel PKC (η/δ) are activated which leads to phosphorylation of p38β through the Ras-
MEKK1-MEK3/6 pathway. Phosphorylated p38β translocate to the nucleus where it 
might phosphorylate E2F1 at Ser403 and Thr433. E2F1 phosphorylation at Ser403 and 
Thr433 might prevent DUB enzymes (USP37) from cleaving K11- and K48-linkages. 
Phosphorylation of E2F1 through Ca2+ induction also prevents its interaction with 
UBC13, which catalyzes specifically K63-linked ubiquitin chains. Together, this favors 
degradation of E2F1 mediated through its association with Cdh1 in differentiated 
keratinocytes. 
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this study would be to determine whether E2F1 binds to the promoter of Rad23A in a UV 
damage induced-dependent manner by chromatin immunoprecipitation (ChIP)-qPCR 
assays.  
Following DNA damage, hHR23A associates with XPC, and subsequently recruits XPC 
to DNA damage sites. The recruitment of hHR23A to DNA damage sites is transient and 
the protein does not accumulate at local DNA damage sites (Bergink et al., 2012). In this 
study, I showed that exogenous expression of E2F1 favours hHR23A localization to 
DNA damage sites. However, whether the interaction between XPC and hHR23A is 
necessary for E2F1 to recruit hHR23A to these DNA lesions has yet to be determined. To 
understand the dynamics between the E2F1-hHR23A-XPC complex, future studies 
should examine whether a mutant hHR23A, defective in interacting with XPC by 
deleting the XPC domain, can be recruited to DNA damage sites in the presence of E2F1 
following UV irradiation. Given that E2F1 could maintain its interaction with a hHR23A 
mutant lacking the XPC sequences (∆XPC; Figure 3.14C), I would expect that the mutant 
hHR23A would be recruited to the damage sites. Moreover, I predict that the interaction 
between E2F1 and hHR23A ∆XPC will not promote efficient DNA repair, since XPC is 
no longer recruited to the damage sites. Together this would reveal whether E2F1 and 
hHR23A are necessary to recruit XPC to DNA damage sites to initiate DNA repair 
successfully. 
E2F1 post-translational modifications are numerous and have been extensively studied; 
however, the specific ubiquitin-modified lysine residues on E2F1 have yet to be 
nonequivocally identified. By identifying sites of protein modification, one can better 
understand the biological role of such covalent modifications. E2F1 substitution at a.a. 
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sites 117, 120, and 125 or 185 were identified as acceptor lysines where ubiquitin 
molecules are catalyzed (Galbiati et al., 2005; Kontaki and Talianidis, 2010). However, 
in keratinocytes, exogenous expression of E2F1 KTR or K185R did not prevent 
ubiquitylation of E2F1 (Appendix 2). Therefore, lysines at position 117, 120, and 125 or 
185 may not be the only acceptor sites where ubiquitin molecules attach. E2F1 has 14 
lysine residues (16 lysines in murine E2F1) and mutating each residue could be very 
challenging. Moreover, this method only indirectly maps ubiquitylation sites (Kaiser and 
Wohlschlegel, 2005). Future studies should utilize protein mass spectrometry analysis to 
identify the direct location of these modifications. One could also identify the type of 
ubiquitin linkages, using proteomic approaches, since E2F1 can be modified to form 
K11-, K48-, or K63-linkages. 
My study also provided new evidence for the involvement of modifications at Ser403 and 
Thr433 in K11- and K48-linked polyubiquitylation of E2F1 and subsequent turnover of 
E2F1 in differentiated keratinocytes. In denaturing polyacrylamide gels, the S403A and 
S403D E2F1 mutant migrated at the same position as analogous samples treated with λ 
phosphatase, indicating that Ser403 is an important contributor to the overall E2F1 
phosphorylation state. Whether phosphorylation at Ser403 is necessary for the 
phosphorylation of other serine/threonine sites will need to be examined in future 
experiments. Phospho-specific antibodies could be used to determine whether 
phosphorylation of Thr433 and other serine/threonine residues is dependent on 
phosphorylation at Ser403. However, commercially available phospho-specific 
antibodies could not detect phosphorylated E2F1 in my hands. The use of 
phosphopeptide mapping could potentially help understand the interplay between 
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phosphorylation at Ser403 and Thr433 in vivo. The generation of a conditional knock-in 
ST/A-E2F1 mouse model could further define the physiological role of the Ser403 and 
Thr433 post-translational modification during epidermal development. 
4.5 Concluding remarks 
The maintenance of genomic integrity is a crucial requirement for cell viability, and its 
disruption can result in aneuploidy and diseases such as cancer in mammals. The 
mechanisms of differentiation and DNA damage repair play crucial roles in the 
homeostasis of a cell. In this thesis, I investigated the regulation of E2F1 stability during 
epidermal DNA repair and differentiation. I showed that the interaction between E2F1 
and hHR23A prevents E2F1 degradation and that together, E2F1 and hHR23A are 
recruited to UV-induced DNA damage sites to promote DNA repair. During keratinocyte 
differentiation, I found that E2F1 residues Ser403 and Thr433 are required for ubiquitin 
K11- and K48-linkage leading to subsequent turnover of E2F1. Modification of these 
same residues prevent E2 ubiquitin conjugating enzyme UBC13 from interacting with 
E2F1 and potentially favour the association of Cdh1 in differentiated keratinocytes. Tight 
control of E2F1 expression thus plays an essential role to ensure proper DNA repair 
following genotoxic stress and differentiation. 
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Appendix 1: Primary epidermal keratinocytes irradiated with UV. 
Keratinocytes isolated from 3-day-old mice were plated at 70% confluence. Twenty-four 
hours later, keratinocytes were subjected to various dose of A. UVB or B. UVC 
irradiation through no filters or through 3-µm polycarbonate isopore filters, and cultured 
for 30 min. DNA was denatured with 2 N HCl and processed for immunofluorescence 
microscopy using anti-CPD antibodies. DNA was visualized with Hoechst 33342. Bar, 16 
μm. 
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Appendix 2: Ubiquitylation of E2F1 proteins in keratinocytes. 
Undifferentiated keratinocytes were transfected with vectors encoding HA-tagged 
ubiquitin and the indicated V5-tagged E2F1 proteins, cultured in Low (-) or High (+) 
Ca2+ medium, treated with MG132 (10 µM) for 6 h, and harvested to prepare whole-cell 
lysates. HA or unrelated IgG immunoprecipitates were isolated from the lysates and 
analyzed by immunoblot with anti-V5 antibodies. The abundance of exogenous E2F1 
proteins in the lysates was analyzed by immunoblot, using γ-Tubulin as loading control. 
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